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Abstract 
Because mutation of the tumor suppressor APC initiates ~80% of all colorectal 
cancers, understanding APC function is central for better diagnostic, preventive, and 
therapeutic strategies for the disease. In-vitro studies have indicated that APC shuttles 
between the cytoplasm and nucleus, using two nuclear localization signals (NLS) and 
five nuclear export signals (NES). To better understand the role of nuclear APC, our lab 
made a mouse model with mutations in both NLS (ApcmNLS) sequences. In this 
dissertation, I report higher Wnt signalling and increased proliferation in intestinal 
epithelial cells from ApcmNLS/mNLS mice, and observe that these mice are more susceptible 
to colitis-induced colon tumorigenesis. Furthermore, ApcMin mice, a well-characterized 
Apc mouse model that carries an Apc truncation mutation, have increased intestinal polyp 
multiplicity, size, and proliferation index when they also carry the ApcmNLS allele. Taken 
together, these data support a role for nuclear Apc in cell proliferation, inhibition of Wnt 
signalling, and tumor suppression. ApcmNLS/Min mice also display extra-intestinal 
phenotypes, including enhanced mammary tumorigenicity and more severe anaemia, than 
in ApcMin/+ mice, suggesting a role for nuclear Apc in other tissues.  
My studies also identified and characterized a polymorphism in the promoter of 
the Pla2ga2 (Mom-1) gene that might be responsible for the attenuated phenotype 
observed in ApcMin/+ mice in some genetic backgrounds. I developed a simple, reliable, 
PCR-based test for this polymorphic allele that will allow easy screening of mouse 
colonies.  
The mechanisms by which cellular APC levels are regulated are not completely 
understood. In this dissertation, I show that induction of the heat-shock response 
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increases APC levels both in colon cancer cell lines and in mouse intestinal epithelial 
cells. I tested two compounds to induce the heat-shock response and found altered tumor 
multiplicity, size, and regional distribution in two mouse models with different germline 
mutations in Apc. I also showed that a novel non-toxic heat-shock response inducer, KU-
32, protects against colitis-mediated tumorigencity in mice. I propose that regulation of 
APC levels via heat-shock response contributes to many aspects of APC and intestinal 
tumor biology, and can serve as a novel molecular target for prevention and treatment of 
colorectal cancer. 
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Chapter1 
Introduction 
Colorectal cancer 
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the 
United States [1]. In 2011, it was estimated that there were ~ 150,000 new colon cancer 
cases and 50,000 related deaths [1]. Although there have been improvements in CRC 
diagnosis and management in recent years, the treatment options of CRC, including 
surgical removal and chemotherapy, are associated with a relatively high morbidity [2]. 
There are many risk factors that have been associated with CRC, including age, diet, 
ethnic background, known genetic alterations, family history of the disease, and chronic 
inflammation in the colon (chronic colitis) [3, 4]. Increased understanding of colon 
cancer will reveal better preventive, diagnostic, prognostic, and therapeutic strategies. 
Genetic susceptibility to CRC 
Cancer is a genetic disease that results from accumulation of genetic mutations 
and epigenetic modifications in the genome [5]. Cancer-related genes are broadly 
classified as proto-oncogenes and tumor suppressor genes. Proto-oncogenes are genes 
encoding proteins that promote cellular growth and proliferation. Cancer-associated 
mutations in proto-oncogenes are usually gain-of-function and drive uncontrolled cellular 
proliferation. On the other hand, cancer-driving mutations in tumor suppressor genes are 
usually loss-of-function. Tumor suppressor genes are further divided into “gatekeepers” 
and “caretakers”. Gatekeeper genes work as breaks on cellular proliferation while 
caretaker genes are responsible for DNA repair to prevent further accumulation of 
oncogenic mutations [5]. Mutations in proto-oncogenes and tumor suppressor genes are 
1 
usually acquired (somatic) in sporadic cases of cancer. However, mutations can also be 
inherited (germline) to result in tumor susceptibility phenotypes. The penetrance of these 
cancer susceptibility phenotypes varies from almost 100% to only slightly increasing the 
risk for a particular cancer. This genetic-associated risk increase for cancer phenotypes is 
one basis for familial cancer predisposition [6].    
Family history of CRC increases the risk in sporadic cases. In addition there are 
also relatively well-characterized CRC susceptibility syndromes [7]. Characterizing the 
genes mutated in these cancer susceptibility phenotypes allows uncovering of various 
molecular pathways in colorectal carcinogenesis, which permits identification of various 
preventive, diagnostic, prognostic, and therapeutic targets.  
There are many CRC susceptibility syndromes that vary in their mode of inheritance, 
penetrance, colonic lesion pathology, and extra-colonic phenotypes [8] (Table 1.1).  All 
of these syndromes are autosomal dominant except for MYH-associated attenuated 
polyposis syndrome, which is autosomal recessive. All of these CRC syndromes are also 
associated with increased risk for other types of cancer. These cancer susceptibility 
syndromes result from mutations in gatekeepers (APC in familial Adenomatous polyposis 
(FAP), BMPR1A and SMAD4 in Juvenile polyposis, and STK11 in Peutz-Jeghers 
syndrome) and caretakers (MLH1, MSH2, PMS2, and MSH6 in hereditary non-polyposis 
colon cancer (HNPCC) syndrome, and MYH in MYH-associated attenuated FAP) [9-14]. 
In addition to these characterized CRC susceptibility syndromes, mutations in other genes 
were also identified in families with increased risk for CRC (see [15] for the list of these 
genes).  
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Familial Adenomatous Polyposis (FAP) 
Familial adenomatous polyposis (FAP) was the first CRC syndrome to be 
characterized [8]. The incidence of FAP is different in different population, and is around 
1/10,000 in Europe [8]. FAP syndrome is characterized by the growth of tens to 
thousands of adenomas (polyps) in the colon, and is transmitted as an autosomal 
dominant trait with almost 100% penetrance by the age of 40. Although these tumors are 
benign, there is a ~1-5% risk for each tumor to undergo a malignant transformation. 
Considering the huge number of polyps that typically develop in FAP patients, without 
intervention, CRC is almost inevitable. FAP patients are usually asymptomatic until the 
age of late twenties, when the polyps are large enough to manifest [16]. In addition to 
CRC, FAP patients have higher risks of developing other cancers such as hepatic, 
pancreatic, thyroid, and duodenal carcinomas. In addition, FAP patients may also present 
with a medulloblastoma brain tumor; Turcot syndrome describes the co-occurrence of 
CRC and medulloblastoma [17, 18]. FAP patients also develop other extra-colonic 
manifestations including desmoid tumors, dental anomalies, and congenital hypertrophy 
of retinal pigment epithelium (CHRPE); Gardner syndrome describes the presence of 
these extra-colonic manifestations with colonic polyps [19]. The only treatment of FAP is 
surgical removal of the colon, usually in a person’s late twenties, to prevent the 
development of cancer. This prophylactic measure is associated with morbidity and does 
not affect the morbidity and mortality from other extra-colonic manifestations associated 
with the condition [16]. Although FAP represents about 1% of all cases of CRC, mapping 
and characterizing its genetic basis resulted in identifying the main colonic gatekeeper 
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gene that is mutated not only in this syndrome but in the vast majority of all CRC, the 
Adenomatous Polyposis Coli (APC) gene.   
Adenomatous Polyposis Coli (APC)  
Discovery 
APC was identified as the candidate gene for FAP (Gardner syndrome) by two 
independent groups [20-22]. First, deletion of the 5p21 chromosomal band was detected 
in a patient with FAP syndrome [23]. Following this cytogenetic finding, genetic linkage 
confirmed the presence of a FAP candidate gene on 5p21 [24, 25].  The group of Bert 
Vogelstein at Johns Hopkins University, in collaboration with the Nakamura group at the 
University of Tokyo, linked several genes present in this chromosomal region (FER, 
MCC, SRP19, TB2 and APC) to patients with FAP and colon cancer [21]. All these genes 
are expressed in the colonic epithelium. Kinzler et al. were able to narrow the list to MCC 
and APC [21]. Nishisho et al. found nonsense mutations in the APC gene in patients with 
FAP and Gardner syndromes [22].  
Ray White’s group at the University of Utah found a large deletion at the 5p21 
locus in 2 unrelated cases with FAP. They found 3 candidate genes in this deletion; 
SRP19, DP1 (deleted in polyposis 1 which turned out to be MCC) and DP2.5 [20, 26]. 
The group searched for mutations in these 3 genes in 61 unrelated FAP patients. They 
characterized exon boundaries of these 3 genes using Northern blots, and screened for 
mutations in the predicted exons using single-stranded conformational polymorphisms 
(SSCP) [20]. They found nonsense mutations and small deletions resulting in frameshifts 
in the DP2.5 gene, which turned out to be the APC gene [20]. 
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Screening sporadic cases of colorectal tumors (benign and malignant) of different sizes 
showed that mutations in the APC gene are present in most of theses cases. In addition, 
APC mutations were also detected in early adenomas and in small tumors. These 
observations suggest that mutations in APC are early, if not the initiating, step in most 
cases of CRC [27]. In addition, using immunohistochemistry, full-length APC has been 
detected in normal colon epithelium and cell lines from sporadic tumors from other 
organs, but not in colonic adenomas, carcinomas, or most CRC cell lines [28]. 
Considering the severity of the phenotype in FAP patients and the finding that APC is 
mutated early in most cases with sporadic CRC, Kinzler and Vogelstein concluded that 
APC is the gatekeeper of the colonic epithelium [7]. Fearson and Vogelstein described a 
genetic model for colorectal carcinogenesis in which different genetic changes in 5 
different pathways are associated with morphological progression of cells to invasive 
carcinoma [29]. The first step in this model is mutation of both APC alleles [7, 29].        
APC structure and functions 
APC gene is formed of 15 exons with the last exon coding for more than three 
quarters of the protein product [7, 20]. The APC gene codes for a large protein, APC, 
2843 amino acids in length, and about 312 kD [20]. Later work identified a small exon 
(exon 10A) that is alternatively spliced in a tissue-non-specific mechanism that adds 18 
in-frame codons to the APC final mature mRNA[30].    
The product of the APC gene is a large multi-domain protein that interacts with 
many proteins and was implicated in many cellular processes (Figure 1.1) [31, 32]. The 
N-terminal part of APC contains an oligomerization domain, allowing APC to make a 
homodimer [33]. APC has a region that has sequence similarity with the armadillo 
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protein (-catenin homologue in Drosophila), and therefore called the armadillo repeat 
region [21]. The middle region of APC contains four 15-amino acid (aa) repeats and 
seven 20-aa repeats that are important in binding and destruction of -catenin (see below) 
[34-36]. Within the 20-aa repeats are three axin-binding Ser-Ala-Met-Pro (SAMP) 
repeats [37]. The C-terminal region of APC binds microtubules both directly and via the 
microtubule-binding domain of EB1 [38, 39]. The most C-terminal region of APC has a 
PDZ domain that binds to the discs large protein, a component of the tight junction [40].    
The most characterized function of APC is to antagonize WNT signaling-induced 
cellular proliferation by targeting the oncoprotein -catenin for proteasomal degradation 
[41]. Two groups demonstrated that APC co-immunoprecipitates with -catenin [34, 42]. 
Further work showed that APC forms a cytoplasmic multi-protein complex with AXIN, 
the serine/ threonine kinase (GSK-3) and casein kinase 1 (CK1). This complex 
phosphorylates and targets -catenin for proteasomal degradation to maintain a low level 
of cytoplasmic -catenin. Canonical WNT signaling inhibits this destruction complex, 
which results in accumulation of -catenin (figure 1.2). 
WNT signaling is a conserved developmental pathway that plays an important 
role in cellular proliferation and differentiation [43]. WNT was discovered through 
cloning of a Drosophila melanogaster gene causing a wing defect (Wingless, Wg) and 
also the identification of the integration site of the mouse tumorigenic virus MMTV 
(Int1) [44, 45]. WNT is a group of secreted ligands that bind to serpentine cell-surface 
receptors of the Frizzled family (FZ). The WNT-FZ complex binds to LRP5/6, 
Disheveled and AXIN and results in inhibiting the -catenin destruction complex. 
Hypophosphorylated -catenin accumulates in the cytoplasm and translocates to the 
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nucleus, where it binds to the co-transcriptional factor TCF/LEF to alter the expression of 
WNT target genes [43]. Most -catenin-responsive genes are induced e.g. MYC, 
CyclinD1 and AXIN2; other genes are downregulated, however, e.g. HATH1 [46-49] (for 
an updated list of WNT target genes see the WNT homepage 
http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes). The effect of WNT 
signaling on cells is usually to drive cellular proliferation and maintain an 
undifferentiated state [43].  
WNT signaling plays an important role in maintaining intestinal epithelial 
architecture [50]. Intestinal epithelium is formed of a single layer of columnar epithelial 
cells that are arranged in finger-like projection (villi, only in the small intestine) and sac-
like invaginations (crypts, in both the small and large intestines); see figure 1.3. It was 
demonstrated that stromal cells at the crypt base secrete WNT ligands that maintain a 
gradient concentration of WNT along the length of the crypt. At the crypt base (highest 
concentration of WNT) intestinal stem cells are located.  These stem cells divide to 
maintain the stem cell population and also produce undifferentiated cells (transient 
amplifying cells; TA). TA cells further divide until they reach the upper 1/3 of the crypt 
(with lower WNT concentration) where these cells start to differentiate to various 
intestinal cell types [43, 45]. It is thought that the inability of APC to antagonize WNT 
signaling results in continuing proliferation, lack of differentiation and intestinal tumor 
formation [51]. 
In addition to antagonizing WNT signaling, APC also has WNT-independent 
roles in other vital cellular functions, including adhesion, migration, cytoskeleton 
organization, spindle formation and chromosome segregation [31]. APC co-
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immunoprecipitates with the adherens junction proteins -catenin and E-Cadherin [34]. 
Full-length, but not truncated, APC co-localizes with microtubules [42] and also 
concentrates on the leading edge of migrating epithelial cells [52, 53]. At this leading 
edge, APC forms a complex with microtubules and the RNA binding protein FMRP.  
FMRP binds to and regulates translation of different RNA transcripts needed for 
formation of pseudopodial protrusion during cellular migration [52]. In addition, 
depolymerization of microtubules results in redistribution of APC in the cell, which 
suggests that APC interacts with microtubules [34, 39]. This interaction involves the C-
terminal part of APC and seems to be unrelated to the protein’s function to antagonize 
WNT signaling [54]. APC has also been shown to interact with the microtubule-
associated protein EB1 [55, 56]. In addition, the Neufeld lab has shown that APC 
interacts with the intermediate filaments Lamin B1 and Keratin 81 in cultured cells [57]. 
Mutations in APC have been associated with chromosomal instability in both colon 
cancer cell lines and mouse embryonic stem cells [58-60]. Moreover, Apc mutations have 
also been shown to affect the sensitivity for microtubule poisons in cultured cells and 
mouse intestinal epithelial cells, inhibiting the spindle assembly checkpoint-induced 
mitotic arrest to low dose of the microtubule poisons [61]. 
 Nuclear APC 
In addition to the cytoplasmic functions described above, APC shuttles between 
the cytoplasm and the nucleus. APC is a large protein that can not diffuse freely into the 
nucleus [62]. In 1997, Neufeld and White, using immuno-fluorescence and cell 
fractionation, found that APC is located in both the cytoplasm and the nucleus. 
Furthermore, they showed that nuclear APC is co-localized with rRNA in the nucleolus 
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[53]. Zhang et al. described 2 monopartite nuclear localization signals in the C-terminal 
half of APC protein (NLS1APC and NLS2APC) [63]. These nuclear localization signals are 
conserved in human, mouse, rat, and fly APC, and have sequence similarity to the nuclear 
localization signal seen in the SV-40 large T-antigen.  NLS1APC and NLS2APC can target 
cytoplasmic -galactosidase to the nucleus [63]. Furthermore, mutation in NLS1APC and 
NLS2APC results in exclusion of the full-length APC from the nucleus in cultured cells 
[63]. Galea et al. showed that truncated APC that lacks both NLS1 and NLS2 can still 
accumulate in the nucleus when nuclear export is inhibited by use of leptomycin B1 
(LMB1) [64]. They further showed that this NLS1-NLS2-independent nuclear import of 
APC requires amino acids 302- 625 (in the armadillo repeat region) [64]. On the other 
hand, nuclear export of APC to the cytoplasm is facilitated by 5 nuclear export signals 
(NES) [62]. Two of these NES are in the N terminal part, 2 are in the middle region, 
while the last one lies in the C-terminal region of the APC [62, 65-68]. 
It has been suggested that nuclear APC has a role in antagonizing WNT signaling 
in a mechanism that does not involve targeting -catenin for destruction [62]. Three 
different mechanisms have been proposed: 1- helping to export -catenin from the 
nucleus; 2- sequestering nuclear -catenin from interaction with the TCF/LEF 
transcription factor and; 3- facilitating import of transcriptional repressors that inhibit -
catenin transcriptional activity [62]. Evidence supporting model one include the 
observation that inhibition of nuclear export of APC, via introduction of NES mutations 
or treatment with the nuclear export inhibitor LMB1, results in accumulation of nuclear 
-catenin in cultured cells [66, 68, 69]. In addition, expression of full-length APC with 
intact nuclear localization signals (NLS1 and NLS2) decreases nuclear -catenin levels, 
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and reduces -catenin transcriptional activity in colon cancer cultured cells that have 
endogenous truncated APC. This WNT-antagonizing activity of APC appears to be NLS-
dependent, since mutation in both NLSs eliminates these effects [69].  
The second proposed mechanism by which nuclear APC can dampen -catenin 
transcriptional activity is through sequestering nuclear -catenin from transcription co-
factor TCF/LEF [62]. Nuclear APC interacts with nuclear -catenin [66, 70]. In addition, 
it has been shown that APC and TCF/LEF bind to the same -catenin domain. Moreover, 
a single APC molecule can bind to up to 10 -catenin molecules [70]. Furthermore, 
inhibition of nuclear export of APC has been correlated with reduced -catenin 
transcriptional activity [65-68]. Considering these data, nuclear APC might compete with 
TCF/LEF for -catenin binding, thus decreasing -catenin transcriptional activity.  
In the third model, APC binds to and helps nuclear import of the transcriptional 
suppressor C terminal-binding protein (CtBP) to antagonize WNT signaling [71]. APC 
binds to CtBP both in vitro and in vivo. The nuclear APC/CtBP complex appears to 
decrease -catenin transcriptional activity in the nucleus. There is no evidence that CtBP 
binds to TCF, however, so perhaps CtBP might sequester nuclear -catenin [71]. Also, 
chromatin immunoprecipitation (ChIP) results found that the APC/CtBP complex (along 
with another transcriptional co-repressor) binds to the promoter of c-MYC, a -catenin 
transcriptional target [72]. Together these results supporting each of the 3 models suggest 
that nuclear APC opposes WNT signaling by multiple mechanisms and at levels [62, 72].  
Other proposed roles for APC in the nucleus include DNA synthesis, cell cycle 
regulation, and DNA repair [62]. Our laboratory has shown that APC interacts with 
Topoisomerase II, an enzyme essential in DNA replication and cell cycle progression 
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[73, 74]. APC interacts with PCNA, FEN-1, and polymerase-, components in long 
patch-base excision repair (LP-BER) [75-80], and can affect CREB-C/EBP- mediated 
transcription [81]. Although the significance is not completely understood, APC appears 
to directly interact with A/T-rich DNA sequences [82]. 
Although accumulated evidence demonstrates roles for wild-type APC in the 
nucleus, two important notes should be considered. First, the above-mentioned data were 
collected using cultured cells and/or purified proteins, which may not reflect APC’s 
function in living organisms. Second, cancer-associated mutations in APC usually result 
in deletion of the C-terminal part of the protein, including many important domains in 
addition to both NLS. This multi-domain loss makes it difficult to dissect the patho-
physiologic role of NLSAPC in the context of normal homeostasis and carcinogenesis. In 
view of these limitations, making an animal model with compromised nuclear APC has 
been necessary to better understand the role of APC in the nucleus.        
Mutations in APC 
Mutations in both APC alleles are detected in the majority of colorectal tumors, 
thus filling Knudson’s two-hit hypothesis for tumor suppressor genes [83]. Knudson’s 
two-hit hypothesis explains the apparent paradox that the multiple polyposis phenotype in 
FAP patients is inherited as an autosomal dominant trait with mutation in only one APC 
allele, while at the cellular level, loss-of-function mutations in both APC alleles are 
required for the development of the adenoma phenotype (recessive) [5]. In FAP 
syndrome, the patients inherit a mutant copy of APC, and polyps are thought to initiate 
following a somatic mutation in the other wild-type APC allele. Considering the large 
number of crypts in the colon, mutation of the second APC allele in an FAP patient 
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happens in tens to thousands of crypts, resulting in the “multiple polyposis” phenotype 
[5, 6]. Consistent  with this interpretation, in the majority of sporadic colorectal cancers, 
somatic mutation of both APC alleles is required in a single colon epithelial cell in order 
to initiate colorectal tumorigenesis [84]. This explains why sporadic CRC usually 
develops as a single lesion and at a later time, relative to tumors in FAP syndrome [5, 
84]. There are no reports for germline mutations in both copies of APC, which suggests 
that loss of APC function is lethal early in development. In addition, homozygous 
mutation of both Apc copies is embryonically lethal in mouse, rat, and zebrafish, which 
reinforces the importance of APC in fetal development [85-87]. 
Comparing APC mutations in tumors from FAP patients suggests that the sites of 
somatic mutations within the APC gene are not random and instead depend on the 
position of the germline mutations [88]. Most germline APC mutations in FAP patients 
are nonsense mutations or small insertions/ deletions that result in frameshifts and 
premature stop codons [89, 90]. The same types of mutations are seen as the second APC 
gene mutation in tumors from these patients [89, 90]. Loss of heterozygosity (LOH) 
refers to loss of the wild-type allele of a gene (usually a tumor suppressor gene in tumor 
cells) with or without duplication of the mutant allele. LOH results from: 1- somatic non-
disjunction and loss of the whole chromosome with or without duplication of the 
homologous chromosome, 2- deletion of a chromosomal locus or 3- mitotic 
recombination [6]. The latter mechanism is most commonly seen in FAP patients [91, 
92]. It is thought that the second APC allele mutation seen in the tumors from FAP 
patients confers selective advantage for tumor development. As LOH in mammalian 
genomes seems to be more frequent than the other mutational events including point 
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mutation, small deletions and insertions  [91, 93], the frequency of APC LOH seen in 
tumors from FAP patients with a specific germline APC mutation implies the selective 
advantage of this mutation on tumorigenicity. It has been shown that if the APC germline 
mutation occurs between the first and second 20 a.a. repeats, the somatic mutation 
usually happens via LOH. Furthermore, if the germline mutation occurs before the first 
20 a.a. repeat, the second hit is usually a nonsense mutation between the first and second 
20 a.a. repeats with reduced frequency of LOH in these patients. These observations 
indicate that a truncation mutation in APC after the first 20 a.a. repeat is not only enough 
but also advantageous for tumorigenesis. Moreover, most APC truncations observed in 
colon tumors result in exclusion of the 3rd 20 a.a. repeat from the protein product [88, 92, 
94]. Combining these mutation patterns defines a region between amino acids 1250- 1464 
where most APC mutations are detected, named the mutation cluster region, MCR (figure 
1.1) [95]. The same interdependence of both somatic APC mutations is also seen in 
sporadic cases of CRC, although it is not possible to determine the time sequence of these 
mutations [92, 94]. This apparent selective advantage of retaining the N-terminal half of 
APC suggests a dominant-negative effect of this truncated allele [35]. Other groups 
proposed the “just right” hypothesis for WNT signaling control as an explanation for this 
selective advantage of the MCR [92, 96]. This hypothesis suggests that truncation of the 
C-terminal half of APC increases WNT signaling to a submaximal level which is ‘just 
right” for tumor development. Neither maximal upregulation of WNT signaling with 
mutations 5’ to the MCR nor minimal upregulation of WNT signaling by mutations 3’ to 
the MCR confer the same tumorigenic advantage to the transformed cells [96].  
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Nieuwenhuis and Vasen performed a meta-analysis for genotype-phenotype 
correlation in FAP patients [97]. They found that germline mutations in the MCR have 
the most severe intestinal polyposis phenotype, developing over 5000 colonic polyps. 
Mutations 5’ or 3’ to the MCR were associated with an intermediate intestinal polyposis 
phenotype. Mutations that result in a truncation in APC after amino acid 1595 or before 
amino acid 157 were associated with an attenuated phenotype with development of few 
polyps [97]. Complete deletion of APC has been reported only rarely and results in an 
intermediate phenotype [23, 98]. As for the extra-colonic phenotypes, Nieuwenhuis and 
Vasen found that extra-colonic manifestations are fairly common in FAP patients (around 
70%). CHRPE is the most frequent phenotype, and was correlated with APC truncation 
between amino acids 311- 1446. Desmoid tumors, on the other hand, were correlated 
with APC truncations 3’ to the MCR, after amino acid 1400. Duodenal and gastric tumors 
were correlated with APC mutations downstream of codon 1395 and 564-1450 [97]. It is 
important to note that these genotype-phenotype correlations are not rigid or complete, 
which suggests roles for other genetic and environmental factors in tumor development 
[97, 99].   
Control of APC levels in the cell  
Although APC has important roles in development and cancer, control of the 
cellular APC level is not well-understood. APC is widely expressed in most tissues [20]. 
Using immunohistochemistry to detect APC, Smith and colleagues found that cells near 
the surface of normal colon mucosa stained more than those in the bottom of the crypts, 
which suggests that the APC level increases with cellular differentiation [28]. Jaiswal and 
Narayan studied 921-bps of APC promoter, including 649 bps 5’ and 272 bps 3’ to the 
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transcription start site. They characterized 3 E-boxes (A, B and M), a CAAT box, an 
OCT1-binding site and an AP2-binding site in the region 5’ to the transcription start site. 
Using chloramphenicol acetyltransferase reporter (CAT) and electrophoresis mobility 
shift assays (EMSA), they found that the transcription factors upstream stimulating factor 
1 and 2 (USF1 & USF2) bind to the 5’ region of the APC cloned promoter area and 
stimulate the expression of the reporter gene [100]. 
Although not completely delineated, the cellular level of APC seems to be 
controlled at different levels. At the transcriptional level, APC mRNA are induced in 
response to the DNA damaging agent N-methyl-N-nitro-N-nitrosoguanidine (MNNG) in 
one colon cancer cell line [101]. This upregulation of APC transcription in response to 
DNA damage seems to occur through the P53 pathway.  Interestingly, this induction was 
not detected in 2 other non-colon cancer cell lines [101, 102]. Another example of control 
of APC transcription was shown by the Nathke and Rocha groups. They showed that 
upregulation of hypoxia-induced factor 1 (HIF-1by growing cultured cells under 
hypoxic conditions, or through direct HIF-1overexpression, reduces APC mRNA and 
protein levels. They also showed that HIF-1binds to the APC promoter sequence [103]. 
Hypermethylation of the APC promoter has also been detected in many cancers including 
breast, endometrial, prostate, and parathyroid [104-107]. However, a direct relation 
between this promoter hypermethylation and expression of APC has not been established, 
and the significance of this promoter hypermethylation is not fully understood [105, 108, 
109].  
At the translation level, APC mRNA has been shown to interact with miRNAs 
and an RNA-binding protein to control APC translation. Overexpression of miR-135 
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family members miR-135a and miR-135b reduced the APC protein level in cultured cells 
[110]. miR-135a and miR-135b decrease the expression of a luciferase reporter construct 
containing the APC 3’UTR region. Interestingly, the same group also showed that both 
miR-135a and miR-135b are upregulated in many colon cancer cell lines [110]. Tao and 
Xu proposed that APC mRNA is a target for miR-27. They showed that miR-27 
downregulation during osteoblast differentiation is correlated with reduction of -catenin 
levels. Overexpression of miR-27 reduced transcription of a luciferase reporter that 
contains the APC 3’UTR region [111]. In addition, Spears and Neufeld have shown that 
APC and the RNA-binding protein MSI1 are in a double-negative feedback loop [112]. 
They and another group have independently shown that MSI1 is a WNT target gene and 
thus inhibited by APC [112, 113].The Neufeld lab has also shown that MSI inhibits APC 
mRNA translation, reducing APC protein level in the cell. Spears and Neufeld reasoned 
that this putative interaction could play a role in cell fate determination and in 
maintenance of the stem cell population [112].  
At the protein level, Choi et al. have shown that expression of APC with ubiquitin 
protein (Ub) reduces the APC level in the cells. This reduction of APC level is inhibited 
by treating the cells with a specific proteasome inhibitor, which indicates that APC is 
degraded by the ubiquitin proteasome pathway [114]. Harris and Nelson found 2 slowly-
migrating phosphorylated forms of APC in human umbilical vein endothelial cells 
(HUVECs). They showed that inhibiting proteasomes with MG132 results in 
accumulation of both forms, while inhibiting GSK3 and CK1 (both kinases components 
of the -catenin destruction complex) results in disappearance solely of the slower 
migrating form. They found that both forms have different half-lives (3.5 hours for the 
17 
 
slower and 30 hours for the faster migrating forms), through inhibition of production of 
new APC via cyclohexamide (CHX) followed by Western blotting. They concluded that 
APC undergoes phosphorylation and destabilization by the -catenin destruction complex 
[115].  
Colon cancer, inflammation and APC 
Chronic colitis is another major risk factor for CRC. Patients with an 
inflammatory bowel disease (IBD, ulcerative colitis, or Crohn’s disease) have 4- 20 fold 
increased risk or suffering CRC relative to the general population [116]. This colitis-
associated CRC is more aggressive than is sporadic CRC and is fatal in 50% of cases [4]. 
As with sporadic CRC, colitis-associated CRC develops from cells through accumulated 
mutations. However, the nature of the mutated genes and the order of their mutation are 
different [117-119]. The first step in most cases of both colitis-associated and sporadic 
colorectal carcinogenesis is upregulation of WNT signaling, but this results from 
different mechanisms [4]. In sporadic CRC, mutation of both APC alleles results in 
accumulation of -catenin in the cell [7]. In colitis-associated CRC, several inflammatory 
pathways inhibit the -catenin destruction complex or directly activate -catenin, 
resulting in upregulation of WNT signaling [4]. Notably, mutations of APC are still 
detected in colitis-associated CRC, though at later stages of carcinogenesis [117-120].  
Many inflammatory mediators have been linked to the pro-tumorigenic effects of 
inflammation in IBD [116]. These inflammatory mediators include IL-1, IL-1. TNF-, 
IL-17, IL-6, IL-10, and EGF [116]. These mediators are secreted by inflammatory cells 
as well as by epithelial cells, and affect cellular survival, proliferation, apoptosis, and 
differentiation [4, 116]. Many inflammatory pathways converge to activate the NF-B 
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pathway [4]; activation of the NF-B pathway was detected in colonic mucosa from IBD 
patients [121]. In addition, activation of the NF-B pathway was shown to increase 
proliferation and decrease apoptosis in CRC cell lines and mouse colon mucosa [121, 
122]. Moreover, activation of NF-B increases levels of total and nuclear -catenin in 
colonic cells in mice, possibly through inhibition of the -catenin destruction complex 
[122]. Inhibiting NF-B using a specific peptide abolishes this activating effect on 
cellular -catenin [122]. Other signaling pathways that are altered in colitis-mediated 
CRC include AKT, KRAS, BRAF, and  TGF- pathways [4]. Inflammation could also 
increase the rate of DNA mutations by increasing the production of reactive oxygen 
species (ROS) [123, 124]. In addition, chronic inflammation was correlated with histone 
modifications and DNA methylation [125]. The protumorigenic effect of chronic colitis 
has been also linked to prostaglandin (PG) formation through induction of 
cyclooxygenase-2 (COX-2) [126]. COX-2 is the rate-limiting step in PGE2 formation 
from arachidonic acid [125]. Through use of cultured cells and mouse models, PGE2 has 
been shown to promote WNT signaling, increase cellular proliferation, inhibit apoptosis, 
promote angiogenesis, and enhance metastasis [127-130].  
Inflammation and WNT signaling are not completely independent factors. As 
mentioned above, inflammation can activate Wnt signaling through many pathways, 
including NF-and PGE2 [131]. In turn, COX-2 has been shown to be a WNT target 
[132, 133]. Moreover, it has been reported that APC mutations can alter retinoic acid 
metabolism to cause Wnt-independent up-regulation of COX-2 [134]. Upregulation of 
COX-2 is not merely restricted to colitis-associated CRC, but was also detected in 
sporadic cases of CRC [125]. Finally, NSAIDs that inhibit COX-2 activity reduce both 
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sporadic and colitis-associated CRC [135, 136]. These results suggest a role for 
inflammation, possibly caused by interaction with colonic bacterial flora, in sporadic 
cases of CRC [126, 134, 137].  
Modeling colitis-associated CRC in mice 
To facilitate studying colitis-associated CRC, the dextran sodium sulfate (DSS) 
rodent model was developed [138]. This model was described first in hamster, then was 
adapted to both rat and mouse [139]. In this model, colonic inflammation is induced by 
giving mice the resin DSS in a concentration of 1-4% in drinking water for 3- 7 days. 
Following DSS exposure, mice are given untreated water for 2-4 weeks.  This cycle could 
be repeated up to four times [138].  
It is thought that the DSS model closely resembles human ulcerative colitis both 
pathologically and molecularly [140]. Administration of DSS models the acute phase of 
the disease. The pathological changes seen during the first cycle in murine colons include 
loss of the crypt structure and ulceration, symptoms that are also seen in the acute phase 
of human disease [141]. Following the first cycle, mucosal regeneration, crypt branching 
and shortening, glandular disorder, and diarrhea are also seen; these also occur in the 
chronic phase of ulcerative colitis in humans. As with the human disease, mice treated 
with DSS also show an increased incidence of colonic tumors [141, 142]. The incidence 
of tumors in these mice varies based on the protocol of DSS treatment; the incidence is 
about 18% at age 120 days in Swiss mice treated with 4 cycles (7 days each) of 4% DSS 
[142]. More than half of the tumors that develop in DSS-treated mice are flat adenomas, 
similar to those seen in the human disease [142]. Some tumors in this model show 
malignant transformation [142]. Molecular changes in tumors from DSS-treated mice 
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also recapitulate those in colitis–associated colorectal carcinogenesis in human [118, 
142].  
To increase the incidence of colonic tumors in DSS-treated mice, several groups 
adopted administration of a mutagen with DSS [140]. The most commonly used mutagen 
is azoxymethane (AOM) [140]. A single intraperitoneal dose of AOM increases the 
incidence of colonic tumors in mice up to 100% [140]. Another advantage of using AOM 
is that it allows reduction of the DSS dose in mice, and decreases the mortality from 
DSS-associated acute colitis. Again, different groups use different regimens of AOM 
treatment: single or multiple doses of 7.4- 20 mg/kg, but a single dose of 7.4mg/Kg of 
AOM alone is insufficient to induce tumors in mice [140]. AOM induces O6-
methylguanine DNA adduct resulting in GA transitions. -catenin mutations in exon 3 
are detected in most tumors from AOM-DSS-treated mice. These mutations are expected 
to prevent phosphorylation and targeting of -catenin by the destruction complex, 
resulting in cellular accumulation and nuclear translocation of -catenin, and 
upregulation of Wnt signaling [143, 144]. Another commonly detected mutation in 
tumors from AOM-DSS-treated mice is a gain-of-function (activating) mutation of Kras 
codon 12 [143]. As mentioned before, both WNT and RAS pathways are usually 
activated in human CRC [7]. 
Heat-shock response 
Heat-shock response refers to an adaptive response to a sudden change in cellular 
environment (stress), which prevents cellular damage through induction of cellular heat 
shock proteins/ molecular chaperons/ stress proteins [145]. Although first described in 
response to heating, other stresses including oxidative and metabolic stresses also induce 
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the heat shock response. Molecular chaperones have many essential functions in the cell 
under both normal and stress conditions. They bind to unfolded proteins, assist them in 
refolding, prevent them from aggregating with themselves or with other proteins, and 
help to solublilize protein aggregates. Molecular chaperones bind to damaged proteins to 
sequester them, refold them, or target them for degradation if the damage is severe [146]. 
Some molecular chaperones also help in translocation of other proteins to different 
cellular compartment such as mitochondria [147]. These abilities explain why some heat-
shock proteins are constitutively expressed, while others are induced in response to 
cellular stress. Heat-shock proteins are classified by their molecular weight, e.g. HSP70 
and HSP90 are 70 and 90 kDa, respectively. Their activity is energy-dependent, obtained 
by hydrolyzing ATP which is accompanied by cycles of binding and releasing the client 
proteins to help refold them. Heat-shock proteins usually function in complexes with 
other proteins (co-chaperones) and help chaperones in their functions [145, 147].   
Activation of heat-shock factor 1 (HSF1) induces the heat-shock response (figure 1.4) 
[148]. In cells under normal (non-stress) conditions, HSF1 is present mostly in a complex 
with other molecular chaperones, including HSP90 [149]. During stress, the damaged and 
unfolded proteins bind chaperones, resulting in release of HSF1 from the complex [149]. 
HSF1 has a nuclear localization signal that directs HSF1 to the nucleus where it 
undergoes phosphorylation and forms a homo-trimer. The HSF1 trimer binds to a specific 
DNA sequence (heat-shock element, HSE) in the promoters of some genes essential for 
responding to the stress, including those encoding the chaperone proteins themselves. 
Binding of HSF1 to HSE reactivates a paused RNA polymerase to transcribe these genes. 
When the stress subsides, molecular chaperones sequester HSF1 in the cytoplasm to stop 
22 
 
the stress response [148, 150]. Increasing the concentration of cellular unfolded proteins 
(e.g. by inhibiting proteasomal degradation) induces the heat shock response by this same 
unfolded-protein response mechanism [145]. 
Given their importance in cell survival, heat shock proteins are emerging drug 
targets [151]. HSP90 inhibitors have toxic effects on cancer cells; some, such as 17-AAG 
and 17-DMAG, are in clinical trials for treatment of patients with advanced malignancies 
[152]. Many cancer cells depend on molecular chaperones for folding onocoproteins, 
even those that are mutated, chimeric, or overexpressed, such as mutated P53 and 
BRCA1 [151]. Inhibition of HSP90 results in reduction in the level of these oncoproteins, 
and sensitizes these cells for other chemo and radio-therapies [153]. One advantage of 
this strategy is that many proteins in different oncogenic pathways are targeted at the 
same time, decreasing the chance of developing drug resistance [146, 151]. However, the 
wide range of HSP90 client proteins also makes these drugs very toxic for normal cells. 
In addition, inhibiting HSP90 results in release of HSF1 from the cytoplasmic complex, 
which then induces expression of heat shock proteins including HSP90 itself (figure 1.4) 
[149]. This feature reduces the efficacy of HSP90 inhibitors as anticancer agents [154]. 
On the other hand, as molecular chaperones are important in assisting with protein 
folding and preventing protein aggregation, induction of heat-shock response has been 
proposed to be useful for the treatment of neurodegenerative disorders characterized by 
accumulation of toxic protein aggregates [155]. Interestingly, HSP90 inhibitors have been 
used to induce heat shock response in these patients. Again, these agents are toxic and are 
not completely safe [156]. 
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The long-term goal of the Neufeld lab is to understand homeostasis of intestinal 
epithelial cells, and how disruption of the normal control mechanisms leads to intestinal 
tumor formation. In the Neufeld lab, we use different models, including colon cancer cell 
lines and different mouse models, to study APC. In chapter 2, I review different germline 
and conditional Apc-rodent models, and discuss the impact of these models on 
understanding intestinal tumorigenicity and different aspects of APC biology. Dr. 
Neufeld has described the localization of APC to the nucleus. She characterized the 2 
nuclear NLS and 3 NES domains of APC. In order to understand the physiologic role of 
nuclear APC within a whole organism, the Neufeld lab has made a new mouse model in 
which nuclear APC is compromised via inactivating knock-in mutations in both Apc NLS 
domains (ApcmNLS/mNLS mice). In chapter 3, I show that ApcmNLS/mNLS mice have 
upregulated Wnt signaling and increased proliferation in intestinal epithelial cells, 
relative to signaling and proliferation in wild-type mice. I also show that ApcMin/+ mice, 
the most widely-utilized mouse model with a germline Apc mutation causing protein 
truncation, develop more and larger intestinal tumors when they also harbor the ApcmNLS 
mutant allele (ApcmNLS/Min).  In chapter 4, I show that ApcmNLS/mNLS mice have a higher 
susceptibility of colitis-associated colon tumors, through use of the AOM-DSS model. In 
chapter 5, I show data characterizing ApcmNLS/Min mice including testing LOH in 
intestinal polyps and some extra-intestinal phenotypes in these mice. In chapter 6, I 
describe characterization of and screening for polymorphic loci in the promoter of Mom-1 
(Pla2ga2) gene in our mouse colonies. I show that this polymorphic allele is associated 
with increase expression of Pla2ga2 and prolonged survival in the Apc mouse model 
Apc1322T/+. The Neufeld lab has also a long interest in studying different mechanisms 
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controlling cellular APC levels, and how control of these levels could affect intestinal 
tumorigenesis. In chapter 7, I show that induction of the heat-shock response increases 
the APC level in colon cancer cell lines and in mouse intestinal epithelial cells. I show 
also the results of a series of experiments in different mouse models testing the effects of 
the induction of the heat-shock response  on intestinal tumorigenesis. The results suggest 
that induction of the heat-shock response using the novel non-toxic small molecule KU-
32 and the commercially available drug 17-AAG changes intestinal tumor number, size 
and regional distribution in mice. In Chapter 8, I summarize the findings of my studies 
and their implications for our knowledge of APC and colon cancer and discuss some 
future directions of these projects. 
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Figure 1.1: APC structural domains. MCR refers to the mutation cluster region. 
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Figure 1.2: Wnt signaling. (A) In the absence of Wnt, the -catenin destruction complex 
is formed. This -catenin destruction complex phosphorylates -catenin and targets it for 
proteasomal degradation. (B) Wnt ligand binds to Wnt receptor Frizzled (FZ), recruiting 
LRP5/6 Disheveled (DSH) and Axin, inhibiting -catenin destruction complex -catenin. 
-catenin accumulates in the cell and translocates to the nucleus where it works as a 
transcription co-activator with TCF/LEF, inducing expression of Wnt target genes such 
as CyclinD1 and cMyc. (Adapted from Neufeld)   
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Figure 1.3: Role of Wnt signaling in maintaining intestinal structure. A schematic 
diagram for the structure of the small intestine shows that the small intestine is made of 
sac-like invaginations (crypts) and finger-like projections (villi). Stromal cells at the base 
of the crypt base secrete Wnt, maintaining a gradient concentration of Wnt along the 
length of the crypt. At the base of the Crypt with the highest Wnt signaling, stem cells 
divide to maintain stem cell population and also give rise to transient amplifying (TA) 
cells. TA cells divide and migrate along the crypt until the upper 1/3 of the crypt (low 
Wnt concentration) where cells start to differentiate into different intestinal types. The 
structure of the colon is very similar except that colon epithelium does not have villus 
structures.  
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Figure 1.4: Induction of the heat-shock response. Under non-stress conditions, heat-
shock factor 1 (HSF1) is sequestered in a cytoplasmic complex containing heat-shock 
proteins, including heat shock protein 90 (HSP90). When the cells are exposed to 
thermal, metabolic, oxidative, or other stress, HSP90 binds to damaged-unfolded 
proteins, helps to refold them and prevents aggregate formation. Binding HSP90 to 
damaged proteins results in releasing HSF1 from the complex. HSF1 goes to the nucleus, 
where it forms a trimer and undergoes phosphorylation. HSF1 trimer works as a 
transcription factor, inducing the transcription of many proteins including heat-shock 
proteins (heat-shock response). Inhibiting HSP90 via 17- AAG, or increasing unfolded 
proteins via inhibiting the proteasome, also releases HSF1 and induces the heat-shock 
response.  
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Chapter 2 
More than two decades of Apc modeling in rodents 
Abstract 
Mutation in the tumor suppressor gene Adenomatous polyposis coli (APC) is the 
initiating step in most colon cancers. To facilitate studying APC functions in intestinal 
development and tumorigenesis, more than a dozen models have been generated 
including mouse, rat, zebrafish, Drosophila, and C.elegans. This review summarizes the 
phenotypes of 35 different rodent Apc models and knowledge gained using these models 
to study Apc, with particular concentration on the most recently developed models. We 
also discuss variation in phenotypes among different models and the correlation between 
genotype and phenotype.   
APC mouse models 
For over a century, mice have been used to study human diseases and to test 
potential drugs and toxins. Among vertebrates, mice have the advantage of relatively 
short life cycles, large litter sizes, ease of care, and conservation with humans of many 
physiological and pathological processes [1]. The APC protein is well-conserved between 
human and mouse, with 87.9% amino acid identity and 91.9% similarity [2]. In addition, 
all characterized motifs in human APC are conserved in murine Apc [2]. This structural 
conservation predicts functional conservation, and makes the mouse a good model to 
study the physiological role of APC in a whole organism. Mice allow experimental 
dissection of physio-pathological roles of APC in intestinal homeostasis and vertebrate 
development, which are less tractable in other models [3]. 
40 
APC mouse models can be divided into 2 broad categories. In the first category, 
mice have a germline mutation in Apc that results in protein truncation or alteration or 
reduced expression of Apc protein in all tissues (figure 2.1). In the latter category, Apc 
gene mutation is induced only in specific mouse tissues at a particular stage of 
development. The phenotypes of the various Apc mutant mice differ, depending on many 
factors that will be discussed below. 
ApcMin/+ 
The Multiple intestinal neoplasia (Min) mouse was first identified in an 
ethylnitrosourea (ENU) mutagenesis screen, [4] and is the best characterized mouse 
model with a germline Apc mutation [2]. ApcMin mice have a nonsense mutation that 
results in truncation of Apc protein at codon 851 [2]. Since its first description in 1990, 
the ApcMin model has been used extensively to study Apc functions in suppression of 
intestinal tumorigenesis and to investigate tumor prevention strategies. Mice homozygous 
for ApcMin die early in embryonic development, but ApcMin/+ mice display both intestinal 
and extra-intestinal phenotypes [2, 4-6]. In the C57Bl/6J background, ApcMin/+ mice live 
for ~120 days and typically develop between 20-100 polyps in their gastrointestinal tract 
[4]. The intestinal polyp phenotype is 100% penetrant. However, the polyp number can 
vary between one and >200 polyps per mouse. Differences in diet, flora, genetic 
background, and genetic modifiers might account for this variability [7, 8]. The vast 
majority of these polyps are in the small intestine, with a few developing in the colon and 
even fewer in the stomach [4, 5]. Histologically, most tumors in ApcMin/+ mice are benign 
adenomas:  polypoidal, sessile, or papillary in nature, with limited dysplasia and atypia. 
Although these polyps can reach the size of 8 mm in diameter, malignant changes are not 
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typically seen. However, in old ApcMin/+ mice, polyps express molecular markers of 
invasiveness seen in malignant tumors, [9] and areas with limited invasion and carcinoma 
in situ have been observed [4]. In addition, ApcMin/+ mice in hybrid genetic backgrounds 
(F1 B6 X BR6 and B6 X SWR) live longer and develop fewer polyps than do mice in the 
B6 background, but show malignant changes and local metastasis to lymph nodes [10]. 
Together, these data suggest that the short life span of ApcMin/+ mice limits the 
accumulation of other genetic mutations in intestinal tumors that are required for 
progression to invasive carcinoma [10].  
LOH in polyps of ApcMin/+ mice  
In both ApcMin/+ mice and in FAP patients, mutation of the wild-type Apc allele is 
required for adenoma formation. However, the nature and predicted mechanism of the 
second mutation is different in ApcMin/+ mice and in human FAP patients. Luongo et al. 
[11] from the laboratory that developed the ApcMin model, bred a ApcMin/+  B6 strain 
mouse with a wild-type AKR strain mouse. Use of PCR with incorporation of P32 -labeled 
thymine revealed a reduction in the ratio of the frequency of the AKR Apc+ allele to the 
frequency of the B6 ApcMin allele in all tested polyps.  This result suggests that LOH is 
required for polyp formation. Furthermore, adenomas had no change in the copy number 
of 6 other polymorphic markers on B6 chromosome 18, the location of the mouse Apc 
gene, and thus it was concluded that loss of the whole AKR chromosome occurred by 
means of mitotic non-disjunction, without duplication of the B6 ApcMin allele [11].  
Although the occurrence of LOH in polyps from ApcMin/+ mice was confirmed 
later in several other studies, the mechanism of LOH suggested from this initial study 
was challenged by subsequent data. In 2002, Haigis et al., from the same laboratory, used 
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FISH to show diploidy of chromosome 18 and of the Apc locus in polyps from B6 
ApcMin/+ mice [12]. There are two potential explanations for these contradictory results.  
First, in the initial study, it was assumed that polyps from B6 X AKR ApcMin/+ mice 
develop by the same mechanism as in B6 ApcMin/+ mice. This might not be the case. 
Second, technical limitations of PCR quantification at the time of the first study should 
inform cautious interpretation of the results.   
Chromosome 18 is acrocentric in mice, and a single recombination event near the 
centromere will appear as a complete loss and duplication of the whole chromosome 
resulting from a mitotic non-disjunction event [12]. To address this issue, Haigis et al. 
bred ApcMin/+ mice with a mouse that has a fusion of 2 acrocentric chromosomes, 7 and 
18 (Robertsonian translocation of chromosome 7 over 18, Rb9, see figure 2.2). They used 
a natural mutation in the Tyr gene in a heterozygous state on the chromosome 7 arm of 
the Rb9 translocation chromosome as a marker for mitotic events that involve the whole 
chromosome versus one arm of the rearranged chromosome. They assessed LOH of Apc 
on one arm (chromosome 18) and LOH of the Tyr gene on the other arm (chromosome 7) 
of the fused chromosome (Rb9) in polyps that developed in these mice. They found no 
evidence for loss of both arms of the rearranged Rb9 chromosome in 77% of tested 
polyps from these mice. In the remaining 23% of the polyps, they could not differentiate 
between loss and duplication of the whole chromosome versus recombination involving 
both arms of the rearranged chromosome as the underlying mechanism of polyp initiation 
(figure 2.2) [12].  In 2003, the same group showed that the presence of the Rb9 
chromosome is associated with reduced tumor burden in ApcMin/+ mice when placed in 
trans, cis, or in homozygous distribution with the ApcMin allele (figure 2.2C) [13]. They 
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concluded that somatic recombination (rather than complete deletion and reduplication of 
the whole chromosome) is the mechanism of polyp formation in these mice. In this case 
the reduction of mitotic recombination that is seen in Rb9 mice would have been 
expected to reduce LOH and the intestinal adenoma burden [13]. However, because 
translocation of the Rb9 chromosome could also affect chromosomal segregation, 
complete loss and duplication of chromosome 18 in adenomas from ApcMin/+ mice 
without a Rb9 chromosome couldn’t be ruled out.  
More recent evidence supports loss and duplication of the entire chromosome 18 
as the mechanism of LOH in polyps from ApcMin/+ mice [14]. Mutation of one allele of 
Atp5a1, also on chromosome 18, decreases the number of polyps in ApcMin/+ mice if the 
mutant Atp5a1 allelle lies on the same chromosome with the ApcMin allele. Furthermore, 
distribution and histopathological characteristics of polyps are different in mice with Apc 
and Atp5a1 mutations in cis distribution, but not in trans, relative to polyps from ApcMin/+ 
mice with the wild-type Atp5a1 allele. Because mutation of both Atp5a1 alleles is lethal 
to cells, a cell that loses chromosome 18 carrying the wild-type Atp5a1 allele should be 
eliminated and thus, complete loss with or without subsequent duplication of 
chromosome 18 would be prevented if mutations in the Apc and Atp5a1 genes are on the 
same chromosome. In contrast, there would not be such a negative selection against loss 
and reduplication of the whole chromosome if mutated Apc and Atp5a1 are in trans 
distribution. Since polyps that formed in the latter situation were indistinguishable from 
those that developed in ApcMin/+ mice with wild-type Atp5a1 alleles, it was concluded 
that loss and duplication of chromosome 18 is the likely mechanism of LOH in polyps 
from ApcMin/+ mice [14].  
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Analysis of these data suggests that loss of the Apc+ allele with locus diploidy is 
the mechanism of the second Apc “hit” needed for the development of most polyps from 
ApcMin/+ mice in the B6 background. Whether this LOH is the result of somatic 
recombination or complete loss and duplication of chromosome 18 is still not completely 
resolved, however. One potential challenge in characterizing the underlying mechanism 
is that, because chromosome 18 is acrocentric, a single somatic recombination proximal 
to the Apc locus will be difficult to distinguish from complete loss and reduplication of 
the whole chromosome [12].  
Mammary gland tumors 
In addition to intestinal tumors, ApcMin/+ mice also develop mammary tumors, but 
at a much lower penetrance (5%) and at a relatively older age (16 ±3.5 weeks) [6]. 
Histologically, these tumors are usually invasive in nature, with areas of adenoacanthoma 
and adenocarcinoma [6]. ApcMin/+ mice treated with the mutagen ENU, exposed to X-
rays, or with a mutation in the DNA repair gene Myh, have increased mammary tumor 
incidence without affecting tumor morphology, which indicates that Apc mutation alone 
is not sufficient for mammary tumorigenesis [15, 16]. Expression of a stabilized form of 
-catenin in mammary epithelium results in the development of tumors in mice with 
wild-type Apc. This is consistent with a role for Apc in inhibiting mammary 
tumorigenesis via antagonizing the Wnt signaling pathway [6, 17, 18]. Although FAP 
patients also have an increased risk of tumors outside the gastrointestinal tract, including 
desmoid tumors, mandibular osteomas, and retinal dysplasias, these patients do not show 
increased susceptibility to breast cancer [19]. In addition, the pathology of the mammary 
tumors seen in ApcMin/+ mice is not typically seen in humans [6]. However, mutation of 
45 
APC and methylation of its promoter have been detected in up to 70% of cases of breast 
cancer in humans, which indicates a role for APC in suppression of mammary neoplasia 
[20-22].  
Extra-intestinal phenotypes  
Although intestinal polyposis is the dominant feature in ApcMin/+ mice, these mice 
show additional changes in other tissues [4, 23]. There is no evidences that LOH is 
necessary for the extra-intestinal phenotypes of ApcMin/+ mice, which suggests that Apc 
haplo-insufficiency is the underlying mechanism. Anemia was the first extra-intestinal 
phenotype to be described in ApcMin/+ mice and was used to predict intestinal polyposis 
before the establishment of ApcMin genotyping [4]. Although the exact pathogenesis is not 
completely understood, anemia in ApcMin/+ mice  is microcytic-hypochromic, consistent 
with chronic blood loss from intestinal lesions as the underlying cause [4]. Old ApcMin/+ 
mice also develop large spleens with enhanced splenic hematopoiesis, which suggests 
that larger spleens might be an extra-medullary compensatory response to anemia. But 
because larger spleens and anemia are not always correlated in ApcMin/+ mice, a different 
mechanism for large spleen development might be at play [23]. Old ApcMin/+ mice can 
also develop myelodysplastic disease, with increased formation of myeloid, granulocytic, 
and erythroid colonies in the spleen [24, 25]. Other hematological changes seen in 
ApcMin/+ mice include rapid thymus regression, depletion of splenic natural killer (NK) 
cells, and loss of B-lymphocyte progenitors in spleen and bone marrow [26]. Using bone 
marrow transplantation, Coletta et al. showed that these changes result from disruption of 
the bone marrow micro-environment in ApcMin/+ mice [26]. Lane et al. suggested that 
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gradual loss of the quiescent hematopoietic stem cells occurs in ApcMin/+ mice, and might 
reflect haplo-insufficiency for the ApcMin allele [25].  
Other extra-intestinal phenotypes include increased number of degenerated and 
undeveloped ovarian follicles, and under-developed testicular seminiferous tubules [23]. 
The cause of these gonadal changes in ApcMin/+ mice is not known. However, conditional 
truncating mutations of Apc in testicular Sertoli cells result in premature germ-cell loss 
and the absence both of Sertoli cell apical extensions and of the blood-testis barrier. 
These changes were not recapitulated by activating mutations in -catenin consistent with 
a Wnt-independent function of Apc in Sertoli cells [27]. Prosperi et al. described 
disruption and involution of mammary glandular structures in ApcMin/+ pregnant females. 
They correlated these changes with altered proliferation, increased apoptosis, and 
interrupted epithelial integrity and polarization in mammary epithelial cells. They did not 
observe changes in transcription of Wnt targets or in nuclear localization of -catenin. 
They concluded that these mammary gland phenotypes represent a Wnt-independent role 
for Apc [28]. In addition, at 15 weeks, ApcMin/+ mice display a change in their serum lipid 
profile called dyslipidemia, with increased serum levels of triacylglycerol, cholesterol, 
and free fatty acids [29-32]. The exact cause of this dyslipidemia is not understood, but 
hyperlipidemia has been correlated with the activity and level of the lipid regulatory 
nuclear receptors PPAR α,  and γ [30, 31, 33]. Treatment of ApcMin/+ mice with the 
nonsteroidal anti-inflammatory agent indomethacin both decreased polyp number and 
improved dyslipidemia in ApcMin/+ mice [34]. These extra-intestinal phenotypes indicate 
that Apc has roles not only in intestinal epithelial cells, but also in development and 
maintenance of other tissues. 
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Use of the ApcMin model to test the effect of environment, genetic alterations, and 
drugs on tumor formation  
In addition to its use as a model of FAP, ApcMin/+ mice have been used 
extensively as a tumor susceptibility model to test the effect of environmental factors, 
mutations in other genes, and drugs on intestinal tumorigenesis. Such studies have 
increased our understanding of both intestinal tumorigenesis and cancer biology in 
general. Details of these studies are summarized in several excellent reviews [3, 7, 8, 35].  
 Modifiers of Min (Mom) 
Studying phenotypic variation in model organisms of different genetic 
backgrounds is a powerful tool to elucidate other genes contributing to the phenotype. 
These genes are classically termed modifiers [35]. Several modifiers have been described 
that can enhance or attenuate intestinal polyposis in ApcMin/+ mice and are called 
Modifiers of Min (Mom) [7, 35]. The first and most characterized modifier locus is Mom-
1 (Pla2g2a gene) which decreases polyp multiplicity in some mouse strains [36, 37] (see 
chapter 6) [14, 36]. A detailed discussion of these modifiers and the mechanism of action 
could be found elsewhere [35]. 
Mouse models expressing truncated Apc protein longer than ApcMin 
APC is a large multi-domain protein that has been implicated in many cellular 
activities in addition to its role in down-regulating Wnt signaling. Most APC domains 
implicated in targeting -catenin for degradation are in the middle region of APC. 
However, most tumor-associated mutations in APC result in loss of the C-terminal 
regions of APC [38, 39]. Interaction of C-terminal APC regions with DNA and with 
microtubules has been proposed to contribute to tumor suppression [40, 41]. Disruption 
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of the interaction between APC and microtubules affects spindle formation and mitosis in 
colon cancer cell lines and in intestinal epithelial cells in ApcMin/+ mice [42]. In addition, 
ApcMin/Min embryonic stem (ES) cells show chromosomal instability (CIN) [43]. These 
observations led to the proposal that loss of the C-terminal domains of Apc promotes 
intestinal tumorigenesis through induction of CIN [43-45]. Three mouse models with 
truncations of the C-terminal third of Apc have been generated; Apc1638N, Apc1638T, and 
Apc1572T. The Apc1638N mouse was made in 1994 by anti-sense insertion of a neomycin-
resistance gene at Apc codon 1660 resulting in a nonsense mutation at codon 1638 [46]. 
Apc1638N/1638N mice die as embryos. Apc1638N/+ mice develop intestinal polyps, but the 
number of polyps (less than 10) is very small compared to the number in ApcMin/+ mice, 
and polyp distribution is also different (gastric and colonic). Intestinal tumors in 
Apc1638N/+ mice are also invasive, with distant metastasis in the liver detected in one 
mouse. Because these mice live longer than do ApcMin/+mice, the invasive phenotype 
could reflect tumor progression over time. Intestinal tumorigenesis is enhanced in this 
Apc mouse model with mutation in other tumor suppressor genes [47-52]. LOH via loss 
of the entire chromosome 18 was suspected in most tumors from Apc1638N mice [53]. 
Haigis et al. showed, however, that the Apc+ allele is maintained in most polyps from 
Apc1638N/+ mice, which suggests the wild-type Apc allele is inactivated or silenced [54]. 
Desmoid tumors and cutaneous cysts develop in 100% of the Apc1638N/+ mice [55]. In 
humans, desmoid tumors occur in FAP patients [56] and also in patients with an 
attenuated form of FAP (AFAP) resulting from germ-line mutations in the 3’  regions of 
APC [57].  AFAP patients develop only a few polyps, mainly in the duodenum [57-59]. 
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It could be argued that the Apc1638N mouse is not the best model of AFAP, since 
only full-length Apc and not the truncated protein has been detected in these mice [46]. 
The explanation for this might be technical in nature. The antibiotic selection cassette 
used to generate the Apc1638N mice is inserted in reverse orientation. Production of an 
antisense Apc transcript might lead to translation inhibition of truncated Apc in Apc1638N 
could therefore be considered an essentially null allele [55, 60, 61].   
The Apc1638T mouse was generated to overcome this technical issue. With the 
antibiotic-resistance gene (hygromycin) inserted in the same orientation as the Apc gene, 
the expression of truncated Apc could be detected. One surprising finding is that 
Apc1638T/1638T mice are viable, whereas Apc1638N/1638T and ApcMin/1638T are not. 
Apc1368T/1638T mice have only slightly elevated Wnt signaling and do not develop 
intestinal or extra-intestinal tumors. Instead, these mice display post-natal growth 
retardation, nipple-associated cutaneous cysts, and lack preputial glands. The significance 
of these phenotypes is not well-understood, but could indicate a role for the C-terminal 
region of Apc in development. The Apc1638T protein retains all 15 a.a. repeats, 1 SAMP 
motif, and 3 of the 20-a.a. repeats, but lacks 2 of the SAMP motifs and 4 of the 20-a.a. 
repeats [60]. Perhaps the remaining functions of the truncated Apc1638T allele are dose-
dependent, and thus the Apc1368T allele is haplo-insufficient for -catenin regulation.  
More recently, the Fodde group developed the Apc1572T mouse model by deleting 
the first SAMP repeat remaining in the Apc1638T mouse [62]. The truncated Apc protein 
in Apc1572T/+ mice is only 66 amino acids shorter than Apc from Apc1638T mice. However, 
the phenotypes of these two mouse models are very different. Unlike Apc1638T, Apc1572T 
germ-line homozygozity is incompatible with viability. One remarkable feature of 
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Apc1572T/+ mice in a B6 background is that they develop no intestinal tumors, but instead 
develop invasive mammary tumors that can even metastasize to the lungs. While 
mammary tumor morphology and LOH of the Apc allele are similar in both Apc1572T/+ 
and ApcMin/+ mice, the incidence of mammary tumors is much higher in Apc1572T/+ mice; 
100% in virgin females and 30% in males compared to only 5% in ApcMin/+ females. -
catenin activity, as assessed by means of a TOPFLASH reporter assay, is higher in 
Apc1572T/1572T ES cells than in wild-type or Apc1638T/1638T ES cells, but lower than in 
Apc1638N/1638N ES cells.  Apc1572T/+ mice do develop intestinal polyps if they also have a 
Smad4Sad allele, which results in defective TGF- signaling [62].  Because the TGF- 
pathway inhibits Wnt signaling [63], the authors propose that in order to develop, a 
mammary tumor needs a certain level of Wnt signaling which is provided by the Apc1572T 
allele. Increased Wnt signaling resulting from reduced TGFsignal, or from a second 
mutant Apc allele, promotes intestinal polyp formation [62]. Although this model might 
explain the development of intestinal polyps in mice heterozygous for both Apc1572T and 
Smad4Sad [64], it does not explain the high penetrance of mammary tumors in these mice, 
given the low penetrance of mammary tumors in other models with higher Wnt signaling. 
In conclusion, data collected from these three mouse models implicated the C-
terminal portion of Apc in control of mammary tumorigenesis and development (Apc1572T 
and Apc1638T mice). However, these models provide no direct evidence for a role of the 
Apc C-terminal region in suppression of intestinal tumorigenesis. Because Apc1638N is 
virtually a null allele, intestinal polyps developing in these mice do not support or refute a 
specific role for the Apc C-terminus in polyp suppression.    
Apc1309 and Apc1322T/+ mice 
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Although ApcMin/+ mice have been used to model APC mutation in humans, 
similarly sized APC truncations are uncommon in both inherited and sporadic human 
colon cancers. Mutations in APC associated with colon cancer typically truncate the C-
terminal half of the protein, leaving the first 20-amino acid (20-a.a.) repeat intact in at 
least one APC allele [65]. As this 20-a.a. repeat can bind to -catenin, one would predict 
differences in cells expressing shorter Apc truncations, such as ApcMin , and cells with 
longer APC (as in human CRC) [66, 67]. The Apc1309 and Apc1322T mouse models were 
generated to express truncated Apc that retains the first 20-a.a. repeat [65, 68, 69]. The 
Apc1309 mouse model was generated by the Noda group in the mid-1990s, while the 
Apc1322T mouse model was made in 2009 by the Tomlinson group. As with ApcMin/+, both 
Apc1309/+ and Apc1322T/+ mice develop polyps mainly in the small intestine, but these 
polyps are more proximal than those from ApcMin/+ mice. Measuring the amounts of 
transcripts of Wnt target genes, Lewis et al. showed that Wnt target gene expression is 
lower in polyps from Apc1322T/+ mice than in polyps from ApcMin/+ mice, as expected 
since the Apc1322T protein include the first 20-a.a. repeat[70].  However, Apc1322T/+ mice 
develop more polyps (> 200 polyps by 12 weeks) and have more intestinal stem cells 
than do ApcMin/+ mice [69]. These results support the “just right” hypothesis that predicts 
that inclusion of the first 20-a.a. repeat in truncated APC proteins will result in only slight 
elevation of Wnt signaling, which is more advantageous to tumor growth than is 
elevation of Wnt signaling to its highest possible level [67]. As to extra-intestinal 
phenotypes, Apc1322T/+ mice develop anemia and large spleens, similar to ApcMin/+ mice 
[69].  Apc1309/+ mice develop an average of ~ 35 intestinal tumors, mainly in the small 
intestine at the age of 12-14 weeks, and have hyperlipidemia that develops at an even 
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earlier age than in ApcMin/+ mice [29, 68]. Potential explanations for this large 
discrepancy in polyp number between mouse models that differ in truncated Apc length 
by only 13 amino acids include the influence of environmental factors, genetic 
background, and experimental procedures, described in more detail later. 
Mouse models expressing truncated Apc protein shorter than ApcMin 
Seven mouse models with mutations upstream to that found in ApcMin have been 
described.  ApcΔ242 [71], ApcΔ474 [72], and ApcΔ716 [73-75] mice have Apc truncation 
mutations at codons, 242, 474, and 716, respectively, while ApcΔ580 [76], Apc580D  [77], 
and ApcΔ14 [78] mice each have a deletion of exon 14, resulting in a frameshift and a 
nonsense mutation at codon 580. ApcΔ15 mice have a deletion of the last Apc exon, 
including the 3’UTR region [79]. These seven mouse models share many phenotypes 
with ApcMin/+ mice, including embryonic lethality in the homozygous state, and in 
heterozygous mice, development of anemia and intestinal polyps predominantly in the 
small intestine that are indistinguishable at the microscopic level [71-79]. Although polyp 
number varies between these seven models (Table 2.1), in most cases, direct comparative 
studies have not been performed. Mammary tumors have been reported for 14.3% of 
ApcΔ580, 18.5% of ApcΔ474, and 9% of ApcΔ14 mice [72, 76, 78]. Is the phenotypic 
variation in polyp number in these mouse models due to the progressive deletion of 
particular Apc domains (see figure 2.1). The ApcΔ716 protein is 134 a.a. shorter than the 
ApcMin protein, and only lacks a C-terminal portion of the armadillo repeat domain. 
Although the three-fold increase in polyp number seen in ApcΔ716/+ mice compared to 
ApcMin/+ mice might result from interruption of the armadillo repeat domain, ApcΔ242/+ 
mice, which have a truncating Apc mutation that eliminates the entire armadillo repeat 
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domain, develop only twice the number of polyps as do ApcMin/+mice.  Furthermore, 
ApcΔ580/+, Apc580D/+, ApcΔ14/+ and ApcΔ474/+ mice, which have truncating mutations in the 
middle of the armadillo repeat domain, have reported intestinal polyp numbers similar to 
that seen in ApcMin/+ mice (Table 2.1). 
 
54 
 
Table 2.1: intestinal phenotypes in mice with truncated Apc longer than ApcMin 
 
 
Mouse 
model 
Polyp 
number 
ApcMin/+  
Polyp 
number* 
Notes Ref 
ApcΔ716 256±55 1/3 of 
those in  
ApcΔ716 
 [75] 
ApcΔ474 123±9.6  No comparative data to ApcMin mice [72] 
ApcΔ242 177±30 106±28  [71] 
ApcΔ14 36±29 34±18 Different distribution than ApcMin/+, 
number of polyps increases in germ-free 
environment  
[78] 
ApcΔ15/+ 184.7 - Tumors are mainly in the ileum, no 
comparative data to ApcMin mice 
[79] 
ApcΔ580 120±37 - No full-length or truncated Apc proteins 
were detected the polyps 
[76] 
* included in the same study 
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Complete deletion of Apc 
The majority of APC mutations seen in CRCs fall into a region referred to as the 
mutation cluster region (MCR), and result in truncation of the C-terminal half of APC 
[80]. Complete deletion of APC has been reported in FAP syndrome only rarely [81, 82], 
leading to the hypothesis that N-terminal APC truncations enhance tumorigenicity in a 
dominant-negative manner. To test the requirement of truncated APC for tumor 
formation, Cheung et al. made a mouse model with complete deletion of all 15 Apc exons 
(ApcΔe1-15) [83]. ApcΔe1-15/+ mice develop intestinal polyps of the same distribution and 
morphology as those seen in ApcMin/+ mice, but with increased frequency. Polyps from 
ApcΔe1-15/+ mice had lower levels of Apc+ mRNA compared to normal tissue, consistent 
with a requirement for loss of the wild-type allele for intestinal tumor development. 
ApcΔe1-15/+ mice also develop more severe anemia than do ApcMin/+ mice, and one ApcΔe1-
15/+ mouse developed a mammary tumor. Female ApcΔe1-15/+ mice showed more severe 
phenotypes than did males. Polyps from ApcΔe1-15/+ mice had lower mRNA levels of Wnt 
target genes Axin2 and c-Jun, and -catenin than did polyps from ApcMin/+   mice [83]. 
Although puzzling in terms of the underlying mechanism, this observation is consistent 
with the hypothesis that there is a level of Wnt signaling optimal for polyp formation, and 
Wnt signling in excess of this level inhibits polyposis [83].  
Apc mouse models with interstitial Apc mutations  
Two mouse models have been recently described in which the engineered 
mutations result in changes within, rather than truncation of, Apc protein:  ApcmNLS/mNLS 
and ApcΔSAMP mouse models. 
 ApcmNLS/mNLS model 
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Apc is perhaps best known as a Wnt signal antagonist. In this capacity, Apc is a 
component of a cytoplasmic complex that targets the oncoprotein -catenin for 
proteasomal degradation [38]. APC also shuttles between the nucleus and the cytoplasm, 
aided by at least 2 nuclear localization signals (NLS) and 5 nuclear export signals (NES) 
[84]. Studies using cultured cells indicate that APC and -catenin can interact in the 
nucleus, resulting in transcriptional repression of Wnt target genes and inhibition of 
cellular proliferation [85, 86]. In addition, nuclear APC interacts with Topoisomerase II, 
a critical enzyme required for DNA replication and a target for traditional cancer 
chemotherapeutics [87]. Moreover, APC has a role in DNA repair and synthesis [88, 89]. 
To study the role of nuclear APC in tissue homeostasis and tumor suppression, a mouse 
model was generated in which nuclear import of Apc is compromised via the introduction 
of mutations into both NLSs (ApcmNLS)  [90]. ApcmNLS/mNLS mice are viable, with no 
alterations in lifespan.  Compared to Apc+/+ mice, intestinal epithelia from ApcmNLS/mNLS 
mice were more proliferative and showed higher levels of Wnt target gene mRNA. In 
addition, ApcMin/+ mice develop more and larger intestinal tumors when they also harbor 
the ApcmNLS allele (ApcmNLS/Min). Together, studies using the ApcmNLS model support a 
role for nuclear Apc in inhibition of proliferation, Wnt signaling, and tumorigenesis [90]. 
ApcΔSAMP model 
To directly examine the contribution of the Apc C-terminus to tumor suppression 
in the Apc1322T/+ mouse model, the Tomlinson lab generated a mouse that expresses Apc 
lacking the amino acids 1322 to 2005 (ApcΔSAMP) [91]. This Apc deletion eliminates all 
but the first 20-a.a. repeat and all SAMP motifs, but retains the C-terminal region of Apc. 
Phenotypes of the Apc1322T/+ and ApcΔSAMP mice were identical with regard to polyp 
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number, distribution, size, and morphology, severity of dysplasia, differentiated and stem 
cell populations, and expression of Wnt target genes. These authors concluded that the C-
terminal region of Apc is not involved in the suppression of intestinal adenoma in mice 
[91].   
Changing the level of Apc expression  
The Taketo laboratory generated two Apc mouse models with reduced Apc 
expression by inserting a neomycin cassette into Apc intron 13 in either reverse 
orientation (ApcNeoR) or forward orientation (ApcNeoF) [92, 93].  The neomycin cassette 
disrupts an enhancer and reduces the level of full-length Apc expressed from the mutant 
allele to 20% of normal levels for ApcNeoR , and to 10% for ApcNeoF. Both alleles are 
embryonically lethal in the homozygous state. By the age of 15 months, ApcNeoR/+ and 
ApcNeoF/+ develop intestinal polyps with relatively low incidence (19% and 50%, 
respectively) and multiplicity (0.26±5.4 and 1.09±8.5 polyps per mouse, respectively). 
The polyps in ApcNeoR and ApcNeoF mice display loss of the wild-type Apc allele and have 
less -catenin stability and accumulation of nuclear -catenin than do polyps from 
ApcΔ716/+ mice [92, 93].   
A transgenic mouse expressing truncated Apc  
Based in part on the tendency of APC mutations in severe forms of FAP 
syndrome to result in truncation of the C-terminal half of Apc, and the ability of the 
truncated form of APC to bind to the full-length allele, it was proposed that particular 
APC truncations act in a dominant-negative manner [94]. A direct test of this hypothesis 
revealed no increased polyp susceptibility in mice carrying a transgene encoding Apc 
amino acids 1-716, even though the truncated Apc protein was detected in intestinal cells. 
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It is possible that dominant -negative Apc truncations lead to increased CIN and 
enhanced loss of the wild-type allele. Since mice in this experiment had two wild-type 
Apc alleles, loss of one would still leave one functional Apc allele and thus no increase in 
polyp formation.  To explore this possibility, the transgene for truncated Apc was 
introduced into ApcΔ716/+ mice [73]. Because intestinal tumor number, distribution, and 
morphology were the same in ApcΔ716/+ mice with and without the truncated Apc 
transgene, it was concluded that truncated Apc does not act in a dominant-negative 
manner [73].  
Conditional Apc mouse models 
 
Mouse models with germline Apc mutations have been useful to probe many 
aspects of Apc biology, especially in intestinal tumorigenesis. However, most of these 
models are limited by a short life span, the predominance of intestinal phenotypes, and 
embryonic lethality in the homozygous state. To study functions of Apc at different 
developmental stages and in organs other than the intestine, investigators have developed 
mice with conditional Apc mutations [95]. A critical component of most conditional 
systems is Cre recombinase, which induces recombination between two loxP1 sites, to 
cause excision of the DNA between these sites. In conditional Apc mouse models, loxP1 
sequences are inserted into introns of the mouse Apc gene flanking particular exon(s). In 
the presence of Cre, excision of the lox-flanked DNA leads to a frameshift mutation and 
truncation of the Apc protein. The specificity of this Apc mutation is achieved by placing 
Cre under control of a tissue- or developmental stage-specific promoter or an inducible 
promoter, or by infecting tissues with Cre-expressing Adenovirus [96]. Table 2.2 
summarizes different conditional Apc mouse models. 
Table 2.2: Mouse models with conditional Apc mutations 
Mouse 
Apc 
mutation 
Organ 
Developmental 
stage 
Notes Ref 
Apc580S Floxed exon 
14 results in 
stop codon 
at a.a. 580 
Colon and 
rectum 
Adult Cre is delivered via 
Adenovirus vector 
injected in the colon 
through the anus. 
Develop colon 
adenomas in the 
distal 3 cm of the 
colon. Malignant 
transformation is seen 
in old lesions. 
[77] 
AhCre-
Apcfl/fl 
Floxed exon 
14 results in 
stop codon 
at a.a. 580  
Small 
intestine, 
large 
intestine. 
Possibly the 
liver 
Adult Cre is expressed 
under Cyp1A 
promoter when mice 
were injected with -
naphthoflavone. 
Upregulation in Wnt 
signaling. Intestinal 
cell differentiation, 
proliferation, 
migration, and 
apoptosis were 
disrupted. Mice died 
after 4 days after 
induction. 
[97] 
Math1-Cre-
ApcFl/Fl 
Excision of 
the last exon 
Cerebellum Day 12.5 
embryonic  
Cre is expressed 
under Math-1 
promoter in Granule 
cells in the 
cerebellum. No 
tumor, cerebellar 
cortical hypoplasia, 
impaired motor 
coordinator and 
ataxia  
[98] 
MMTV-
Cre- 
Apcflox/flox 
Ptenflox/flox 
Floxed exon 
14 results in 
stop codon 
at a.a. 580 
Salivary 
glands 
?? Cre is expressed 
under MMTV 
promoter on B6X129 
background. In this 
background, MMTV 
promoter is active in 
salivary gland and 
less active in 
mammary gland. 
[99] 
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Salivary gland tumors 
only with Pten 
deletion.   
LckCre-
Apclox/lox468 
Excision of 
exons 11 
&12 
resulting in 
frameshift 
splicing 
exons 10-13 
and 
truncated 
Apc (468 
a.a.)  
Thymus Starts at CD44-
CD25+ double-
negative 3 
(DN3) stage 
and complete 
by DN4 stage of 
lymphocyte 
development  
Cre is expressed 
under Lck promoter 
during the 
development of 
thymocytes. Thymic 
atrophy, reduced T-
lymphocyte receptor 
rearrangement, 
increasing 
proliferation of pre-T 
cells, chromosomal 
segregation defects, 
T-cell developmental 
delay. 
 
[100
] 
K14-Cre-
ApcCKO/CKO 
 
K14-Cre-
ApcCKO/+ 
 
Floxed exon 
14 results in 
stop codon 
at a.a. 580 
Ectodermal 
derived 
tissues 
including 
mammary 
glands 
Day 9.5 
embryonic 
Cre is expressed 
under Keratin-14 
promoter in 
epidermal tissues. 
Growth retardation, 
premature death, 
abnormalities in 
epidermal derived 
tissues including: hair 
follicles, cornea, and 
teeth.  Thymus 
hypoplasia, squamous 
metaplasia in the 
thymus 
(homozygous),  
mammary tumors in 
76.5% in 
heterozygous 
females. 
[76, 
101] 
Ahmr2-
Cre-
Apcflox/flox 
Floxed exon 
14 results in 
stop codon 
at 580 
Uterine 
stroma (in 
females) 
Sertoli cells  
(in males) 
Fetus 
 
Cre is expressed 
under anti-Mullerian 
hormone type II 
receptor in 
mesenchyme of fetal 
Mullerian duct. 
Progressive uterine 
hyperplasia and 
endometrial 
carcinoma. Apc has a 
[27, 
102] 
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cell-non-autonomous 
role as an 
endometrial tumor 
suppressor protein. 
Large spleens (in 
females);  
 abnormal 
spermatogenesis, loss 
of the apical part of 
Sertoli cells, 
disruption of tight 
junctions, no tumors 
(in males).     
ApcΔex14/ 
Δex14 
Floxed exon 
14 results in 
stop codon 
at a.a. 580 
Liver  Adult Cre under CMV 
promoter is delivered 
using Adenovirus 
injected 
intravenously. High 
viral dose causes 
hepatomegaly, 
hepatocellular 
hyperplasia and 
death. 
Low viral dose 
causes hepatocellular 
carcinoma  
[103
] 
Vil-
CreERT2-
Apclox/lox 
Floxed exon 
14 results in 
stop codon 
at a.a. 580 
Small and 
large 
intestine 
Adult Cre is expressed 
under Villin promoter 
when the mice are 
injected with 
Tamoxifen. 
Upregulation of Wnt 
signaling, increased 
proliferation and 
apoptosis, decreased 
migration, increased 
number of cells 
committed to Paneth 
cell differentiation. 
[104
] 
AhCre-
Apcfl/fl 
Floxed exon 
14 results in 
stop codon 
at a.a. 580  
Kidney Day 14.5-18.5 
embryonic 
Cre is expressed 
under Cyp1A 
promoter with no -
naphthoflavone 
induction. Renal 
carcinoma in ~1/4 of 
mice at 6 months, 
[105
] 
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increased incidence 
with co-existence of 
p53 mutations 
WAP-Cre-
ApcCKO/CKO 
 
WAP-Cre-
ApcCKO/+ 
 
Floxed exon 
14 results in 
stop codon 
at a.a. 580 
Lactating 
epithelial 
cells 
Lactation Cre is expressed 
under WAP promoter 
(Whey Acidic 
Protein). Mammary 
tumors in nulliparous 
and multiparous 
females (less 
than20%) 
[76] 
Col2a1-
Cre-
Apc15lox/15lox 
Excision of 
the last exon 
Mesenchym
al cells 
Day 9.5 
embryonic in 
sclerotome   
Day 12.5- 16.5 
embryonic in 
chondrogenic 
and osteogenic 
cells.  
Cre is expressed 
under Col2a1 
(collagen-2a-1) in 
mesenchymal cells. 
Embryonic lethal, 
defective cartilage 
and bone 
differentiation  
[106
] 
 
ApcCKO/CKO
-LSL-Kras 
Floxed exon 
14 results in 
stop codon 
at a.a. 580 
Distal colon Adult Cre is delivered via 
adenovirus vector 
injected in the colon 
through the anus, 
resulting in excision 
of Apc exon 14 and 
expression of mutant 
constitutively active 
Kras. 
Adenocarcinoma in 
the distal colon that 
show spontaneous 
metastasis to the liver 
after 24 weeks 
[107
] 
Ahmr2-
Cre-
Apc15flox/15flo
x 
 
Excision of 
the last exon 
Uterine 
myometriu
m  
?? Cre is expressed 
under anti-Mullerian 
hormone type II 
receptor in 
mesenchyme of fetal 
Mullerian duct. 
Myometrial defects, 
dystocia, reduced 
number of 
endometrial glands 
[108
] 
Pgr-Cre-
Apcflox/flox 
Excision of 
the last exon 
Uterine 
endometriu
m& 
?? Cre is expressed 
under progesterone 
receptor. Myometrial 
[108
] 
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myometriu
m 
and endometrial 
defects, 
endometriosis 
interna-like changes 
FabplCre;
Apc15lox/+ 
Excision of 
the last exon 
Distal small 
intestine and 
large 
intestine 
?? Cre is expressed 
under fatty-acid 
binding protein-1 
(Fabp1) promoter in 
some cells. Develop 
adenoma and 
adenocarcinoma 
mainly in large 
intestine 
[79] 
Pms2-
ApcCKO/+ 
Floxed exon 
14 results in 
stop codon 
at a.a. 580 
 ?? Out-of-frame Cre that 
reverts back to frame 
stochastically. Rate 
of transformation is 
higher in 
Apc1638N/CKO and 
ApcMin/CKO mice 
relative to ApcCKO/+ 
mice 
[109
] 
References marked by the same color refer to studies done using the same Apc 
conditional mutation 
What have we learned and what remains to be learned using Apc mouse models 
The Apc mouse models have been valuable tools for studying the role of Apc in 
intestinal homeostasis and tumor suppression. They have aided in discovery of various 
pathways important in colon carcinogenesis. Apc mouse models were also useful for 
testing the effect of various environmental and genetic factors on intestinal 
tumorigenesis, and for testing potential chemoprevention and therapeutic agents. The 
many positive contributions of Apc mouse models have been reviewed elsewhere [80, 
110]. As with most experimental systems, deeper investigation of Apc mouse models has 
led to increased understanding, but has also revealed more questions to be answered.  
Some of these mysteries and challenges for future investigation will be highlighted here. 
What variables control polyp distribution in intestines of different Apc mouse 
models? 
Tumors in the first Apc mouse model, ApcMin/+, occur mainly in the small 
intestine, while germline mutation of APC in FAP patients results in tumors 
predominantly in the large intestine. The Apc rat model (PIRC) has tumors in both small 
and large intestines [5, 57, 111]. In addition to this inter-species variation, mouse models 
with different germline Apc mutations show different distributions of intestinal polyps.  
Analysis of ApcMin/+ mice with different genetic backgrounds has led to the 
explanation that polyp distribution is somehow linked to the mechanism by which the 
wild-type Apc allele is lost [54]. Haigis et al. showed that in a B6 background, ApcMin/+ 
mice develop polyps mainly in the ileum, and loss of the wild-type Apc allele occurs by 
means of LOH. In an AKR background, ApcMin/+ mice develop polyps predominantly at 
the ileo-cecal junction, and inactivation of the wild-type Apc allele is achieved through 
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allelic silencing. In the B6 background, ApcMin/+ mice with additional mutations that 
inactivate the mismatch repair gene Mlh develop polyps all over the small intestine, and 
loss of the wild-type Apc allele is achieved through a point mutation. Apc1638N/+ mice 
develop polyps in a similar distribution, and appear to retain the wild-type  Apc allele 
[54]. 
Mechanistically, two models that are not mutually exclusive could account for the 
correlation between polyp distribution and loss of the wild-type Apc allele. In the first 
model, the molecular machinery in different intestinal regions determines the mechanism 
of the second Apc “hit” and hence the distribution of polyps. This model is supported by 
the finding that polyps in which the wild-type Apc allele is inactivated by the same 
mechanism (eg. ApcMin/+ Mlh-/-  and Apc1638N/+ mice) have the same distribution [54]. 
However, the finding that both Apc1322T/+ and ApcMin/+ mice lose the wild-type Apc allele 
through LOH, yet have different polyp distributions, does not support this model. A 
second model proposes that polyp growth is dictated by the Apc status but also by the 
particular environment of the different intestinal regions, independent of the mechanism 
of the second Apc mutation. Supporting this hypothesis, ApcΔ716/+ mice with an additional 
mutation of Cdx2 exhibit more colonic and fewer small intestinal polyps, yet whether or 
not Cdx2 is mutated, loss of the wild-type Apc allele occurs via LOH [112]. Similarly, a 
colonic shift of polyps has been described in ApcMin/+ mice with an additional BubR1 
mutation, although the mechanism of loss of the wild-type Apc allele in these mice was 
not reported [113]. Mutation of both Cdx2 and BubR1 increases chromosomal instability 
and changes the proliferation and apoptotic indices in intestines of ApcΔ714/+ and ApcMin/+ 
mice, respectively [112, 113]. Further support for the second model comes from ApcMin/+ 
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mice in a 129/Sv background, where additional mutations that inactivate Smad3 result in 
more colonic tumors than in ApcMin/+ mice; yet in both cases, loss of the wild-type Apc 
allele is achieved through LOH [114].  Finally, PPAR agonists increase colonic but not 
small intestinal tumors in ApcMin/+ mice [30, 31]. PPARis expressed in higher quantities 
in the colon and cecum relative to the small intestine, which might account for this 
differential effect [31].  
Perhaps some of these mechanisms can be clarified by studying ApcMin-FCCC mice 
that were generated by mating C57Bl/6J ApcMin/+ mice with C57Bl/6JNIcr mice. ApcMin-
FCCC/+ mice develop more colon polyps than do ApcMin/+ mice, but the molecular basis 
behind this polyp shift has not been determined [115]. Further clarification of the 
underlying mechanism that controls polyp distribution might be achieved through careful 
analysis of ApcΔ14/+ and Apc580D/+ mice, which carry the same mutation but appear to 
have different polyp distributions. ApcΔ14/+ mice develop more colonic polyps than do 
ApcMin/+ mice, and Apc580D/+ mice develop a similar number of colonic polyps as do 
ApcMin/+ mice [76, 78]. An important caveat to consider is that there are no published 
studies that directly compare Apc580D/+ and either ApcΔ14/+ or ApcMin/+ mice. 
Why do different Apc mutations result in altered multiplicity of intestinal polyps?  
There is evidence that variation in intestinal polyp distribution among different 
mouse models can be explained by the nature of the Apc mutations in theses polyps. We 
propose that differences in polyp number in the various mouse models results from one or 
more of the following contributing factors: 
1- Different rates and mechanisms of wild-type Apc allele loss (e.g. LOH, mutations of 
the wild-type copy of Apc, gene silencing).  
67 
As discussed above, the mechanism of loss of the second wild-type Apc allele is 
different in different Apc mouse models. Because this second Apc “hit” is thought to be 
required for polyp initiation [11, 53, 75], the rate at which second hits occur will directly 
affect the number of intestinal polyps. Increasing the expected rate of these second “hits” 
through introduction of genomic instability, X-ray exposure, or injection with a mutagen, 
significantly increases the number of polyps in ApcMin/+ and Apc1638N mice [16, 47, 52, 
116, 117]. Mutations in Apc might also induce CIN, which would theoretically affect the 
rate of the wild-type Apc allele loss [44].  
In Apc1638N/+ mice, which develop relatively few intestinal polyps, the second Apc 
“hit” is usually an inactivation of the wild-type Apc allele, which is predicted to be a rare 
event [54]. On the other hand, ApcMin/+ mice, where the wild-type Apc allele is lost by 
means of a more frequent LOH event, develop considerably more polyps [54]. Loss of 
the wild-type Apc allele in both ApcMin/+ and Apc1322T/+ mice, however, is reported to 
occur via LOH, yet these two mouse models have widely different polyp numbers [69]. 
Furthermore, several groups have reported that although loss of both Apc alleles is 
required to activate Wnt signaling, this Apc loss is not sufficient for full activation of Wnt 
signaling (as assessed through nuclear translocation of -catenin) [118-120]. Although 
the mechanism and rate by which the wild-type Apc allele is lost might contribute to the 
control of intestinal polyp number in Apc mouse models, it is unlikely that these are sole 
defining parameters.  
2- Different rates of polyp growth due to differences in Wnt signaling  
Polyps must reach a certain size to be detectable. If two polyps are initiated at the 
same time, the more rapidly growing polyp will be detectable earlier than will be the 
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slowly growing polyp. The most recognized function of Apc is to antagonize the Wnt 
signaling pathway through inhibition of -catenin’s activity as a transcription co-factor 
[38]. As Wnt signaling drives cellular proliferation, we might expect that mice with 
different Apc mutations, and therefore different levels of Wnt signal activation, would 
display corresponding changes in cellular proliferation. This simplistic interpretation is 
challenged by findings in the Apc mouse models.  First, the correlation between Wnt 
signaling activity and cellular proliferation does not appear to be linear. On one hand, the 
frequency of polyps from Apc Δ716/+ mice, which have highly elevated Wnt signaling, is 
higher relative that of ApcMin/+ mice with less Wnt signal elevation [74]. Polyps from 
ApcNeoR/+ and ApcNeoF/+ mice, which have less -catenin stability and accumulation of 
nuclear -catenin, are also less frequent than are polyps of ApcΔ716/+ mice with more Wnt 
signal elevation [92, 93]. However, Apc1322T/+ and ApcΔe1-15/+ mice have more polyps than  
do ApcMin/+ mice, yet the level of Wnt signaling is higher in ApcMin polyps, consistent 
with the “just right hypothesis” [70, 83]. Second, the correlation between mutations in 
Apc and Wnt signaling activity is not fully understood. For example, complete deletion of 
Apc in polyps results in less Wnt signaling activity than in polyps genotyped as 
ApcMin/Min [83]. Further, Wnt signal up-regulation in ApcmNLS/mNLS and Apc1638T/+ mice 
does not result in robust polyp development [60, 90]. Direct comparison of Wnt signaling 
activities and proliferation rates in ApcneoF/+, ApcneoR/+, ApcmNLS,mNLS, Apc1638T/+, 
Apc1322T/+ , and ApcΔe1-15/+ mice would help to establish the contribution of Wnt signaling 
and polyp growth to phenotypic variation. Finally, ApcΔ14 and ApcΔ242/+  mice were 
reported to exhibit more severe intestinal polyposis than do ApcMin/+ mice [71, 72, 78]. 
ApcΔ14 and ApcΔ242/+  mice have mutations 5’ to that of ApcMin/+ mice, and Apc should 
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therefore lack portions of the armadillo repeats. A direct assessment of Wnt signaling 
between ApcΔ14, ApcΔ474/+, and ApcΔ242/+ mouse models would be informative.   
3- Different abilities to evade growth inhibitory effects  
Another explanation of variation in polyp number among different Apc mouse 
models is negative selection of particular Apc genotypes. This negative selection could 
contribute to the “Just right” hypothesis. Support for negative selection contributing to 
polyp phenotypes is provided by the observation that addition of Cdx2 or BubR1 
mutations to ApcΔ716/+ or ApcMin/+ mice, respectively, results in reduced polyp multiplicity 
and increased apoptotic indices in the small intestines, despite the increased proliferation 
index in these cells [112, 113].  
4- Distinctive effects on differentiation  
Another possible source of differences in intestinal polyp number in different Apc 
mouse models is the effect of Apc genotypes on enterocyte differentiation. For instance, 
compared to ApcMin/+ mice, Apc1322T/+ mice have a higher proportion of Paneth cells and 
cells that express stem cells markers (Lrg5, Bmi1, Msi1 and CD44), not only in 
adenomas (presumably the result of LOH) but also in apparently normal intestinal 
epithelial cells [70]. It is possible that different cell fates resulting from different Apc 
genotypes alter tumor initiation or growth. Again, Wnt signaling is one of several factors 
proposed to affect differentiation. 
5- Contributions of other genetic or environmental factors with potentially differential 
effects dependent on genotype  
The effect of genetic and environmental factors on intestinal polyp multiplicity in 
Apc mouse models, particularly in ApcMin/+ mice, has been well established. Polyp 
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multiplicity in ApcMin/+ mice varies greatly (20-100/mouse) across laboratories [7, 35]. 
This inconsistency might result from variations in diet, emergence of genetic modifiers, 
and even from different methods of polyp detection. The many genetic modifiers 
described in ApcMin/+ mice potentially have different effects, dependent on the particular 
Apc allele, although this has not been examined thoroughly. In addition, modifier genes 
are present and can even emerge in what is considered a congenic strain [121]. 
Environmental factors, such as intestinal flora, might also contribute to phenotypic 
variation [8]. While intestinal flora appear to slightly increase the number of polyps in 
ApcMin/+ mice [122], ApcΔ14/+ mice raised in pathogen-free conditions showed significant 
increases in intestinal polyp number. It is important to note that mice with Apc mutations 
might respond differently to intestinal flora than do wild-type mice [123]. Another major 
environmental factor that clearly affects the mouse phenotype is diet. The effect of diet 
on the number of polyps in ApcMin/+ mice has been shown in several different studies 
[124-126]. Although typically defined, the concentration of various vitamins, fiber, and 
total fat varies greatly between laboratory mouse diets. In our own experience, switching 
the mouse diet from Lab diet 5001 (Purina) to Harlan 2018 had a dramatic effect on 
polyp multiplicity in our ApcMin/+ mouse colony. Notably, the new diet has increased fat 
by 24% and decreased fiber, vitamin D, and folic acid by 42%, 67%, and 44%, 
respectively. We compared the number of polyps in 10 ApcMin/+ mice fed the new diet to 
the recorded number of polyps in 25 age-matched mice on the old diet. We found that the 
polyp burden per mouse significantly increased from 45.9±4.5 in ApcMin/+ mice on the 
old diet to 81±9.3 in ApcMin/+ mice on the new diet (p= 0.0006).  As a second dramatic 
example from personal experience, we obtained two male Apc1322T/+ mice from the 
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Tomlinson laboratory at age 5 weeks. At the age of 16 weeks, the number of polyps in 
one mouse was only 50% of the number reported by the Tomlinson group [69]. By the 
second generation of breeding with our C57BL/6J mice, the Apc1322T/+ mice had roughly 
one-third the number of polyps originally reported.  This informal observation is 
reminiscent of the epidemiological study that showed that the incidence of colon cancer 
in U.S. immigrants moved toward that of U.S. natives, with second-generation 
immigrants trending even closer to that of US natives [127]. Diet likely plays a major 
factor in the phenotypic variation from one laboratory to another. Unfortunately, these 
inter-laboratory variables confound direct comparison of the phenotypes of different 
mouse models studied in different laboratories.  
6- Differences in cellular migration and adhesion  
Apc interaction with cytoskeletal components, including actin filaments and 
microtubules, is thought to affect cell adhesion and migration [41, 128]. It was predicted 
that decreased cellular adhesion and migration in cells with APC mutations would 
enhance tumor formation [129]. Apc interacts with cytoskeletal protein through its C-
terminal domain, which is absent in most Apc mouse models (figure 2.1). Adding the C-
terminal Apc domain to Apc1322T (as in ApcΔSAMP mice) does not change the phenotype 
[91]. However, it has been proposed that effects on the cytoskeleton alter tumor 
progression at later stages (e.g. invasion and metastasis) [130], which don’t occur in most 
Apc mouse models. Current evidence in support of a direct role of the C-terminal region 
of Apc in observed intestinal phenotype variation among different Apc mouse models is 
lacking. 
7-Differences in technologies used to generate the mouse model 
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Additional contributing factors for consideration include the different 
technologies used to generate these various Apc mouse models. The ApcMin/+ mouse was 
generated by chemical mutagenesis that resulted in a single base-pair change in the Apc 
gene [4]. Many other models, such as Apc1309, Apc1638N and Apc1638T, were generated 
through insertion of an antibiotic-resistance gene into the Apc gene, thus introducing a 
nonsense mutation [46, 60, 68].  In ApcneoF and ApcneoR alleles, the antibiotic-resistance 
gene disrupts an enhancer sequence in an intron 13 [92, 93]. The Apc1322T model was 
generated via Cre-Lox-mediated deletion, and the ApcmNLS model contains mutations 
“knock-ins” to the Apc gene, with the antibiotic-resistance gene subsequently removed by 
means of Cre-Lox-mediated deletion [69]. The Apc1638N/+ and Apc1638T/+ models, which 
differ only by orientation of the inserted neomycin-resistance gene, provide clear 
evidence for the contribution of extraneous DNA to phenotypic variation [60]. Apc1638N/+ 
mice express so little truncated Apc protein that they might be considered virtually null 
[53]; yet the described phenotype of Apc1638N/+ mice is not similar to that of the ApcΔe1-15 
model, which has a complete deletion of the Apc gene [53, 83]. The neomycin-resistance 
gene clearly affects the phenotypes of these mice and if inserted in reverse orientation, 
might affect not only Apc expression, but also expression of genes upstream of Apc. 
Another example of a possible effect of the induced mutation is seen in ApcΔ474/+ mice, 
which have a duplication of Apc exons 7-10.  This feature makes it difficult to dissect the 
effects of duplication of four Apc exons from the effects of deleting the rest of the protein 
[72]. 
8-Differences in expression of the mutant allele 
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When analyzing the phenotypes of different Apc mouse models, another 
consideration is the level of expression of the mutant allele. Although normal expression 
levels of truncated Apc protein have been verified in ApcΔ716, ApcMin/+, Apc1322T, and 
Apc1638T mice, this is not universally the case [60, 69, 131]. In Apc580D, ApcΔ14, ApcΔ474, 
and ApcΔ242 models, the truncating mutation occurs before the final exon (15), and thus 
there is the possibility of nonsense-mediated RNA decay.  Remarkably, the truncated Apc 
was not detected in intestinal polyps from ApcΔ580/+ mice and ES cells from ApcΔ15/+ mice 
[76, 79], which suggests that these might also be virtually null alleles. A related 
consideration is the effect of the introduced mutation (and possibly the antibiotic 
selection cassette) on Apc folding. Although most of the Apc protein is thought to be 
natively unfolded [132], the effects of mutations on inherently folded domains of Apc 
and the consequences of potential folding defects in relation to phenotype, are not 
understood. 
Why do different Apc mutations sometimes cause extra-intestinal phenotypes?  
As with the intestinal phenotype, the underlying mechanism for variation in extra-
intestinal phenotypes in different Apc mouse models is not completely understood. Some 
phenotypes, such as anemia, seem to correlate with the severity of intestinal polyposis. In 
contrast, mammary gland tumors in Apc mouse models appear to correlate with the 
severity of polyposis in only a few cases, such as in the ApcMin/+ and ApcΔ474/+ models. 
Very few ApcMin/+ mice develop mammary tumors, whereas ApcΔ474/+ mice develop 
mammary tumors at a rate that is almost double that seen in ApcMin/+ mice [6, 72]. 
ApcmNLS/Min females also have enhanced mammary tumorigenicity (see chapter 5). There 
are no reports of mammary tumor development in Apc mouse models with the most 
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severe intestinal polyposis (ApcΔ714, Apc1322T, and ApcΔSAMP), however [69, 74, 91]. 
Perhaps mice with severe polyposis die relatively early, before mammary tumors have a 
chance to develop. Apc1572T/+ mice, which develop no intestinal polyps, have a fully-
penetrant mammary tumor phenotype in females. There is a hypothesis that Wnt 
signaling must be “just right” to support mammary tumorigenesis [62]. Evidence 
supporting this hypothesis comes from ApcΔ580/+ and K14-cre-ApcCKO/+ mice, where 
mutations in the wild-type Apc allele in mammary tumors cluster around codon 1530 
(eliminating all 3 SAMP repeats from the truncated Apc) [101]. K14-cre-ApcCKO/+ mice 
are a conditional model in which the ApcΔ580 allele is expressed only in ectodermal 
derived tissues including the mammary gland [76, 101] 
Apc rat models 
To overcome some of the limitations of Apc mouse models, Amos-Landgraf et al. 
used an ENU mutagenesis screen to generate a rat model with a germline nonsense 
mutation at Apc codon 1137 (Apcam1137) [111]. Rats homozygous for the Apcam1137 allele 
die as embryos. Apcam1137/+ rats develop both small intestinal and colonic polyps with 
100% penetrance, and are called “PIRC” rats for Polyposis In Rat Colons [111, 133]. The 
polyps in PIRC rats are adenomas with malignant changes, with local invasion seen in 
old rats. No signs of metastasis have been detected in these rats. As seen in humans with 
germline Apc mutations, the polyps from PIRC rats show -catenin nuclear translocation 
in advanced but not in early adenomas. As with ApcMin/+ mice, intestinal polyps in PIRC 
rats show LOH. Because chromosome18, which carries the Apc gene in rats, is 
metacentric, pyrosequencing could be used to demonstrate that LOH in PIRC rats 
predominantly occurs by means of homologous recombination [111]. The greater width 
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of rat intestines and colons, relative to those of mice, allows for growth of larger 
intestinal tumors, which allows study of tumor progression beyond the early stage. Wider 
colons and higher colonic tumor multiplicities also facilitate longitudinal endoscopic 
studies of tumorigenesis [111]. Male PIRC rats have more polyps than do females [83]. 
Although most Apc mouse models do not show a gender bias, male ApcMin-FCCC/+ mice 
also develop more colonic polyps than do females. In contrast, female ApcΔe1-15/+ mice 
display more severe phenotypes than do males [83]. In humans, women appear to be 
slightly less affected by colon cancer than do men [134]. PIRC rats also show high 
incidence of jaw tumors, which are the main cause of morbidity in female PIRC rats 
[111]. This extra-intestinal phenotype has also been described in patients with FAP 
syndrome [135].   
A second Apc rat model was generated by use of ENU as a chemical mutagen 
[136]. This rat model (Kyoto Apc Delta or KAD rat) has a nonsense mutation in the Apc 
gene, resulting in deletion of the C-terminal 321 amino acids. This terminal deletion does 
not appear to affect life expectancy even in homozygous KAD rats, and no spontaneous 
polyps develop in the intestines of these rats. However, KAD rats showed enhanced 
inflammatory-induced colon tumorigenicity, which suggests a Wnt-independent role of 
the C-terminal domain of Apc in tumor suppression [136].  
In summary, rodent models with Apc mutations were first generated more than 2 
decades ago, even before identification of human APC. Studies of 35 rodent models with 
germline and conditional Apc mutations has led to greater understanding of the role of 
Apc in development, differentiation, and homeostasis of intestinal epithelial cells. In 
addition, these models have allowed exploration of the role of Apc in intestinal and extra-
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intestinal development and tumorigenesis. Mouse and rat models with germline Apc 
mutations have permitted experimental testing of different molecular pathways and 
investigation of genetic and environmental contributions to tumor formation, not only in 
the gastrointestinal tract but also in other tissues. These models have also facilitated 
testing different preventive and therapeutic agents in preclinical studies. However, 
additional work is required to clarify some of the less understood features of Apc rodent 
models so as to maximize their usefulness. Standardizing genetic and environmental 
variables and conducting comparative studies of these Apc models is expected to enhance 
our understanding of Apc and of cancer biology.    
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Figure 2.1: Apc protein structure and the location of germline mutations from 
various Apc-models  
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Figure 2.2: Using a Robertsonian translocation of chromosome 7 over 18 to test for 
the mechanism of LOH in ApcMin/+ mice. (A) Schematic diagram for chromosomes 7, 
18, and Rb9. The Apc locus on chromosome 18 is marked with a black line. (B) 
Schematic diagram of using a natural mutation on the chromosome 7 arm of the Rb9 
translocation chromosome to test if LOH in polyps from ApcMin/+ is caused by somatic 
recombination or by mitotic non-disjunction. Left side shows the chromosomal 
arrangement and status of the Tyr and Apc alleles on both arms of the Rb9 chromosome 
in both germline and normal tissues. On the right, the expected Tyr and Apc alleles on 
both arms of Rb9 chromosome if LOH is the result of somatic recombination (upper 
result) or mitotic non-disjunction (lower). (C) Average polyp numbers in ApcMin/+ mice is 
decreased when Rb9 chromosome is present in cis, trans, or homozygous distribution 
with the ApcMin allele. (Adapted from Haigis and Dove 2003 [13]) 
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Chapter 3 
The data and opinions in this chapter were published previously and reformatted for this 
dissertation [1] 
A knock-in mouse model reveals roles for nuclear Apc in cell proliferation, Wnt 
signal inhibition and tumor suppression 
Abstract  
Mutation of the tumor suppressor adenomatous polyposis coli (APC) is 
considered an initiating step in the genesis of the vast majority of colorectal cancers.  
APC inhibits the Wnt signaling pathway by targeting proto-oncogene -catenin for 
destruction by cytoplasmic proteasomes.  In the presence of a Wnt signal, or in the 
absence of functional APC, -catenin can serve as a transcription co-factor for genes 
required for cell proliferation such as cyclin D1 and c-Myc. In cultured cells, APC 
shuttles between the nucleus and cytoplasm, with nuclear APC implicated in inhibition of 
Wnt target gene expression. Taking a genetic approach to evaluate the functions of 
nuclear APC in the context of a whole organism, we generated a mouse model with 
mutations that inactivate the nuclear localization signals of Apc (ApcmNLS). ApcmNLS/mNLS 
mice are viable and fractionation of embryonic fibroblasts (MEFs) isolated from these 
mice revealed a significant reduction in nuclear Apc compared to Apc+/+ MEFs.  The 
levels of Apc and-catenin protein were not significantly altered in small intestinal 
epithelia from ApcmNLS/mNLS mice. Compared to Apc+/+ mice, ApcmNLS/mNLS mice 
displayed increased proliferation in epithelial cells from the jejunum, ileum, and colon.  
These same tissues from ApcmNLS/mNLS mice displayed more mRNA from three genes up-
regulated in response to canonical Wnt signal, c-Myc, Axin2, and Cyclin D1, and less 
mRNA from Hath 1 which is down-regulated in response to Wnt. These observations 
suggest a role for nuclear Apc in inhibition of canonical Wnt signaling and control of 
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epithelial proliferation in intestinal tissue. Furthermore, we found ApcMin/+ mice, which 
harbor a mutation that truncates Apc, have increased polyp size and multiplicity if they 
also carry the ApcmNLS allele. Taken together, this analysis of the novel ApcmNLS mouse 
model supports a role for nuclear Apc in control of Wnt target genes, intestinal epithelial 
cell proliferation and polyp formation. 
Introduction 
The tumor suppressor protein adenomatous polyposis coli (APC) is large, with 
multiple subcellular localizations and functions.  Mutation of the APC gene is considered 
the initiating event in the formation of most intestinal polyps, the precursors to colorectal 
cancer [2-4]. As such, an intense investigation of potential APC functions involved in 
tumor suppression has led to identification of APC as a Wnt signaling pathway antagonist 
[5]. In this capacity, APC is part of a cytoplasmic protein complex that targets the proto-
oncoprotein -catenin for proteasome-mediated destruction [6]. APC has also been 
observed in nuclei of cultured colon cells and colonic epithelia from human tissue using 
conventional and confocal immunofluorescent microscopy and immunoelectron 
microscopy [7-9].  Nuclear APC has three proposed roles in regulating Wnt signaling.  
First, nuclear APC binds to nuclear -catenin and likely competes with transcription 
factor TCF/LEF for β-catenin binding [10]. Second, nuclear APC has been implicated in 
the nuclear export of -catenin [11-13].  Finally, the interaction of nuclear APC with 
transcriptional corepressor CtBP further contributes to the modulation of Wnt signaling 
[14]. In addition to its role as a repressor of -catenin, nuclear APC has been implicated 
in DNA synthesis and repair [15, 16].  
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Because APC is a large protein (~310 kDa), it is unable to simply diffuse into the 
nucleus but must instead be actively transported through nuclear pores [17, 18]. Several 
domains of APC have been proposed to mediate this nuclear entry, including two 
monopartite nuclear localization signals (NLS) in the central part of the protein [19], as 
well as an armadillo repeat region closer to the N-terminus [20]. In addition, 
phosphorylation of APC regulates its localization [19] and relative levels of nuclear and 
cytoplasmic APC appear to correlate with the proliferative status of a cell [21]. 
Although many mouse models have been generated with alterations in Apc, they 
either produce no Apc protein [22], full-length Apc at a reduced level [23], or a truncated 
Apc [24-30]. Elimination of the C-terminal portion of Apc leads to at least partial loss of 
function and mice homozygous for mutations that truncate Apc typically do not develop 
beyond embryonic day 8 [31]. To date, no mouse model with targeted disruption of the 
two Apc NLSs has been generated.  
To assess the functions of nuclear Apc in the context of a whole organism, we 
introduced germline mutations into the mouse Apc gene that result in inactivation of the 
two characterized Apc NLSs (ApcmNLS). Inactivation of the two APC NLSs was 
previously shown to attenuate the ability of full-length exogenous human APC to enter 
the nucleus [19]. In the present study, mice heterozygous (ApcmNLS/+) or homozygous 
(ApcmNLS/mNLS) for mutant Apc NLS were viable. Intestinal epithelial cells in 
ApcmNLS/mNLS mice showed increased levels of Wnt target gene expression and more 
proliferation compared to their wild-type littermates. For the past two decades, the 
ApcMin/+ mouse has been a popular model organism to study Apc mutation-driven 
tumorigenesis [32]. ApcMin/+ mice have a missense mutation in Apc that results in 
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truncation of the C-terminal 2/3 of the protein. ApcMin/+ mice develop 20-60 intestinal 
polyps at the time of their natural death, ~120 days of age.  We found that ApcMin/mNLS 
mice displayed significantly more intestinal polyps than ApcMin/+ mice and these polyps 
were larger.  Together, these results suggest that nuclear Apc participates in regulation of 
Wnt signaling, proliferation and tumor suppression.   
Materials and methods: 
Creating the Gene Replacement Vector 
The homologous sequences of DNA used for the targeting construct were 
obtained from a lambda phage library of genomic DNA isolated from 129 mouse ES cells 
(generously provided by Kirk Thomas and Mario Capecchi, University of Utah). This 
library was screened for fragments of Apc containing the two primary Apc nuclear 
localization signals (NLSs). Following identification of an Apc NLS-containing plaque by 
hybridization to a radioactive probe, a 14 kb stretch of mouse genomic DNA (Apc exons 
14, 15 and surrounding introns) was isolated from the phage and inserted into the 
pBluescript KSII+ vector (Stratagene). An EcoRI fragment containing both Apc NLSs 
was subcloned into the pUC19 vector. Mutations that inactivated each NLS and 
introduced novel restriction sites were inserted by PCR mutagenesis (Figure 3.1B). A 
second pUC19 vector was modified to destroy its EcoRI restriction site and introduce 
Nhe I and Not I sites. An 11,537 bp region of Apc (NheI/NotI) was subcloned into this 
modified vector. The EcoRI fragment of Apc containing wildtype NLSs was replaced by 
the same fragment with mutant NLSs.  Using restriction sites for KpnI and AflII in the 
noncoding region 3’ to Apc exon 15, a tACE-Cre-Neor cassette, flanked by two LoxP 
sites was introduced into the pUC19 vector containing the Apc gene fragment with 
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mutant Apc NLSs. This tACE-Cre-Neor cassette included a neomycin resistance gene 
(Neor) driven by the promoter for RNA polymerase II and was linked to a gene encoding 
Cre recombinase under control of the testes-specific murine angiotensin-converting 
enzyme (tACE) promoter [33].  The HSV thymidine kinase gene controlled by the 
phosphoglycerate kinase (PGK) promoter was inserted upstream of the Apc homology 
sequences in the pUC19 vector to create the 19,947 bp targeting vector (Figure 3.1A).  
Electroporation into Embryonic Stem Cells 
The targeting construct DNA was cleaved with Not I restriction endonuclease to 
linearize at a unique site 3’ of the region homologous to Apc. Digestion with Not I was 
followed by two phenol/chloroform extractions before the linearized gene replacement 
vector was electroporated into R1 mouse embryonic stem cells [34] at the Transgenic and 
Gene-Targeting Institutional Facility at The University of Kansas Medical Center. Cells 
were selected for growth in 300μg/mL G418 (Cellgro) and 2μM ganciclovir (Roche). 
Following 8-10 days of culture in selective media, each surviving colony was picked and 
expanded into two separate wells. DNA was isolated from one well for genotype analysis 
and the cells in the remaining well were frozen in 96-well plates for injections. 
Screening and Verifying Targeted ES cell lines 
Identification of ES cell lines containing mutations in both Apc NLSs was 
accomplished using a two-step PCR screen and the following primer sets: wildtype Apc 
NLS1 forward and NLS2 reverse, wNLS1fw (5’-CTA AGA AAA AGA AGC CTA CTT 
CAC) and wNLS2rv (5’-GGC CTT TTC TTT TTT GGC ATG GC); mutant Apc NLS1 
forward  and NLS2 reverse, mNLS1fw (5’-GCA GCC GCG GCA CCT ACT) and 
mNLS2rv (5’-TTG AAG GCC TTT TTG CGG CC) (Figure 3.1C). To identify 
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homologous cassette insertion at the 3’ end, a primer annealing to DNA in the 
LoxP/tACE promoter region of the tACE-Cre-Neor cassette (5’-CCT GGC CCA TGG 
AGA TCC AT) was used with a primer annealing to genomic Apc 3’ of the targeting 
construct (5’-CAT ACC ACC CAC CAT CCC TA) or with a primer annealing to the 3’ 
end of the targeting construct (TCT CCC ATT GCT TAT GGC AAC) as a positive 
control (Figure 3.1H). Cell lines were also screened for correct incorporation of the 5’ 
end of the targeting construct using PCR. The reverse primers wNLS2rv and mNLS2rv 
were used in conjunction with the following primer that anneals to a region of genomic 
DNA upstream of the 5’ end of the targeting construct: (5’-AAA TTG AAC TCA GGA 
CCT TCT C) (Figure 3.1F).  PCR products digested with SstII produced a 6100bp DNA 
product if mutant Apc NLS1 was present (Figure 3.1G). Each cell line with correct 
homologous recombination was further evaluated by determining the karyotype of 40-50 
cells.   
Generation of Chimeric Mice 
For the generation of chimeric mice, ApcmNLS/+ ES cells were injected into 
C57BL/6J blastocysts at the Gene Targeting and Transgenic Facility at the University of 
Virginia. Male chimeric mice that carried the mutant copy of Apc were bred to C57BL/6J 
females originally obtained from The Jackson Labs (Bar Harbor, Maine). Black progeny 
were culled and agouti colored progeny were genotyped using tail DNA isolated 
following a protocol from The Jackson Laboratory 
(http://www.jax.org/imr/tail_nonorg.html) and PCR to screen for the presence of the 
mutant nuclear localization sites. Verification of selection cassette loss in the ApcmNLS/+ 
progeny was conducted using PCR with the following primers: forward primer, 5’-TCG 
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GCC ATT GAA CAA GAT GGA-3’ and reverse primer, 5’-ATT CGC CGC CAA GCT 
CTT CA-3’ (Figure 3.1E). 
Mouse Husbandry 
Mice were maintained in the Animal Care Unit at the University of Kansas 
according to animal use statement number 137-01. The research complied with all 
relevant federal guidelines and institutional policies.  The chimeric mice were bred with 
C57BL/6J mice from The Jackson Labs (Bar Harbor, Maine).  ApcmNLS/+ progeny from 
the original mating of male chimeric mice with female C57BL/6J mice were repeatedly 
backcrossed to the inbred C57BL/6J mice 10-18 times to generate a line that was 
considered to be congenic (N10-N18). Detailed records including the date of birth, 
lineage, coat color, sex, genotype and date of sacrifice were maintained for each 
individual mouse. For the survival curve, N1 male and female ApcmNLS/+ mice were bred 
and F1 progeny were housed with same sex siblings for the duration of the study (n=18 
for Apc+/+; 19 for ApcmNLS/+; and 18 for ApcmNLS/mNLS mice). Cause of death for mice in 
the survival study was not determined because mice were allowed to die naturally and 
thus most were not collected for many hours after their death. Mice were fed ad libitum 
with Purina Lab Diet 5001 and were housed in cages in adjoining animal rooms. 
Congenic mice weighed at different times between ages 6 and 14-weeks showed no 
significant differences comparing Apc+/+ and ApcmNLS/mNLS mice. ApcMin/+ mice were 
purchased from The Jackson Labs and were maintained by breeding males with 
C57BL/6J females. ApcMin/mNLS mice were generated by breeding male ApcMin/+ mice 
(from Jackson Labs) with congenic (N10-N15) female ApcmNLS/+  mice. 
Mouse genotyping  
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After weaning, mouse pups were tagged with a metal ear tag or by injection of an 
implantable electronic transponder (Bio Medic Data Systems Inc.) into the subcutaneous 
space above the shoulders. The Apc genotype of each mouse pup was determined using 
isolated tail DNA and PCR to screen for the presence of the wild-type and mutant NLS 
coding sequences using the following primers: forward, 5’-
TAGTGATGCGGTGAGTCCAA-3’ and reverse, 5’-ACCAAGTCCAACAAGCATCC-
3’.  Reaction conditions were: 94°C for 5 min., 35 cycles of 94°C for 1 min., 54°C for 1 
min., 68°C for 1 min., final 3 min. at 68°C.  PCR products (295 bps) were cut with SacII 
restriction enzyme. The restriction enzyme does not cut the wildtype allele but cuts the 
mutant allele into 2 fragments of 235 and 60-bp (Supplemental Fig. S 3.1). The ApcMin 
allele was detected using the standard PCR protocol published by the Jackson 
Laboratories (http://jaxmice.jax.org).    
Analysis of gross and microscopic pathology, polyp measurement 
The gross and cellular histology of intestinal tissues were examined in the N1-
N13 generations of ApcmNLS mice and in fourteen-week old ApcMin/+ mice and 
ApcMin/mNLS mice. For each mouse, GI tract from the stomach to the anal canal was 
dissected, opened longitudinally and fixed in 10% buffered formalin. Using a dissecting 
microscope, an investigator blind to the animal’s genotype examined the intestinal 
luminal surface for any irregularities and polyps. Regions of tissue with abnormalities 
were recorded, removed from the surrounding tissue and stored in 10% buffered 
formalin. Tissue that appeared grossly abnormal was sent for pathologic evaluation. 
Intestinal polyps were located and diameter measured with the aid of a dissection 
microscope (Leica, MZ8) equipped with an eyepiece graticule and calibrated to a 50-mm 
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scale stage micrometer with 0.1 and 0.01-mm graduation.  Fourteen-week old 
ApcMin/mNLS and ApcMin/+ mice were analyzed for this study.   
Evaluation of proliferation in intestinal epithelia 
For proliferation analysis, congenic mice were injected with EdU, and intestinal 
tissue prepared and stained as described [35].  Briefly, at the time of sacrifice, mouse 
small and large intestines were removed and opened lengthwise. The colon, and 
proximal, middle and distal regions of the small intestine were individually rolled as 
described [36] to form multiple “Swiss Rolls”. The sections of rolled colon and small 
intestine were incubated in fixative [4% paraformaldehyde, 0.1% triton X-100, in PBS] 
on ice for 1 hour, rinsed in PBS and incubated in 2.5 M sucrose at 4°C overnight. After 
PBS rinse, rolled tissue sections were frozen in OCT tissue freezing media (VWR) at -
20°C. Sections were sliced immediately or stored at -80°C. Tissue cryosections (7μm) 
were made using a Leica CM1900 cryotome and adhered to glass slides coated with 
histomount (Invitrogen) for immunohistochemistry. Slides were air dried for 
approximately 1 min. then tissue slices were permeabilized in 70% methanol before 
staining for EdU as described [37].  For each tissue in each genotype, 50-100 crypts were 
analyzed for proliferation by scoring the number of EdU-positive cells and the total cell 
number by DAPI stain in a crypt cross section.  Samples were coded so that analysis 
could be performed by a trained observer blind to the study parameters. Data from 3 mice 
of each genotype were collected to determine proliferation in the various intestinal 
tissues.  Only crypts with 40 or more cells in cross section were scored.   
Immunohistochemistry of intestinal epithelia and polyps 
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Tissues were fixed in 10% saline-buffered formalin 16-20 hr then stored in 70% 
ethanol. Tissues were embedded in paraffin and sectioned at 6-µm. 
Immunohistochemistry for -catenin and Ki-67 was performed using the Histomouse kit® 
(Invitrogen, Cat# 95-9541) according to the manufacturer's protocol and with mouse 
monoclonal anti--catenin antibodies (1:100, BD Biosciences, Cat# 610153) and rat anti 
mouse Ki-67 antibodies (1:20, Dako, Cat# M7249).  Tissues were coded allowing the 
analysis to be performed by an observer blind to the tissue genotype. Normal appearing 
Jejunum, Ileum and colon tissues from at least 3 mice of each genotype (Apc+/+, 
ApcmNLS/+, and ApcmNLS/mNLS) were examined for -catenin localization. In addition, 6 
polyps from 4 ApcMin/+ mice and 7 polyps from 3 ApcMin/mNLS mice were examined for -
catenin localization. After surveying the entire length of tissue for -catenin localization, 
the average distribution was recorded and representative images captured using 20X and 
40X objectives. The polyps were also scored for Ki-67 by counting Ki-67 positive cells 
per field at 40X magnification.  Three fields were photographed and scored for each 
polyp. The p-values for all proliferation studies were calculated using unpaired, two-
tailed t-tests and GraphPad Prism software.   
Isolation of mouse intestinal epithelial cells: 
Isolation of intestinal epithelial cells was performed with modifications to a 
previous protocol [38]. Immediately after sacrifice, small and large intestines were 
removed from congenic mice, opened lengthwise and rinsed with cold PBS. Tissue was 
incubated in 0.04% sodium hypochlorite for 15 min. on ice and then rinsed in cold PBS. 
The colon and small intestine were then incubated on ice for 15 min in individual 15mL 
conical tubes containing EDTA/DTT solution (1.5-3mM EDTA and 0.5mM DTT in 
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PBS). EDTA/DTT solution was poured off and replaced with cold PBS. Tubes were 
shaken forcefully for 10 sec. to release the epithelial cells from the underlying tissue. The 
intestinal tissue was removed and placed in a fresh 15mL conical tube of EDTA/DTT 
solution, and the process was repeated two additional times. The released epithelial cells 
were collected by centrifugation at 700xg for 5 min. at room temperature. Pellets of the 
colon epithelia from all three rounds of extraction were resuspended in PBS with protease 
inhibitors and combined into one sample. Because the surface area of the small intestine 
is significantly greater than that of the colon, there was no need to combine the epithelial 
tissue from the replicate extractions. The small intestinal epithelial cells from the second 
round of extraction were used in the experiments described here. Cell pellets were lysed 
in Reporter Lysis Buffer (Promega) with protease inhibitors [aprotinin, leupeptin and 
pepstatin each at 10 g/ml and 1 mM PMSF] and briefly sonicated. Samples were boiled 
after addition of Sample Buffer [3X Sample Buffer: 6% w/v Sodium Dodecyl Sulfate, 
30% Glycerol, 150mM Tris pH 6.8, ~0.2mg/mL Bromophenol Blue] and resolved by 
SDS-PAGE before transfer to nitrocellulose membranes.  
Immunoblot analysis of Apc and -catenin in intestinal tissue and MEF 
fractionation 
Immunoblots were processed as described [39]. Membranes were probed with the 
following primary antibodies diluted as indicated in 5% nonfat dry milk/TBST: rabbit 
anti-APC M2 (1:3000,[40]), mouse anti--catenin (1:2000, BD Biosciences, Cat# 
610153), mouse anti--tubulin (1:50, Developmental Studies Hybridoma Bank), rabbit 
anti-fibrillarin (1:1000,  ab5821 AbCam), -actin (1:2000,Sigma). The following 
secondary antibodies were diluted as indicated: HRP goat anti-mouse (1:10-25,000, 
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Zymed) and HRP goat anti-rabbit (1:10-25,000, Bio-Rad). Blots were developed using 
Western Lightning Chemiluminescence Reagent Plus (PerkinElmer) or SuperSignal West 
Femto Maximum Sensitivity Substrate (Pierce) and a Kodak Image Station 4000R. Band 
analysis was conducted using Kodak ID Image Analysis Software with protein levels first 
normalized to -actin and then values for the  Apc+/+ samples set to 1. The p-values were 
calculated using Mann-Whitney nonparametric test. MEFs of each genotype were 
isolated from congenic (N10-N18) mice on three independent occasions following the 
protocol as described [41].  Independently isolated early passage MEFs were subjected to 
fractionation in five independent experiments as described [9]. Nuclear Apc and -
catenin were calculated based on the band intensity in the nuclear fraction divided by the 
intensity of the nuclear plus the cytoplasmic bands. The p-values were calculated using 
unpaired, two-tailed t-tests and GraphPad Prism software. 
Analysis of mRNA using real time RT-PCR 
For preparation of RNA, 200-µl of suspended epithelial cells were added to 1-ml 
Trizol® (invitrogen) and tubes were stored at -80oC until used. RNA extraction was 
performed using Trizol® according to the manufacturer’s protocol. For making cDNA, 
1µg total RNA was incubated for 1 hour at 42oC with the cDNA reaction mix containing 
1 mM dNTPs, 1µg random hexamer primers (NEB), 1X M-MLuV enzyme buffer (NEB) 
and 200 units M-MLuV RT enzyme (NEB). The reverse transcriptase enzyme was then 
inactivated by heating at 95oC for 5 minutes. Quantitative PCR was carried out for c-Myc, 
Axin2, Cyclin D1, BTEB2, and Hath1 cDNA from the mouse intestinal epithelial cells. 
The cDNA of the house keeping gene HGPRT was used as an internal control. Table 3.1 
shows the primers used. 
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Table 3.1: primers used for quantifying canonical and non-canonical Wnt targets in 
mouse intestinal epithelial cells 
Gene Forward primer Reverse primer 
c-Myc 5’- TCCTGTACCTCGTCCGATTC-3’ 5’- GGTTTGCCTCTTCTCCACAG-3’ 
Axin2 5’- TGTGAGATCCACGGAAACAG-3’ 5’- CTGCGATGCATCTCTCTCTG-3’ 
Cyclin D1 5’- TTGACTGCCGAGAAGTTGTG-3’ 5’- AGGGTGGGTTGGAAATGAAC-3’ 
Hath1 5’-ACATCTCCCAGATCCCACAG-3’ 5’-ACAACGATCACCACAGACCA-3’ 
BTEB2 5’-CTCCGGAGACGATCTGAAAC-3’ 5’-GAACTGGAGGGAGCTGAGG-3’ 
HGPRT 5’- TGCTCGAGATGTCATGAAGG-3’ 5’- TATGTCCCCCGTTGACTGAT-3’ 
 
PCR reactions were performed using a DNA engine Opticon 2 system (MJ 
research) with SYBR green detection system. The total reaction volume was 25µl 
containing 1X DyNAmoTM HS SYBR® Green qPCR Kit (Finnzymes), 15 picomoles of 
each primer and 3 µl of 1:2.5 diluted cDNA. Each reaction was done in triplicate and 
repeated three times. The reaction condition was initial denaturation at 95oC for 15 
minutes followed by 40 cycles of denaturation at 94oC for 20 seconds, annealing at 54oC 
for 30 seconds and extension at 72oC for 30 seconds. The fluorescence was measured at 
the end of every cycle and a melting curve was analyzed between 40oC and 95oC with 
0.2oC increment. Samples were only included in the analysis if the melting curve was a 
single peak at the expected temperature.  Average ΔC(T) was calculated for different 
genotypes relative to the house keeping gene transcript while ΔΔC(T) of Wnt target 
cDNA for ApcmNLS/+ and ApcmNLS/mNLS was calculated relative to the Apc+/+ mice. The p-
values were calculated using Mann-Whitney nonparametric test and GraphPad Prism 
software.   
Results  
Mutation of two Apc NLSs in ES cells and generation of mutant mice   
To introduce specific mutations that inactivate both Apc NLSs in mouse 
embryonic stem (ES) cells and ultimately generate ApcmNLS/mNLS mice, we constructed a 
gene-targeting vector (Figure 3.1A). The targeted mutations alter a total of six amino 
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acids in Apc, four in NLS1 and two in NLS2 (Figure 3.1B).  These mutations substitute a 
neutral alanine for the basic lysine residues in the mono-partite NLSs and have been 
shown to inhibit nuclear import of exogenously expressed APC [19].  Each NLS is 
adjacent to a SAMP repeat region (so named because they each contain a central Ser-Ala-
Met-Pro) which is involved in APC binding to axin. However, mutation of both NLSs 
does not appear to interfere with axin binding as full-length APC with mutations in both 
NLSs still interacts with axin (Supplemental Fig. S3.2). These mutations also establish 
two novel restriction sites, Sst II in NLS1 and Eag I in NLS2 which were utilized for 
screening purposes (Figure 3.1B). The targeting vector contains an 11.5 kb genomic Nhe 
I/ Not I fragment encompassing exons 14 and 15 of Apc as well as the surrounding 
introns.  The entire Apc region of the vector was validated by sequencing.  The positive 
selection marker contained in a germline-induced self-excision cassette was placed in the 
intron following Apc exon 15 [33]. In mice, the tACE promoter initiates transcription of 
Cre-recombinase during spermatogenesis, inducing Cre-mediated self-excision of the 
selectable Neor marker in the germline of the transgenic animals. Following self-excision, 
only one 34 bp minimal LoxP element remains in the last Apc intron.  The targeting 
construct also contains a copy of the herpes simplex virus thymidine kinase gene (TkHSV) 
to allow negative selection of homologous recombinant ES clones. 
Identification of homologous recombinant ES clones was accomplished using 
PCR with different primer pairs inside and outside the targeting construct.  Of the 161 ES 
cell clones that survived positive and negative selection, 107 contained Apc with both 
mutant NLSs (Fig. 3.1C, 3.1D). Eight of these ES cell clones were identified as 
homologous recombinants by PCR to verify correct insertion of the 3’ region of the 
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vector (Fig. 3.1F, 3.1H). Two were further analyzed by PCR and then subjected to 
restriction digestion in order to verify correct insertion of the 5’ region of the vector and 
to confirm that both mutant NLSs were integrated (Fig. 3.1F, 1G). One ES line with 
normal karyotype in 75% of the 50 cells analyzed was used for the initial blastocyst 
injections. From these injections, 11 chimeric mice, 4 females and 7 males, were 
obtained; 3 males showed evidence of germline transmission when bred with wild-type 
C57BL/6J mice. 
Elimination of the Neor/Cre selection cassette in ApcmNLS/+ mice  
In the Apc1638N mouse model, a Neor selection gene inserted in exon 15 of Apc 
resulted in a dramatic decrease in the expression of the mutant Apc [24, 42].  Thus it was 
critical to ensure that the Neor gene was excised from the ApcmNLS/+ mice.  Excision of 
the Neor cassette in animals was verified by PCR analysis using oligos within the 
Neor/Cre selection cassette to prime DNA amplification of genomic DNA isolated from 
ApcmNLS/+ mice in the N1 and N2 generations (Figure 3.1E).   
ApcmNLS/mNLS mice are viable 
Many of the previously generated Apc mouse models display early embryonic 
lethality as homozygous mutants. When ApcmNLS/+ mice were interbred, both ApcmNLS/+ 
and ApcmNLS/mNLS mice were obtained. Thus, the two characterized monopartite nuclear 
localization signals of Apc are not essential for viability. ApcmNLS/mNLS mice showed no 
obvious growth defects compared to their wild-type littermates in generations N1-N13.  
ApcmNLS/mNLS mice are fertile, giving birth to litters of typical size. A long term survival 
analysis of 55 progeny from first generation ApcmNLS/+ females bred to first generation 
ApcmNLS/+ males revealed no significant difference in mouse survival between 
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ApcmNLS/mNLS and Apc+/+ mice (data not shown). Thus, it appears that mutation of Apc 
NLS sequence has limited impact on the lifespan of the mice.  
Reduced nuclear Apc in embryonic fibroblasts isolated from ApcmNLS/mNLS mice  
Because of complications associated with fractionation of cells obtained from 
intestinal tissue, we used mouse embryonic fibroblasts (MEFs) isolated from congenic 
(generation N11) mice to determine effects of ApcmNLS on subcellular Apc localization 
(Fig. 3.2A).  In Apc+/+ MEFs, more than one-third of the total Apc was associated with 
the nuclear fraction (Fig. 3.2B). ApcmNLS/mNLS MEFs were significantly compromised for 
nuclear Apc distribution, with eleven percent of the total Apc associated with the nuclear 
fraction. ApcmNLS/+ MEFs showed an intermediate phenotype, but nuclear Apc was not 
significantly different from that in Apc+/+ MEFs.   -catenin distribution was similar in all 
MEF lines (Fig. 3.2C).  Moreover, -catenin appeared predominantly at cell-cell 
junctions in intestinal tissue from Apc+/+, ApcmNLS/+ and ApcmNLS/mNLS mice as assessed 
by immunohistochemistry (Supplemental Fig. S3.3A).  A few crypts showed limited 
nuclear -catenin staining in cells near their base, but this was consistent for all mouse 
genotypes (Supplemental Fig. 3.3B).   
Apc and -catenin levels in intestinal tissue 
To determine if the single Lox P site remaining in the last Apc intron impacts Apc 
level in ApcmNLS mice, we measured the relative amount of Apc in whole cell protein 
lysates prepared from epithelial cells isolated from mouse jejunum, ileum and colon (Fig. 
3.3).  The Apc level did not vary significantly in epithelia from jejunum or ileum tissue 
isolated from ApcmNLS/mNLS, ApcmNLS/+ and Apc+/+ mice. Unexpectedly, colon epithelia 
from ApcmNLS/mNLS mice had higher levels of Apc than colon epithelia from Apc+/+ mice. 
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Because Apc targets proto-oncoprotein -catenin for destruction, higher Apc levels 
would be expected to result in reduced -catenin levels. Unexpectedly, colon tissue from 
ApcmNLS/mNLS mice showed higher levels of -catenin than colon tissue from Apc+/+ mice. 
In the small intestine, -catenin levels were not altered in ApcmNLS/mNLS mice compared 
to Apc+/+ mice. 
Increased expression of Wnt targets in intestinal epithelia of ApcmNLS/mNLS mice 
Based on previous studies performed in cultured cells, we proposed that nuclear 
APC binds nuclear -catenin and sequesters it from transcription factor TCF/LEF.  
Consequently, Wnt target genes activated by the -catenin/TCF/LEF complex are down-
regulated by nuclear APC [11]. Thus we predicted that cells defective in nuclear Apc 
would be less able to dampen Wnt target gene expression. To test this prediction, mRNA 
isolated from intestinal epithelial cells was evaluated for relative expression of various 
Wnt-regulated genes (Figure 3.4). Three genes typically up-regulated in response to a 
canonical Wnt signal, c-Myc, Axin2, and Cyclin D1 showed  higher expression 
throughout the intestinal epithelia of ApcmNLS/mNLS mice compared to Apc+/+ mice.  In 
these same tissues, Hath 1, a gene down-regulated in response to a canonical Wnt signal 
showed lower expression throughout the intestinal epithelia of ApcmNLS/mNLS mice 
compared to Apc+/+ mice.  BTEB2, a gene reportedly up-regulated in response to non-
canonical Wnt signal, showed no expression alterations in jejunum or ileum from 
ApcmNLS/mNLS mice compared to Apc+/+ mice. Unexpectedly, in colon tissue, BTEB2 
expression was higher in both ApcmNLS/mNLS and ApcmNLS/+ mice compared to Apc+/+ 
mice. 
Increased proliferation in intestinal epithelia of ApcmNLS/mNLS mice 
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Given the increased expression of c-Myc and Cyclin D1 in intestines of 
ApcmNLS/mNLS mice, we expected to find an accompanying increase in proliferation. To 
evaluate epithelial cell proliferation in intestinal tissue, mice were analyzed 4 hours after 
injection with the thymidine analogue EdU. Crypts from jejunum, ileum and colon each 
displayed significantly more proliferating cells in ApcmNLS/mNLS mice than in ApcmNLS/+ 
and Apc+/+ mice (Fig. 3.5).    
Enhanced polyp formation in intestines of ApcMin/mNLS mice  
Mice with germline truncating mutations in Apc occasionally display a few 
adenomatous polyps in the colon, with the great majority of polyps found in the small 
intestine [31].  Therefore, we targeted both colon and small intestine for our initial 
phenotypic analysis. No adenomatous polyps of the small intestine were identified in any 
of the ApcmNLS/+ mice from generations N1-N4 analyzed for intestinal lesions (n=33). 
One dysplastic colon polyp was found in an ApcmNLS/mNLS mouse (Fig. 3.6A-D). A polyp 
was also found in the stomach of another ApcmNLS/mNLS mouse (generation N11). 
The few intestinal lesions observed in the ApcmNLS/mNLS mice left open the possibility that 
nuclear Apc participates in polyp suppression.  To examine this more efficiently, 
congenic ApcmNLS/+ mice were bred with ApcMin/+ mice. Polyp number, size and 
distribution were compared in 14-week old progeny ApcMin/+ and ApcMin/mNLS mice. 
Significantly more polyps were found in the jejunum and the ileum of ApcMin/mNLS mice 
than in ApcMin/+ mice (Fig. 3.7A and supplementary Fig S3.4).  There were only a few 
polyps observed in any colon tissue with no significant variation between ApcMin/+ and 
ApcMin/mNLS mice (Fig. 3.7B and supplementary Fig S3.4). Even fewer polyps were 
observed in the stomach and duodenum tissues, but the average polyp number was 
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slightly larger in ApcMin/mNLS mice than in ApcMin/+ mice (Fig. 3.7B and supplementary 
Fig S3.4).  Combining results from the entire G.I. tissue, we observed nearly twice as 
many polyps in ApcMin/mNLS mice than in ApcMin/+ mice (Fig. 3.7C). These results suggest 
that the ApcmNLS enhances polyp initiation or development in the ApcMin mouse model.  
Furthermore, the average polyp size was significantly larger in jejunum and ileum tissue 
of ApcMin/mNLS mice compared to ApcMin/+ mice (Fig. 3.7D). Collectively, the results from 
this study suggest that nuclear Apc contributes to a tumor suppressor phenotype. 
Increased proliferation in intestinal polyps from ApcMin/mNLS mice  
To begin to explore the mechanism of enhanced polyp formation in ApcMin/mNLS 
mice, we examined cellular proliferation and -catenin distribution in polyps from 
ApcMin/mNLS and ApcMin/+ mice. Strong nuclear -catenin staining was observed in polyps 
from both ApcMin/mNLS and ApcMin/+ mice (Fig. 3.7F, a-d). In contrast, -catenin appeared 
predominantly at the cell-cell junctions of normal intestinal cells from both ApcMin/mNLS 
and ApcMin/+ mice.  Although nuclear -catenin was prevalent in both ApcMin/mNLS and 
ApcMin/+ polyps, not every cell with nuclear -catenin was positive for proliferation 
marker Ki-67 (Fig. 3.7F, e-h). Closer examination of Ki-67-positive cells revealed that 
polyps from ApcMin/mNLS mice had significantly more proliferating cells than polyps from 
ApcMin/+ mice (Fig. 3.7E).  Combined with the observation that there were more polyps 
and these polyps were larger in intestines of the ApcMin/mNLS mice than in the ApcMin/+ 
mice (Fig. 3.7 A-D), it is likely that contributions of nuclear Apc to regulation of cellular 
proliferation impact tumor suppression in this newly developed model. 
Discussion 
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Nuclear APC has been observed in cultured cells, in cells of various model 
organisms and in human tissues [43]. Roles for nuclear APC in DNA repair and 
replication as well as Wnt signal regulation have been proposed [10, 12, 14-16, 44]. 
However, to date, experimental manipulation of nuclear APC has been confined to 
cultured cells. In this report, we describe a new mouse model with mutations "knocked-
in" the Apc gene which inactivate the two canonical Apc NLSs [19].  To our knowledge, 
the ApcmNLS/mNLS model is the first mouse generated to specifically inhibit nuclear import 
of any protein by knock-in mutations that target and inactivate an NLS.  ApcmNLS/mNLS 
mice were viable and displayed increased proliferation of epithelia throughout the small 
intestine and colon.  Epithelia from jejunum, ileum, and colon also exhibited increased 
canonical Wnt signaling as evidenced by increased expression of genes up-regulated by 
canonical Wnt signal (cyclin D1, c-myc and Axin 2) and decreased expression of genes 
down-regulated by canonical Wnt signal (Hath 1).  This increased Wnt signaling could 
explain the enhanced proliferation observed in these same tissues.  Although only 
occasionally observed in ApcmNLS/mNLS mice, polyps in jejunum and ileum were 
significantly more abundant and larger, with increased proliferative index in ApcMin/mNLS 
mice compared to ApcMin/+ mice, implicating nuclear Apc in suppression of polyp 
formation. 
The best characterized role for nuclear APC involves negative regulation of Wnt 
signaling [10, 14].  Based on studies performed in cultured cells, it was proposed that 
nuclear APC binds to nuclear β-catenin, sequestering it from a complex with activated 
TCF/LEF [10] and mediating -catenin export to the cytoplasm [11-13].  There is also 
evidence that APC can interact with transcriptional corepressor CtBP [14], resulting in 
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inhibition of TCF/LEF-mediated transcription and dampening of a Wnt signal [45].  Our 
data indicate that Wnt signaling is up-regulated in ApcmNLS/mNLS mice, supporting a role 
for nuclear Apc as a negative regulator of Wnt signaling. Of note, in this study, the 
alterations in Wnt gene expression occurred without increased -catenin levels. This 
finding supports an alternate mechanism that does not require destruction of -catenin for 
Apc to elicit dampening of a Wnt signal.  We also found that cells from ApcmNLS/mNLS 
mice had no increase in nuclear -catenin, consistent with a role for nuclear Apc in 
transport of transcription repressors to the -catenin/TCF/LEF complex and/or 
sequestration of nuclear -catenin.  However, as cells from ApcmNLS/mNLS mice displayed 
some nuclear Apc, we can not fully exclude the possibility that Apc also plays a role in 
nuclear export of -catenin.   
Some Wnt target genes such as c-Myc and cyclin D1 are associated with cell 
cycle progression [46, 47].  If nuclear Apc down-regulates Wnt signaling, then reduced 
nuclear Apc should lead to enhanced TCF/LEF-mediated transcription, increased 
expression of c-Myc and cyclin D1, and consequently, more proliferation.  Our finding 
that intestinal epithelia of ApcmNLS/mNLS mice display increased Wnt signaling, including 
up-regulation of c-Myc and cyclin D1, and increased proliferation further supports a role 
for nuclear Apc in control of cell cycle progression.   
The mutations introduced into Apc were minimal, and we expected the phenotype 
of ApcmNLS/mNLS mice would be more subtle than that of previous Apc mouse models 
which express truncated Apc proteins. The combined six amino acid substitutions in Apc 
NLS1 and NLS2 do not appear to impact Apc binding to -catenin or axin (supplemental 
Fig S3.2). Apc and -catenin levels in epithelia isolated from either jejunum or ileum 
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were similar in ApcmNLS/mNLS and Apc+/+ mice (Fig. 3.3). Therefore, the alteration in 
expression of canonical Wnt targets seen in these tissues did not likely result from 
compromised -catenin degradation and it is likely that the observed phenotypes of 
ApcmNLS/mNLS mice result from compromised nuclear import of Apc.  
Nuclear Apc entry was severely compromised, but not entirely eliminated in 
MEFs from ApcmNLS/mNLS mice (Fig. 3.2). The two Apc NLSs that were inactivated in our 
mouse model are each classic monopartite NLSs, which bind to importin-in the 
cytoplasm to target protein transport through the nuclear pore [48, 49].  The continued 
presence of some Apc in the nuclei of MEFs isolated from ApcmNLS/mNLS mice supports 
the existence of alternative processes by which Apc may gain nuclear access.  In the 
mouse model described here, the two canonical NLSs are eliminated, but the Armadillo 
repeat domain which has been previously implicated in nuclear import of APC remains 
intact [20].  In human polyp tissue and colon cancer cell lines, the Armadillo repeat 
domain has been proposed to mediate nuclear entry of truncated forms of APC that lack 
the canonical NLSs [7, 50]. Moreover, the 15-amino acid repeat region of APC (aa. 959-
1338) can facilitate nuclear import of a fused green fluorescent protein [39].  It is possible 
that one or both of these auxiliary Apc domains binds to nuclear import machinery 
directly, or may allow Apc binding to other proteins that are able to facilitate nuclear 
import or retention of Apc.   
The most surprising result from this study was that ApcMin/mNLS mice had nearly 
twice as many polyps as ApcMin/+ mice (Fig. 3.7C). Furthermore, polyps from ApcMin/mNLS 
mice were larger on average than those from ApcMin/+ mice (Fig. 3.7D).  Together, these 
observations are consistent with a role for nuclear Apc in suppression of polyp initiation 
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or progression.  ApcmNLS/mNLS mice showed increased proliferation and Wnt signaling, 
either of which would be expected to enhance polyp formation. A recent report showed 
an association of Wnt target gene up-regulation with increased intestinal adenomas in 
Apc1322T/+ mice [51].  It is also possible that the observed increase in polyp number and 
size might result from a role for nuclear Apc in suppressing polyp progression, once the 
polyp is initiated.  In this scenario, polyps would initiate at the same rate in ApcMin/mNLS 
and ApcMin/+ mice, but would more rapidly grow large enough for detection in the 
ApcMin/mNLS mice.  Our finding of increased proliferation in polyps from ApcMin/mNLS mice 
compared to ApcMin/+ mice does not distinguish between these two scenarios, but does 
implicate nuclear Apc regulation of cell proliferation as a contributing factor to tumor 
suppression.   
In the current study, three separate parameters each showed a response in the 
colon distinct from that seen in the jejunum or ileum.  Epithelia from jejunum or ileum 
did not display elevated levels of either Apc or -catenin (Fig. 3.3).  In contrast, colon 
epithelia displayed Apc and -catenin protein levels that were significantly higher in 
ApcmNLS/mNLS mice compared to Apc+/+ mice.  This finding confirms that high levels of 
Apc do not always result in constitutive -catenin degradation.  Changes in expression of 
Wnt target genes were consistent with elevated canonical Wnt signaling in jejunum, 
ileum and colon tissues from ApcmNLS/mNLS mice compared to Apc+/+ mice (Fig. 3.4).  
However, BTEB2, a gene not regulated by canonical Wnt signaling, was unchanged in 
jejunum and ileum, but was elevated in colonic epithelial cells from ApcmNLS/mNLS mice 
compared to Apc+/+ mice.  Finally, unlike small intestinal tissue, colon tissue from 
ApcMin/mNLS mice did not show elevated polyp size or multiplicity compared to ApcMin/+ 
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mice (Fig. 3.7B, 3.7D). Why do the colon and small intestine tissues show distinct 
responses to manipulation of Apc NLSs?  We speculate that this variability might result 
from potential alternate feedback responses (chromosomal instability, apoptosis, survival) 
dependent on tissue type.  Moreover, colon tissue lacks villi, performs a distinct function 
and maintains a different flora than the small intestine.  Although not completely 
understood, humans and rats with germline APC mutations are prone to colon polyps, 
whereas mice with similar Apc mutations have polyps predominantly in the small 
intestine.  Any of these factors might contribute to the differences seen in colon and small 
intestinal tissue from ApcmNLS mice.  Future studies utilizing the novel ApcmNLS/mNLS 
model might offer clues to some of these longstanding puzzles in Apc biology. 
In summary, the novel ApcmNLS/mNLS mouse model contains a subtle alteration that 
inactivates both Apc NLSs.  Increased expression of Wnt targets and increased 
proliferation in intestines of adult ApcmNLS/mNLS mice implicate nuclear Apc in control of 
cellular proliferation and Wnt signaling.  The finding of increased numbers and size of 
small intestinal polyps in ApcMin/mNLS mice compared with ApcMin/+ mice implicates 
nuclear Apc in tumor suppression. Future studies of this novel mouse model will 
elucidate nuclear Apc contributions to other cellular events critical for tissue homeostasis, 
such as DNA repair, transcription regulation and cell cycle progression.  
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Figure 3.1. Generation of ApcmNLS/+ mouse ES cell lines.  (A) Schematic representation 
of Apc NLS targeting vector.  Drawn roughly to scale, the vector includes Apc exons 14 
and 15 (dark blue), with surrounding introns (light blue).  A Neomycin resistance gene 
(Neor, purple) inserted in the final Apc intron is flanked by Lox P sites (green) that will 
facilitate its excision when expressed in the testes where the tACE promoter (murine 
angiotensin-converting enzyme) drives expression of Cre recombinase.  The herpes 
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simplex virus thymidine kinase gene (TkHSV) allows negative selection of homologous 
recombinant ES cell clones.  (B)  Mutations in Apc NLS1 and NLS2 result in amino acid 
substitutions inactivating the nuclear localization signals and also introduce unique 
restriction enzyme sites for screening purposes. (C)  Analysis of ES cell lines with PCR 
using primers specific for the wildtype (wt) or mutant (m) Apc NLS allowed 
identification of 107 lines with both Apc NLS1 and NLS2 mutated. (D) Samples 2 and 4 
in the gel image shown each have both Apc NLSs mutated.  PCR reaction without 
template DNA (neg). (E) Excision of the Ace-Cre-Neor selection cassette was verified in 
N2 ApcmNLS/+ mice using PCR with primers specific for Cre. Genomic DNA isolated 
from wild type (WT) and ApcmNLS/+ ES cell lines was used as a negative and positive 
control, respectively, for the Cre primer PCR (Cr). PCR using primers specific for wild 
type sequence (wt) and mutant sequence (m) confirmed that the mouse analyzed was 
ApcmNLS/+ and demonstrated genomic DNA quality sufficient for PCR analysis. (F) 
Scheme to determine correct integration of the 5’ and 3' ends of the targeting vector. (G)  
Correct integration of the 5’ end of the targeting vector was established by PCR analysis 
using a primer specific for mutant Apc NLS2 with a second primer that recognizes 
genomic sequence outside the targeting construct and upstream of a correctly integrated 
vector.  Products of this PCR reaction were digested with Sst II to confirm integration of 
mutant Apc NLS1. (H) PCR analysis using a primer unique to the targeting construct 
with a second primer that recognizes genomic sequence outside the targeting construct 
and downstream of a properly integrated vector allowed identification of 8 recombinant 
ES cell lines that had correctly integrated the 3’ end of the targeting vector (samples 1 
and 2).  TC, targeting vector control product is ~ 1800 bp if targeting vector is integrated 
into genomic DNA.  AI, Apc integrated product is ~ 2500 bp if targeting vector is 
properly inserted into the Apc gene.   
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Figure 3.2. Reduced nuclear Apc levels in MEFs from ApcmNLS/mNLS mice.  
(A) Mouse Embryonic Fibroblasts (MEFs) isolated from congenic Apc+/+, ApcmNLS/+ and 
ApcmNLS/mNLS mice were subjected to fractionation followed by immunoblot. A single 
blot, probed for Apc, -catenin, tubulin (cytoplasmic marker) and fibrillarin (nuclear 
marker) is shown. (B) Apc band intensities were determined and results from five 
independent fractionation experiments performed on three different isolations of MEF 
cells are presented as the fraction of the total Apc protein in the nucleus ± SEM. 
ApcmNLS/mNLS MEFs displayed significantly less nuclear Apc than Apc+/+ MEFs (p = 
0.012).  (C) -catenin distribution, determined as in (B), was similar in all MEF lines. 
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Figure 3.3. Apc and -catenin levels in intestinal epithelia from ApcmNLS/+ and 
ApcmNLS/mNLS mice.  Epithelial cells were isolated from three intestinal segments 
(jejunum, ileum and colon) of congenic Apc+/+, ApcmNLS/+ and ApcmNLS/mNLS mice. 
Proteins from whole cell lysates were resolved using SDS-PAGE. Immunoblots were 
probed for Apc, -catenin and -actin which served as a loading control (top panels). 
Band intensities were determined for four samples from each genotype and are presented 
as average band intensity ± SEM relative to -actin and normalized to the Apc+/+ sample 
which was set to 1 (middle and bottom panels). Apc and -catenin levels appeared 
comparable in epithelial cells isolated from jejunum and ileum of mice of each genotype.  
Using the Mann-Whitney nonparametric test, colon tissue from ApcmNLS/mNLS mice 
showed significantly higher levels of both Apc (p = 0.017) and-catenin (p = 0.01) than 
colon tissue from Apc+/+ mice. 
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Figure 3.4. Elevation of Wnt target gene expression in ApcmNLS/mNLS mice.  Epithelial 
cells were isolated from three intestinal segments (jejunum, ileum and colon) of congenic 
Apc+/+, ApcmNLS/+ and ApcmNLS/mNLS mice. For each sample, mRNA levels of three genes 
up-regulated by canonical Wnt signaling (cMyc, Axin2, and Cyclin D1), one gene which 
is down-regulated by canonical Wnt signaling (Hath1), and one gene which is not 
regulated by canonical Wnt signaling (BTEB2), each normalized to HGPRT 
(housekeeping gene, control) were determined using real time quantitative RT-PCR.  
Results from 4-6 mice are presented as average mRNA level relative to that found in the 
Apc+/+ sample ± SEM.  p values < 0.05 as calculated using the Mann-Whitney 
nonparametric test, are indicated with *. Levels of Hath 1 mRNA in jejunum samples 
from ApcmNLS/mNLS mice were around the lower limit of detection, precluding calculation 
of a C(T) for some samples.   
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Figure 3.5.  Increased epithelial cell proliferation in intestines of ApcmNLS/mNLS mice. 
Representative images of crypts from EdU-labeled intestinal tissue isolated from Apc+/+, 
ApcmNLS/+ and ApcmNLS/mNLS mice with white line denoting crypt border (left panels). 
Dapi staining allowed identification of cell nuclei. Scale bar, 10 m. Right panels, the 
average number of EdU-positive cells per crypt cross section normalized to the total crypt 
cell number is presented with error bars indicating SEM. Samples were collected from 3 
mice of each genotype.  Top, jejunum tissues showed a significant increase in 
proliferation in ApcmNLS/mNLS mice compared to Apc+/+ mice (p < 0.0001). Middle, ileum 
tissues showed a significant increase in proliferation in ApcmNLS/mNLS mice compared to 
Apc+/+ mice (p < 0.05). Bottom, colon tissues showed a significant increase in 
proliferation in ApcmNLS/mNLS mice compared to Apc+/+ mice (p < 0.0001).  
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Figure 3.6.  Polyps in ApcmNLS/mNLS mice. (A) Low power magnification of lesion in 
colon of ApcmNLS/mNLS mouse. scale bar, 1 mm. (B) Same lesion with higher 
magnification of region outlined by white box in (A) showing epithelial atypia.  Nuclei 
are enlarged with loss of polarization. scale bar, 100 m. (C) Higher power magnification 
of region with cell atypia from (B) showing enlarged nuclei. scale bar, 25 m.  (D) A 
progression of atypia is shown in the same tissue (approximate area shown in black box 
in (A)) from lower right with more polarized nuclei to upper left with enlarged non-
polarized nuclei. A representative dysplastic crypt is outlined in white.  scale bar, 50 m.   
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Figure 3.7.  ApcMin/mNLS mice have more and larger polyps than ApcMin/+ mice. 
Polyps were identified and measured in fourteen-week old ApcMin/+ (n=12) and 
ApcMin/mNLS (n=8) mice. (A) Results presented as average polyp number per mouse ± 
SEM indicate significantly more polyps in the jejunum (p = 0.035) and the ileum (p = 
0.0002) of ApcMin/mNLS mice compared to ApcMin/+ mice. (B) Polyps were also identified 
in the colon, stomach, and duodenum but showed no statistically significant differences 
in ApcMin/mNLS and ApcMin/+ mice.  (C) Results from all G.I. tissues combined (jejunum, 
ileum, colon, stomach, duodenum) indicate significantly more polyps in ApcMin/mNLS 
compared to ApcMin/+ mice (p = 0.0021). (D) Diameters of all polyps are shown as a box 
and whisker plot.  Polyps in both jejunum and ileum were significantly larger in 
ApcMin/mNLS mice than in ApcMin/+ mice (p < 0.0001). (E) Significantly more proliferation, 
as determined by Ki-67 expression, was observed in polyps isolated from the ileums of 
ApcMin/mNLS mice than ApcMin/+ mice (p = 0.0003). (F) A tissue section of polyp from 
ApcMin/+ or ApcMin/mNLS mice stained for -catenin (a-d) with subsequent section stained 
for Ki-67 (e-h).  Scale bar in (a) is 200 m and also corresponds to (c), (e), and (g).  
Panels (b) (d) (f) and (h) show higher power magnifications of regions indicated with 
black boxes in the previous panels, with 50 m scale bar shown in (b). 
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Supplemental Figure S3.1.  Genotyping ApcmNLS/mNLS mice.  Genomic DNA from 
congenic mice was amplified by PCR using the primers described in Materials and 
Methods.  Product DNA was cut with SacII restriction enzyme to distinguish ApcmNLS 
from Apc+. 
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Supplemental Figure S3.2.  Mutations in APC NLS1 and NLS2 do not interfere with 
axin or -catenin binding.  293T cells were transfected with expression constructs for 
flag-tagged full-length APC or APC with mutations in both NLS1 and NLS2 
(APCmNLS1,2).  Anti-flag antibody was used to precipitate protein from transfected 
cells (Tfxn) or control untransfected cells.  Precipitated proteins were analyzed for the 
presence of axin and -catenin by immunoblot 
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Supplemental Figure S3.3.  -catenin distribution similar in intestinal epithelia from 
Apc+/+, ApcmNLS/+, and ApcmNLS/mNLS mice.  (A) At least three mice from each genotype 
were analyzed for -catenin localization.  In all normal intestinal tissues, -catenin 
appeared predominantly at the cell-cell junctions, with occasional nuclear distribution in 
cells near the crypt base (red arrows).   (B) Determination of crypts that contained any 
cells with nuclear -catenin revealed a similar number in mice from each genotype 
(p=0.826). 
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Supplemental Figure S3.4.  ApcMin/mNLS mice have more polyps than ApcMin/+ mice.  
Polyps identified in 14-week old mice (see Fig. 7) are presented as scatter plots.  Lines 
indicate the sample median.  
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Chapter 4 
The data and opinions in this chapter were submitted for publication in “Gastroenterology” and 
reformatted for this dissertation  
Nuclear Adenomatous polyposis coli suppresses colitis-associated tumorigenesis in mice 
Abstract 
            Because mutation of tumor suppressor gene APC is the initiating step in most colorectal 
cancers (CRC), understanding the full spectrum of APC functions will illuminate better 
diagnostic, preventive and therapeutic strategies for the disease. Although APC shuttles between 
the cytoplasm and nucleus, testing proposed roles for nuclear APC in the context of a whole 
organism was only recently made possible using a mouse model compromised for nuclear Apc 
which we generated by introducing germline mutations that inactivate the Apc nuclear 
localization signals (ApcmNLS). Our previous analysis of ApcmNLS mice revealed a role for nuclear 
Apc in regulation of Wnt signal transduction and intestinal cell proliferation as well as in tumor 
suppression.  In humans, chronic colitis significantly increases CRC risk and APC mutations 
occur late in this cancer progression. In the current study, we show increased expression of 
inflammatory mediators cyclo-oxygenase-2 (Cox-2) and macrophage-inflammatory-protein-2 
(MIP-2) in colon epithelial cells from ApcmNLS/mNLS mice, suggesting a role for nuclear Apc in 
suppressing colitis-mediated colon cancer. To test this hypothesis, we initiated colon tumors with 
a single injection of the mutagen, azoxymethane (AOM) and promoted the tumors with repeated 
oral administration of dextran sodium sulfate (DSS) to induce colonic inflammation. When 
treated with AOM-DSS, ApcmNLS/mNLS mice developed more colonic tumors than treated 
wildtype mice. Tumors from treated ApcmNLS/mNLS and wildtype mice had the same spectrum of 
-catenin mutations, proliferation rates and histopathological features, consistent with the 
ApcmNLS allele enhancing colitis-associated tumor initiation rather than progression. 
ApcmNLS/mNLS mice had increased weight loss and colonic lymphoid follicles implicating nuclear 
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Apc in suppression of AOM-DSS-induced colitis. These findings reveal novel functions for 
nuclear Apc and also indicate a critical protective role for Apc early in inflammation-induced 
colon tumorigenesis. 
Introduction 
As the second leading cause of cancer-related deaths in the United States, colorectal 
cancer (CRC) is responsible for nearly 50,000 deaths each year. Inflammation is considered a 
major risk factor for CRC and one fifth of all persons with inflammatory bowel disease (IBD) 
develop colon cancer. This colitis-associated cancer is characterized by poor prognosis and 
relatively high mortality rate of ~50% [1]. Anti-inflammatory drugs such as Aspirin and 
Celebrex can reduce the risk of CRC, not only in persons with IBD but also in the general 
population [2]. A better understanding of the contribution of inflammation to the underlying 
biology of CRC is needed to develop more effective preventive, diagnostic and therapeutic 
regimens. 
Adenomatous polyposis coli (APC) is the primary CRC suppressor gene, with APC 
mutations implicated in initiation of >80% of all CRC. The APC gene product is a large (310 
kDa) multi-domain protein, which localizes to both the cytoplasm and the nucleus [3]. APC has 
many cellular functions, the best characterized of which is antagonizing the Wnt signaling 
pathway [4]. In this capacity, APC forms a cytoplasmic complex with axin, GSK3, and other 
proteins that targets the oncoprotein -catenin for proteasome-mediated degradation [5]. APC 
also shuttles between the cytoplasm and the nucleus using at least 2 nuclear localization signals 
(NLS) and 5 nuclear export signals (NES) [6].  
APC has several proposed nuclear functions. APC and -catenin can interact in the 
nucleus [7] and we provided evidence that this interaction leads to transcriptional repression of 
Wnt target genes and ultimately inhibition of cellular proliferation [6]. We also showed that 
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nuclear APC interacts with Topoisomerase II, a critical enzyme required for DNA replication 
and a target for traditional cancer chemotherapeutics [8]. Studies from other groups implicate 
nuclear APC in DNA repair [9] and synthesis [10]. Until recently, analyses of nuclear APC 
activities relied on purified proteins or cultured cells as there was no animal model to enable 
characterization of nuclear APC functions in the context of a whole organism. 
To better understand the role of nuclear APC in tissue homeostasis and tumor 
suppression, we generated a mouse model in which the nuclear import of Apc is compromised by 
the introduction of mutations into both NLSs [11].  We found that these mutant mice 
(ApcmNLS/mNLS) have  higher rates of cellular proliferation than their wild-type counterparts and 
increased expression of Wnt target genes [11]. We also found that ApcMin/+ mice, the most widely 
utilized mouse model of intestinal polyposis mediated by truncating germline Apc mutation, 
develop more and larger intestinal tumors when they also harbor the ApcmNLS allele 
(ApcmNLS/Min). Together these data suggest a tumor suppressor function for nuclear Apc [11]. 
In the current study, we tested the potential roles for nuclear Apc in the AOM-DSS 
mouse model of colitis-mediated colon cancer. In this model, colon cancers are initiated with a 
single injection of the mutagen, azoxymethane (AOM) and are promoted with repeated oral 
administration of dextran sodium sulfate (DSS) to induce colonic inflammation [12]. Using this 
model, we examined the requirement of nuclear APC in suppression of colitis-associated CRC.  
In contrast to the small intestinal tumors that predominantly develop in ApcMin mice, the AOM-
DSS-treated mice develop tumors in the colon, the site of tumor formation in humans with 
mutated APC [13]. Furthermore, most mouse models with germline Apc mutations express 
truncated Apc lacking both -catenin degradation and nuclear localization domains. However, 
Apc mutations are not typically found in colon tumors from AOM-DSS-treated mice. Rather, 
mutations in -catenin that render it incapable of Apc-mediated destruction are considered the 
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initiating step [12]. This feature allows us to distinguish tumor suppressor functions of nuclear 
Apc from the cytoplasmic role of Apc in targeting -catenin for destruction. 
Here we show that nuclear Apc suppresses colon tumorigenesis in the AOM-DSS mouse 
model. We provide evidence that this tumor suppression is at the initiation stage of 
tumorigenesis. Based on the cumulative data obtained using the ApcmNLS model, we propose that 
nuclear Apc protects against colitis-associated colon tumorigenesis by suppressing inflammation, 
inhibiting Wnt signaling and increasing colonocyte proliferation. 
Materials and methods 
Mouse Husbandry 
Mice were maintained at the Animal Care Unit at the University of Kansas according to 
animal use statement number 137-01. The research complied with all relevant federal guidelines 
and institutional policies. Mice were fed ad libitum with Purina Lab Diet 5001 and were housed 
in cages in adjoining animal rooms. All mice are C57BL/6J and ApcmNLS/mNLS mice are congenic 
(>F15). 
Analysis of mRNA from colon epithelial cells by real-time reverse transcription–PCR 
Colon epithelial cells from ApcmNLS/mNLS and Apc+/+ were isolated, mRNA was extracted 
and quantitative polymerase chain reaction (QPCR) of the cDNA was performed as described 
using primers listed in Table 4.1 [11].  
Analysis of colons 
  Fifteen ApcmNLS/mNLS and 8 Apc+/+ mice received an intra-peritoneal injection of 7.5 
mg/Kg AOM at the age of 6 weeks followed by 3 cycles, 5 days each, of 2.5% of Dextran 
Sodium Sulfate (DSS) in the drinking water at 7, 10 and 13 weeks. Fourteen ApcmNLS/mNLS and 
10 Apc+/+ mice were not treated and served as control groups. Mice were sacrificed at 24 weeks, 
then the large intestine was removed, measured, opened longitudinally and fixed in 10% buffered 
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formalin overnight followed by 70% ethanol until use. Colonic tumors and lymphoid follicles 
were identified and measured by an investigator blind to the animal’s genotype using a dissecting 
microscope with 10X magnification and with the aid of an eyepiece graticule calibrated to a 50-
mm scale stage micrometer with 0.1 and 0.01-mm graduation (Leica). 
Histopathological examination 
All tumors and representative lymphoid follicles were dissected from the surrounding 
tissues, processed and paraffin-embedded. Sections (8 m) were stained with hematoxylin-eosin 
and examined by a pathologist. 
Detection of -catenin and Kras mutations 
DNA was extracted using the QIAamp DNA FFPE tissue kit (Qiagen) from 3-8 manually 
microdissected, 8 m sections of paraffin-embedded tissue for each tumor and amplified using 
primers spanning -catenin exon 3 and Kras exon 1 listed in Table 4.2. Gel purified PCR 
products were sequenced (ACGT Inc.).  
Assessment of proliferation 
Paraffin embedded tumors were sectioned at 8-µm and stained for proliferation marker 
Ki-67 as described [11]. Images from at least three fields per tumor (100 m x 100 m) were 
analyzed for Ki-67 positive cells at 40X magnification.   
Statistical Analysis 
p-values were calculated using Student t-test, Mann-Whitney non parametric tests, 
Fisher’s exact test and GraphPad Prism software as indicated in figure legends. 
Table 4.1: Primers to quantify targets that were differentially expressed in ApcMin/+ polyps  
Gene Forward primer Reverse primer 
Cox-1 5’-AAGGAGTCTCTCGCTCTGG-3’ 5’-CTGGTTCTGGCACGGATAGT-3’ 
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Cox-2 5’-CATTCTTTGCCCAGCACTTC-3’ 5’-GGCGCAGTTTATGTTGTCTG-3’ 
CXCR-2 5’-AGCAGAGGATGGCCTAGTCA-3’ 5’-TCCACCTACTCCCATTCCTG-3’ 
P21 Cip 5’-TTGCACTCTGGTGTCTGAGC-3’ 5’-GGGCACTTCAGGGTTTTCTC-3’ 
MIP-2 5’-CAGACTCCAGCCACACTTCA-3’ 5’-CAGTTCACTGGCCACAACAG-3’ 
HGPRT 5’- TGCTCGAGATGTCATGAAGG-3’ 5’- TATGTCCCCCGTTGACTGAT-3’ 
 
 
Table 4.2: Primers for mutation analysis of -catenin and K-Ras in tumors 
-catenin 5’-TTCAGGTAGCATTTTCAGTTCA-3’ 5’-TGCTAGCTTCCAAACACAAATGC-3’ 
Kras 5’-TGTAAGGCCTGCTGAAAATG-3’ 5’-GCACGCAGACTGTAGAGCAG-3’ 
 
Results 
Increased expression of inflammatory mediators in colon epithelial cells from ApcmNLS/mNLS 
mice 
Loss of the wildtype Apc allele in intestinal epithelial cells of ApcMin mice resulted in 
development of tumors that showed differential gene expression. Although some up-regulated 
genes were not previously characterized Wnt targets, many were, illustrating the importance of 
Apc in antagonizing Wnt signal-induced cellular proliferation [14].  Our lab previously showed 
that ApcmNLS/mNLS mice have higher expression of Wnt target genes in intestinal epithelial cells 
[11]. To determine if other genes reported to be differentially expressed in apparently normal 
colon epithelial cells of ApcMin mice also have altered expression in ApcmNLS/mNLS mice, 
expression levels of Cyclo-oxygenase-1 (Cox-1), Cyclo-oxygenase-2 (Cox-2), CXCR-2, p21Cip 
and  Macrophage inflammatory protein-2 (MIP-2) were compared in colon epithelial cells from 
ApcmNLS/mNLS and Apc+/+ mice. There were no significant differences in the expression levels of 
Cox-1, CXCR-2 and p21Cip in ApcmNLS/mNLS samples relative to Apc+/+ samples (data not shown). 
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However, Cox-2 and MIP-2 mRNA levels were each significantly higher in colon epithelial cells 
from ApcmNLS/mNLS compared with Apc+/+ mice (Figure 4.1). 
ApcmNLS/mNLS mice have higher susceptibility to colitis-associated colon tumorigenesis. 
Inflammation is a major risk factor for the development of colorectal cancer [1].  Both 
Cox-2 and MIP-2 are involved in inflammation. Cox-2 is the rate-limiting step in arachidonic 
acid conversion to inflammatory mediators including prostaglandins [15]. MIP-2 is a pro-
inflammatory chemokine [16]. The finding that both Cox-2 and MIP-2 are up-regulated in colon 
epithelial cells from ApcmNLS/mNLS mice indicates a potential role for nuclear Apc in 
inflammation. We previously showed that the ApcmNLS allele increases intestinal tumorigenecity 
in mice harboring a germline mutation that results in Apc truncation, ApcMin [11]. Considering 
these findings, we hypothesized a role for nuclear Apc in the protection against colitis-associated 
tumorigenicity. To test this hypothesis, we treated 6 week old ApcmNLS/mNLS and Apc+/+ mice with 
a single dose of the mutagen Azoxymethane (AOM). This was followed by 3 cycles, 5 days 
each, of 2.5% Dextran Sodium Sulfate (DSS) administered in the drinking water at 7, 10 and 13 
weeks (Figure 4.2A). Five of fifteen treated ApcmNLS/mNLS mice (33%) developed rectal prolapse 
and were sacrificed at age 20.6, 20.6, 21, 21 and 22.6 weeks, whereas only one of eight treated 
Apc+/+ mice required early termination (at 22.9 weeks) due to rectal bleeding. The remaining 
mice were sacrificed at 24 weeks. In addition, two untreated control groups of ApcmNLS/mNLS and 
Apc+/+ mice were sacrificed at 24 weeks of age, at which time none displayed detectable colon 
tumors.  While all of the ApcmNLS/mNLS treated mice developed at least one colonic tumor, over 
one-third of the treated Apc+/+ mice remained colon tumor-free at the end of the study (Figure 
4.2B, 4.2C, 4.2D). Moreover, tumor numbers in treated ApcmNLS/mNLS mice were more than 
double that of treated Apc+/+ mice (Figure 4.2E).  Histopathological examination of 20 tumors 
from ApcmNLS/mNLS mice and 10 tumors from Apc+/+ mice indicated that all were polypoidal, 
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semi-flat or flat adenomas with some degree of atypia (Figure 4.2F). Moderate to marked 
lymphoplasmacytic infiltration was observed in most tumors with varying degree of 
inflammatory reactions. We conclude that AOM-DSS-treated ApcmNLS/mNLS mice have higher 
tumor incidence and multiplicity than Apc+/+ mice and that tumor histology is similar in all mice. 
Nuclear Apc suppresses the initiation of colitis-associated tumorigenesis  
To determine the mechanism by which ApcmNLS increases tumor formation in the AOM-
DSS model, we investigated several predicted contributory elements. Weight loss and shortening 
of colon length are used as inflammation parameters in AOM-DSS mouse models [17]. We 
found that treated ApcmNLS/mNLS mice lost significantly more weight than treated Apc+/+ mice 
relative to the corresponding untreated control groups (Figure 4.3A). Colon lengths were reduced 
by 11% in treated ApcmNLS/mNLS mice and by only 8% in treated Apc+/+ mice, but this trend did 
not reach statistical significance (Figure 4.3B). Untreated ApcmNLS/mNLS and Apc+/+ mice had 
similar numbers of lymphoid follicles visible with the aid of a dissecting microscope and 10X 
magnification (Figure 4.3C). However, the treated ApcmNLS/mNLS  mice had significantly more 
visible lymphoid follicles than the treated Apc+/+  mice (Figure 4.3C). Together, these data 
suggest that there is more severe inflammation in AOM-DSS-treated ApcmNLS/mNLS mice than in 
treated Apc+/+ mice. 
Tumor size in treated ApcmNLS/mNLS  and Apc+/+ mice did not significantly differ (Figure 
4.3D), nor did proliferation level as assessed by proliferation marker, Ki-67 (Figure 4.3E & F). 
Taken together, it appears that tumor growth is not affected in ApcmNLS/mNLS mice. 
Tumors from treated ApcmNLS/mNLS and Apc+/+ mice have similar spectrum of -catenin 
mutations and no Kras mutations 
Stabilizing mutations in -catenin exon 3 and activating mutation of Kras codon 12 are 
characteristics of tumors from mice treated with AOM-DSS. We found mutations in -catenin 
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exon 3 in each of the 10 Apc+/+ tumors examined and in 24/25 ApcmNLS/mNLS tumors examined 
(Figure 4.4A). Furthermore, the specific missense mutations in -catenin were similar in both 
groups (Figure 4.4B, 4.4C). No mutations were found in exon 1 of kras in tumors from either 
group (data not shown). These results implicate nuclear Apc in inhibiting initiation of 
inflammation-induced tumorigenicity in mice. 
Discussion 
Promiscuous Wnt signaling is a hallmark of CRC in both sporadic and colitis-associated 
cases but this promiscuity is the result of different genetic events. While APC mutation is the 
initiating event in most sporadic cases, APC-independent -catenin activation is a typical early 
event in colitis-associated CRC. Interestingly, in colitis-associated-CRC, mutation of APC still 
occurs, however at a later stage of tumor formation [1]. This suggests two distinct tumor 
suppressor roles for APC that must be eliminated during CRC progression. Some APC 
function(s) need to be abolished early, including regulation of Wnt signaling, while the other 
activities must be eliminated later for the cancer to progress. In sporadic cases of colon cancer, 
both roles for APC are eliminated early by mutating APC. On the other hand, in colitis-
associated cancer, the early development of a colon tumor is typically associated with APC-
independent -catenin nuclear translocation [1].  In a mouse model of colitis-associated CRC, 
colon tumors are initiated by a single injection of the mutagen AOM which leads to “stabilizing” 
mutations in -catenin, followed by treatment with DSS to induce inflammation in the colon 
[12]. Injection with a single dose of AOM without subsequent DSS treatment results in only a 
very low tumor incidence [18], emphasizing that aberrant regulation of Wnt signaling by -
catenin stabilization is not sufficient for tumor formation.  In humans, most colon cancers display 
mutations in APC while tumors in other organs often show mutations in other Wnt pathway 
components [4].  This difference could be explained, at least in part, if the second tumor 
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suppressor function of APC is particularly critical in the colon. In addition, nonsense mutations 
that truncate the C-terminal 200- 300 amino acids of APC do not alter Wnt signal regulation but 
are associated with increased tumorigenesis in both humans [19, 20] and in the AOM-DSS rat 
model [21]. In contrast, more severe truncation of APC can initiate tumor formation in both 
humans and rodent models, highlighting the importance of other tumor suppressor function(s) of 
APC. Here we provide evidence that nuclear APC functions in suppressing initiation of colitis-
associated CRC.   
In this study, we found that ApcmNLS/mNLS mice have increased colitis-associated tumor 
susceptibility as indicated by an increase in both tumor incidence and multiplicity after treatment 
with AOM-DSS. One possible explanation for this finding is that nuclear Apc suppresses 
inflammation in the colon. In support of this idea, we found up-regulation of the inflammatory 
mediators, Cox-2 and MIP-2 in normal colon epithelial cells from ApcmNLS/mNLS mice (Figure 
4.1). Many inflammatory mediators are up-regulated in ApcMin/+ polyps including Cox-1, Cox-2, 
MIP-2, osteopontin  (OPN), CXCR-2, growth-related oncogene- Gro- [14]. While Cox-2 is 
generally considered a Wnt target [22-24], the other genes are not known to be regulated by Wnt 
signaling, suggesting a Wnt-independent role for Apc in gene regulation and protection against 
inflammation. In this study, colons from AOM-DSS-treated ApcmNLS/mNLS mice had more visible 
lymphoid follicles than those from treated Apc+/+ mice. Lymphoid follicle incidence has been 
correlated with the degree of colonic inflammation and mucosal destruction [25]. Furthermore, 
tumors adjacent to lymphoid follicles have more cellular proliferation than tumors more distant 
from lymphoid follicles [25].         
We found no change in tumor size or tumor cell proliferation in treated ApcmNLS/mNLS 
mice, suggesting nuclear Apc suppresses tumor initiation rather than tumor progression. In 
addition, there were no histo-pathological differences in tumors from Apc+/+ and ApcmNLS/mNLS 
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mice and they possessed the same spectrum of exon 3 -catenin mutations. Together, these 
findings suggest loss of nuclear APC function initiates colon tumors at a step prior to Wnt signal 
dysregulation. The idea that APC mutation can initiate tumors before Wnt dysregulation is 
supported by findings in humans and in rodent and zebrafish models. In most early lesions from 
FAP patients, both copies of APC are mutated, however aberrant Wnt activation is not observed 
until lesions are advanced [26, 27]. In PIRC rats, which carry a germline mutation in Apc, 
nuclear -catenin is detected in late but not early adenomas [28]. Furthermore, results from a 
study using a zebrafish model led to the proposal that Wnt signaling dysregulation is the second 
of two steps necessary for tumor initiation after apc mutation and the transcriptional co-repressor 
CtBP1 is required for the first step [29]. Of note, previous data had implicated nuclear APC in 
facilitating the nuclear import of CtBP1 [30].      
Nuclear APC can repress Wnt target gene expression both in-vivo and in tissue culture 
cells. The proposed mechanisms for this repression, supported by analysis of the ApcmNLS/mNLS 
mouse model include; 1) nuclear APC sequestration of -catenin to prevent interaction with 
LEF-1, and 2) APC facilitated interaction of the transcription repressor CtBP1 with the 
promoters of Wnt target genes [6, 11]. Considering these findings, higher Wnt target expression 
might contribute to the increased colitis-associated tumorigenicity in ApcmNLS/mNLS mice. We 
propose that in Apc+/+ mice, nuclear Apc can reduce expression of Wnt target genes in cells with 
stabilized -catenin by sequestering -catenin from LEF-1 or by importing the co-repressor 
CtBP1. In contrast, in colon cells from ApcmNLS/mNLS mice, Apc nuclear import is compromised 
thus, Apc cannot repress transcription mediated by a stabilized -catenin.  
Inflammation and Wnt signal up-regulation are not completely independent factors. 
Inflammation can activate Wnt signaling through many pathways including NF- . 
Moreover, it has been reported that APC mutations can alter retinoic acid metabolism, leading to 
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Wnt-independent up-regulation of Cox-2. The induced Cox-2 increases PGE2 synthesis, which 
in turn activates Wnt signaling [31, 32]. On the other hand, Wnt signaling can increas
inflammatory response through up-regulation of some inflammatory mediators including Nitric 
oxide synthase2 (NOS-2) [
e 
33] and Cox-2 [24]. Cox-2 is involved in colorectal tumor formation 
and often up-regulated in colon cancer [32]. Cox-2 inhibitors have been used to treat CRC [2, 
34]. Besides being the rate limiting enzyme in the synthesis of inflammatory mediators, Cox-2 
also induces the anti-apoptotic Bcl2 [35], the angiogenic VEGF [36]and the pro-tumor cytokine, 
IL-23 and inhibits the tumor suppressor cytokine IL-12 [37].   
In conclusion, using the novel ApcmNLS/mNLS mouse model, we provide evidence that 
nuclear Apc contributes to suppression of colitis-associated CRC initiation. Further studies using 
the ApcmNLS/mNLS mouse model will allow elucidation of less characterized tumor suppressor 
functions of APC. Ultimately, this knowledge is expected to lead to better diagnostic, prognostic 
and therapeutic approaches for colorectal cancer.   
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Figure 4.1: Differential expression of inflammatory mediators in ApcmNLS/mNLS mice  
Cox-2 and MIP-2 mRNA levels were each significantly higher in colon epithelial cells from 
ApcmNLS/mNLS mice than from Apc+/+ mice (p <0.001 for Cox-2 and p<0.05 for MIP-2, Mann-
Whitney non-parametric test). Messenger RNA levels were normalized to mRNA for the 
housekeeping gene HGPRT and are presented as average fold change calculated using ΔΔC(t). 
Error bars represent s.e.m. “*” indicates statistical significance. 
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Figure 4.2: ApcmNLS allele increases tumor incidence and multiplicity in AOM-DSS mouse 
model. (A) AOM-DSS treatment protocol. Representative samples of large intestines from 
treated Apc+/+ (n=8) (B) and ApcmNLS/mNLS (n=15) mice (C), scale bars = 1cm. (D) Tumor 
incidence was significantly higher in treated ApcmNLS/mNLS mice compared to treated Apc+/+ mice 
(p < 0.05, Fisher’s exact test). (E) ApcmNLS/mNLS mice had significantly more colon tumors than 
Apc+/+ mice (p < 0.05, using student t-test). Error bars represent s.e.m and significant values are 
indicated with *. (F) Histopathology of representative polypoidal (top) and semi-flat (bottom) 
colonic tumors from treated ApcmNLS/mNLS mice. Higher magnifications of boxed areas are 
presented. Scale bars 200 m (left panels), 100 m (middle) and 50 m (right). 
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Figure 4.3: Nuclear Apc protects against colitis-associated tumor initiation rather than 
progression. (A) The average weight change of AOM-DSS-treated mice is shown relative to the 
untreated mice from both ApcmNLS/mNLS and Apc+/+ groups. ApcmNLS/mNLS mice lost significantly 
more weight than Apc+/+ mice (p<0.01, using Student t-test). (B) The reduction of colon length in 
treated ApcmNLS/mNLS and Apc+/+  mice relative to their respective untreated control groups is 
presented as average ± s.e.m. (p=0.24) (C) The average number of visible lymphoid follicles was 
significantly more in treated ApcmNLS/mNLS mice relative to treated Apc+/+ mice (p<0.05, using 
Student t-test) (D) The diameters of colon tumors from treated ApcmNLS/mNLS and Apc+/+ mice 
presented as box and whiskers plots showed no significant difference in the size of the tumors 
from each treated mouse group (p>0.05, using Student t-test). (E) Box and whiskers plots of 
proliferation marker Ki-67-positive cells per (100 m x 100 m) high-power field (hpf) from 
ApcmNLS/mNLS and Apc+/+ mice showed no significant difference between groups (p>0.05, using 
Student t-test). (F) Representative images of Ki-67 staining, scale bar = 100 µm.  
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Figure 4.4: Tumors from treated ApcmNLS/mNLS and Apc+/+ mice have the same spectrum of 
-catenin mutations. (A) Representative sequencing chromatographs showing a G->A (middle) 
or a C->T (lower) mutation (arrows) or the normal control -catenin coding sequence (top). (B) 
The distribution of -catenin exon 3 mutations found in tumors from ApcmNLS/mNLS and Apc+/+ 
mice is displayed as the relative frequency at each codon. (C) The predicted amino acid 
alterations resulting from the missense mutations in exon 3 of -catenin are presented for tumors 
from treated ApcmNLS/mNLS (top) and Apc+/+ (bottom) mice.  
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 Chapter 5 
Loss of heterozygozity and extra-intestinal phenotypes of ApcmNLS/NLS mice 
Abstract 
This chapter contains additional data from studies of the ApcmNLS/Min mice.  The 
chapter is divided into two parts.  In the first part, we show that polyps from ApcmNLS/Min 
mice show loss of heterozygosity (LOH) with loss of the ApcmNLS allele. We discuss 
possible explanations and our future directions.  In the second part, we show that 
ApcmNLS/Min mice have more severe anemia, enlarged spleens and enhanced mammary 
tumorigenicity relative to ApcMin/+ mice, which indicates that ApcmNLS enhances extra-
intestinal phenotypes in ApcMin mice.  We also provide data regarding LOH in two 
mammary tumors that developed in ApcmNLS/Min mice; loss of ApcMin appears to occur in 
one tumor  
Part 1: Loss of heterozygosity (LOH) in intestinal polyps from ApcmNLS/Min mice 
Introduction 
As described in Chapter 2, there is loss of the wild-type Apc allele in most 
intestinal tumors that develop in ApcMin/+ mice [1, 2]. This loss of heterozygosity (LOH) 
is thought to be required for tumor formation in these mice. ApcmNLS/mNLS mice typically 
do not develop intestinal polyps. However, as shown in Chapter 3, ApcMin mice that carry 
the ApcmNLS allele (ApcmNLS/Min) develop more intestinal tumors, with tumors larger in 
size than ApcMin/+ mice [3]. To test for LOH in intestinal polyps from ApcmNLS/Min mice, 
we measured the relative abundance of the ApcmNLS and ApcMin alleles in genomic DNA 
extracted from mouse tails and intestinal polyps using the quantitative real-time 
polymerase chain reaction (qPCR). We used 2 TaqMan® probes, each labeled with a 
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different fluorescent dye (6-FAM and HEX), and specific for the ApcmNLS or ApcMin allele, 
respectively. We found a reduction in relative abundance of the ApcmNLS allele and an 
increase in relative abundance of the ApcMin allele in genomic DNA isolated from 
intestinal polyps compared to DNA from tails of ApcmNLS/Min mice. We concluded that 
LOH occurs in polyps from ApcmNLS/Min mice, resulting in loss of the ApcmNLS allele. 
Materials and methods 
Genomic DNA extraction 
For each of 5 ApcmNLS/Min mice, three ileal tumors were isolated from freshly 
dissected, longitudinally opened, small intestines with the aid of a dissecting microscope. 
The tumors were digested using 100 µg proteinase K in a 200-µl total reaction volume at 
55o C for 2 hours, followed by inactivation of the enzyme by heating at 95 o C for 5 
minutes. Genomic DNA from the tumors and tails was then purified using the standard 
phenol/chloroform separation method and DNA from 3 tumors from each mouse was 
combined for analysis.  
Quantitative PCR    
Primers were designed to flank Apc-NLS2 and produce a PCR product of 152 bp. 
Two TaqMan® probes were designed to recognize either mutant Apc-NLS2 sequence 
(ApcmNLS allele) or the wild-type sequence (found in the ApcMin allele); table 5. 1. The 
mutant NLS2 probe has 6-FAM and the wild-type probe has HEX at its 5’ end, and both 
probes include the quencher Iowa black® IDT (IABkFQ). PCR reactions were carried out 
using an Opticon 2 DNA Engine Thermocycler with every reaction performed in 
duplicate. The reaction mix contained 1X HS DyNamo qPCR mix (NEB), 15 picomoles 
of each primer and probe, and approximately 250 ng DNA. The reaction was initially 
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heated at 95 o C for 15 minutes to activate the polymerase followed by 40 cycles of 
denaturation at 94 o C for 20 seconds, annealing at 54 o C for 20 seconds, and extension at 
72 o C for 30 seconds. This was followed by detection of fluorescence. The change of the 
relative abundance of the ApcmNLS to ApcMin alleles in the tumor and tail DNA from every 
mouse was calculated using ΔC(t). 
Table 5. 1: primers used in qPCR for LOH analysis in polyps from ApcmNLS/Min mice 
 
Primer (probe) Sequence 
NLS2 QPCRF  5’-TTC TAG GGC TCT GCT TTT CG-3’ 
NLS2 QPCRR 5’-CGA AGA CAC CCC TGT CTG TT-3’ 
NLS2 TaqMan probe 
(ApcmNLS probe) 
5’-6-FAM/AGG CCT TTT TGC GGC C-3’IABkFQ 
NLS2 TaqMan probeN 
(ApcMin probe) 
5’-HEX/CCA AAA AAG AAA AGG CCT TCA AG-3’ IABkFQ 
 
 
Results 
We found a significant reduction in abundance of the ApcmNLS allele compared to 
the ApcMin allele in the polyps relative to the tail DNA of the same mice (the relative 
abundance is 0.05, p =  0.015873, Mann-Whitney test); figure 5.1A. 
Discussion 
LOH of the wild-type Apc allele is required for the development of intestinal 
polyps in ApcMin/+ mice [1, 2]. The mechanism of LOH in ApcMin/+ mice is believed to be 
either complete loss and duplication of the whole chromosome carrying Apc 
(chromosome 18) or somatic recombination involving the q arm of the acrocentric 
chromosome 18. This LOH results in two copies of the mutant allele (ApcMin) in polyp 
cells [4, 5]. We found that polyps from ApcmNLS/Min mice have an increased abundance of 
the ApcMin allele relative to the ApcmNLS allele, consistent with loss of ApcmNLS allele in 
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these polyps (figure 5. 1A). Although our data suggest duplication of ApcMin allele as well 
(we see increased amounts of the ApcMin allele in the polyps), comparing the abundance 
of both alleles with another DNA locus on another chromosome will allow us in the 
future to differentiate between complete loss and “loss and duplication” of the ApcMin 
allele in the polyps.  
Our results of loss of the ApcmNLS allele in polyps from ApcmNLS/Min mice are 
interesting in light of the data showing that ApcmNLS/Min mice develop more intestinal 
polyps than do ApcMin/+ mice. Furthermore, the polyps from ApcmNLS/Min mice are larger 
and have a higher proliferative index compared to those from ApcMin/+ mice[3]. 
Considering that the ApcmNLS allele is lost in polyps from ApcmNLS/Min mice and the Apc+ 
allele is lost  in the polyps from ApcMin/+ mice, why would there be an increase in the 
number (figure 5. 1B), size, and proliferative index of polyps from ApcmNLS/Min mice 
relative to ApcMin/+ mice?   
A non-autonomous role for the ApcmNLS allele in intestinal tumorigenicity that 
increases the rate of tumor growth after the occurrence of LOH could provide one 
explanation. Enhanced tumor growth could increase the number of polyps detected, by 
allowing these polyps to reach the detection size limit earlier. Recently, it has been shown 
that a conditional mutation of Apc in uterine stroma results in development of 
endometrial tumors, a result that supports a non-autonomous role for Apc in other tissues 
[6, 7]. Alternatively, the ApcmNLS allele may increase the number of polyps in ApcmNLS/Min 
mice by increasing the rate of LOH in these cells. Mutation of Apc has been associated 
with chromosomal instability [8]. Furthermore, nuclear APC interacts with TopoII, an 
enzyme important for DNA replication [9]. Another possible mechanism is through 
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activation of Wnt signaling in cells with the ApcmNLS allele. Wnt signaling increases 
chromosomal instability [10, 11]. We have shown that the ApcmNLS allele has a role in 
stimulating Wnt signaling activity in intestinal epithelial cells (Chapter 3) [3].  
One caveat to consider when interpreting the experimental data is that the DNA 
from 3 different polyps from the ileum was combined for each mouse. It is possible that 
loss of the ApcmNLS allele does not occur in every polyp. To test this possibility, we will 
extract DNA from individual polyps from jejunums, ileums and colons from different 
ApcmNLS/Min mice, and will test for LOH. Another important note is that we detected, 
albeit in very small amounts, the ApcmNLS allele in the polyps. We think that this trace 
amount of ApcmNLS allele represents the normal tissues in the polyps such as vascular and 
connective stromal tissue. To test this prediction, we are planning to stain polyps from 
these mice with an antibody that recognizes the c-terminal portion of Apc. This antibody 
should recognize the ApcmNLS but not ApcMin protein and will allow visualization of LOH 
in individual tumor cells within the polyps. In conclusion, our preliminary data suggest 
that loss of the ApcmNLS allele occurs in intestinal tumors that develop in ApcmNLS/Min 
mice.  
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Figure 5.1: LOH in intestinal polyps from ApcmNLS/Min mice. (A) A representative 
example of real-time PCR results quantifying the ApcmNLS  (solid lines) and ApcMin 
(dashed lines) alleles from genomic DNA extracted from three intestinal polyps (red) and 
the tail of the same mouse (green). There is a decrease in the abundance of the ApcmNLS 
allele compared to that of the ApcMin allele in intestinal polyps. (B) A diagram shows the 
Apc protein structure predicted in normal cells and in intestinal polyps. 
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Part 2: The ApcmNLS allele enhances extra-intestinal phenotypes in ApcMin mice 
Introduction 
In addition to intestinal polyps, ApcMin/+ mice develop other manifestations 
outside the gastrointestinal tract [12]. ApcMin/+ mice develop progressive microcytic-
hypochromic anemia [13]. Chronic blood loss from intestinal polyps is thought to be the 
etiology of this anemia. Other studies, however, showed that changes in the bone marrow 
microenvironment of ApcMin/+ mice may also participate in anemia development [14]. 
ApcMin/+ mice also develop large spleens (splenomegaly) [14]. Another interesting extra-
intestinal phenotype seen in older female ApcMin/+ mice is the development of mammary 
tumors [15]. This mammary tumorigenesis is characterized by low penetrance (~5%) and 
late development (16 ± 3.5 weeks) [15]. Other extra-intestinal phenotypes in ApcMin/+ 
mice include changes in immune cell production, gonadal abnormalities, and abnormal 
lipid profiles (see chapter 2) [14, 16-18]. 
Mice carrying both the ApcMin and ApcmNLS alleles showed enhanced intestinal 
tumorigenicity [3]. We examined ApcmNLS/Min mice for extra-intestinal manifestations and 
found these to be more severe as well. ApcmNLS/Min mice develop more severe anemia and 
larger spleens compared to ApcMin/+ siblings. Two out of seven 17-weeks-old ApcmNLS/Min 
females developed mammary tumors while none of seven ApcMin/+ female littermates 
developed mammary tumors. These data suggest that the ApcmNLS allele also enhances 
extra-intestinal phenotypes in ApcMin mice. 
Materials and methods 
Dissection and weighing of liver, spleens and mammary tumors  
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After being euthanized by use of CO2,
 ApcmNLS/Min, ApcMin/+ and Apc+/+ mice 
were weighed. The livers and spleens were removed, washed in PBS, weighed, and fixed 
in 10% saline-buffered formalin overnight, then soaked in 70% ethanol. The ratio of liver 
and spleen weight to total body weight per mouse was determined. Mammary tumors 
found in two older ApcmNLS/Min mice were dissected from the skin and processed in a 
similar manner.   
Complete blood count analysis 
Immediately after euthanasia with CO2, blood (0.5 - 1 ml) was drawn from the 
mouse by means of intra-cardiac puncture with a 20G heparinized needle. The blood was 
sent to “Physician Reference Laboratory” (Overland Park, KS) for complete and 
differential blood count (CBC) analysis. 
Genomic DNA extraction from mammary tumors 
About 1 mg of fixed tumor tissue was isolated from the tumor by use of a new 
scalpel and then minced into small pieces. DNA was extracted using the QIAamp DNA 
FFPE tissue kit (Qiagen) according to manufacturer instructions. 
Determination of LOH in mammary tumors 
Q-PCR for the relative abundance of the ApcmNLS allele relative to the ApcMin 
allele in genomic DNA from mammary tumors and tails of the same mice was performed 
as described previously for the polyp analysis. Samples were analyzed twice in duplicate.  
Histopathological examination of mammary tumors 
Wedge-shaped regions of each tumor extending from the outer surface to the 
center were paraffin-embedded. Sections (8 m) were stained with hematoxylin-eosin 
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and examined by a murine pathologist, Dr. Ruth Sullivan at the University of Wisconsin 
Medical Center.  
Results 
ApcmNLS/Min mice have more severe hematological abnormalities than do ApcMin/+ 
mice 
  Blood collected from 10 Apc+/+, 21 ApcMin/+ and 13 ApcmNLS/Min mice was 
analyzed for complete and differential blood count. There were no significant differences 
in platelet counts or in total or differential white blood cell counts (table 5. 2). However, 
ApcmNLS/Min mice developed significantly more severe anemia than did ApcMin/+ or Apc+/+ 
mice, as indicated by the reduction of hemoglobin (Hg) concentration, hematocrit (HCT) 
value, and red blood cell (RBC) count (figure 5. 2 A-C).  
The average spleen weight as a percentage of total body weight is greater in 
ApcmNLS/Min mice (0.82%) than in Apc+/+ (0.4%) and ApcMin/+ (0.48%) mice. This trend, 
however, did not reach statistical significance (p= 0.054 and 0.09 respectively), as shown 
in figure 5. 2 D. There was not a significant difference in the normalized liver weight 
among different Apc genotypes (data not shown). 
The ApcmNLS allele enhances mammary tumorigenicity in ApcMin  mice 
ApcMin/+ female mice develop mammary tumors, although with a low penetrance 
(5%) and at relatively older ages [15]. We found that at 17 ± 1 weeks of age, 2 of 7 older 
ApcmNLS/Min females and 0 of 7 ApcMin/+ littermates developed mammary tumors. The 
weights of the tumors were 3.2g (mouse #649) and 0.55g (mouse #650). Both tumors 
were firm in consistency, lobular, white in color, and attached to the skin but freely 
movable over the chest wall. When examined for histopathology (figure 5. 3 A-B), both 
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tumors were squamous, with nodules of extensive keratin production and pilar tumors. 
No signs of invasion were seen in the mammary tumor from mouse #649 while #650 
showed extension of the tumor around skeletal muscle, suggestive of minimal invasion. 
LOH in mammary tumors from ApcmNLS/Min mice 
To gain insight as to the mechanism of mammary tumor development in 
ApcmNLS/Min mice, we measured the relative abundance of the ApcmNLS and ApcMin alleles 
in both mammary tumors and in tails from the same mice. In one mouse (#649) there was 
reduction, although small, of the proportion of the ApcmNLS allele in the tumor tissues 
relative to tail tissue (figure 5. 3 C). Surprisingly, there was marked reduction of the 
ApcMin allele in the tumor cells of the other mouse (#650), as shown in figure 5. 3 D. 
Discussion 
ApcMin/+ mice develop intestinal and extra-intestinal phenotypes [19]. ApcmNLS/Min 
mice develop more severe intestinal polyposis than do ApcMin/+ mice. Furthermore, the 
polyps that develop in ApcmNLS/Min mice are larger and have more mitotic cells, as 
indicated by positive staining for Ki-67 antigen [3]. We found that ApcmNLS/Min mice 
develop more severe extra-intestinal phenotypes than do ApcMin/+ mice. ApcmNLS/Min mice 
have more severe anemia, larger spleens, and increased incidence of mammary tumors. 
Although these extra-intestinal manifestations do not include all of the extra-intestinal 
phenotypes described for ApcMin/+ mice, they are consistent with more severe phenotypes 
in ApcmNLS/Min relative to ApcMin/+ mice, which implies a role for nuclear Apc in extra-
intestinal functions of Apc. Other described extra-intestinal phenotypes in ApcMin mice, 
including abnormal lipid profile, abnormal testicular architecture, and aberrant 
immunocyte maturation and abundance, could also be examined in the future. 
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The underlying mechanism for the extra-intestinal phenotypes in ApcMin/+ is not 
completely understood [14]. Anemia in ApcMin/+ mice is thought to result from chronic 
blood loss in feces as the result of intestinal polyposis [13]. As ApcmNLS/Min mice develop 
more intestinal polyps than do ApcMin/+ mice [3], the severe anemia seen in ApcmNLS/Min 
mice could represent this enhanced intestinal polyposis. However, studies have also 
shown haploinsufficiency for the ApcMin allele in hematopoietic stem cell homeostasis in 
the bone marrow in ApcMin/+ mice [16, 17]. Based on this observation, nuclear Apc may 
have a role in maintaining the bone marrow microenvironment. Future work could 
investigate this possibility.  
ApcMin/+ mice also develop larger spleens [12]. These spleens have extra-
medullary hematopoiesis, suggesting a compensatory mechanism for anemia as their 
underlying cause [20]. However, You et al. have shown that enlarged spleens could 
develop in non-anemic ApcMin/+ mice, which indicates that other factors may predispose 
these mice to enlarged spleens [14]. ApcmNLS/Min mice also develop larger spleens 
compared to ApcMin/+ littermates. These large spleens could represent either a 
compensatory mechanism to more severe anemia in these mice or a role of nuclear Apc 
in the spleen. Pathological and functional analyses of these spleens could provide clues as 
to the mechanism of this phenotype. Interestingly, first generation ApcmNLS/mNLS mice 
(N1) showed enlarged spleens. Pathological analysis of some of these spleens from 
ApcmNLS/mNLS mice showed malignant transformation of immune cells causing histiocytic 
sarcoma (data not shown). This again supports a role for nuclear Apc in immunocyte 
homoeostasis.  
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Another tumor susceptibility phenotype that was observed in ApcmNLS/Min female 
mice is mammary tumorigenesis. Mammary tumors have been described in ApcMin/+ 
mice, but at low incidence and at relatively older ages. In our colony, we found that 2/7 
ApcmNLS/Min mice developed mammary tumors by age 17 weeks, while none of the 7 
ApcMin/+ littermates developed recognizable mammary tumors. At the histopathological 
level, the mammary tumors that developed in ApcmNLS/Min mice were indistinguishable 
from those described for ApcMin/+ mice, consistent with a more severe phenotype rather 
than a completely different one. Another important note is that the number of mice in this 
experiment is relatively small. We hope to raise more old female mice of both genotypes 
for a more systematic analysis of mammary tumorigenicity. However, considering the 
low penetrance of the phenotype, the number of older female mice needed for such an 
experiment makes this experiment costly. 
Analysis of LOH in mammary tumors from ApcmNLS/Min mice revealed loss of the 
ApcMin allele in one tumor and loss of the ApcmNLS allele in the other tumor. Interestingly, 
the tumor with signs of local invasion is the one that showed loss of the ApcMin allele. 
This is interesting because we have not seen increased mammary tumor susceptibility in 
ApcmNLS/mNLS female mice. Although we do not have a complete explanation for this 
apparent paradox, some considerations should be taken into account. It is thought that 
mutation of Apc is not enough for the development of mammary tumors [21]. The 
reduction of the relative abundance of either allele was not as dramatic as seen in 
intestinal polyps. Although, this could represent the inclusion of normal stroma, it could 
also indicate that LOH happens in some, but not all cells. A laser-capture micro-
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dissection of different regions of the tumors followed by staining of these tumors with 
antibodies against the Apc c-terminus may answer this question.  
In conclusion, ApcmNLS/Min mice show enhanced extra-intestinal phenotypes 
including anemia, enlarged spleens, and enhanced mammary tumorigenesis. Future work 
will uncover the role for nuclear Apc in extra-intestinal tissues. 
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Table 5. 2: CBC with differential blood count in Apc+/+, ApcMin/+, and ApcmNLS/Min 
mice 
 Apc+/+ 
n= 10 
Mean± SEM 
ApcMin/+ 
n= 21 
Mean± SEM 
ApcmNLS/Min 
n = 13 
Mean± SEM 
Red blood cell count (RBC) 
(x 106/mm3) 
7.93± 0.21 7.1± 0.24 5.99± 0.38* 
Hemoglobin concentration 
(gm/dl) 
12.56± 0.26 11.2± 0.37 9.61± 0.63* 
Hematocrit 
(%) 
38.01± 0.97 36.33± 1.24 30.33± 1.8* 
Mean Corpuscular Volume (MCV) 
(fL) 
48.02± 0.69 51.2 ± 0.56 50.88± 1.13 
Mean Corpuscular Hemoglobin levels 
(MCH) (pg) 
16.0± 0.22 15.78± 0.12 16.02± 0.24 
Mean Corpuscular Hemoglobin Conc. 
(%) 
33.38± 0.59 30.9± 0.40 31.68± 0.88 
Platelet Count 
(x 103/ mm3) 
869± 70 913± 69 953± 102 
White Blood Cell Count (WBC) 
(x 103 /mm3) 
10.64± 2.2 10.55± 0.77 9.77± 1.1 
 
Differential WBC count 
Segmented neutrophils 
(%) 
9.11± 1.97 9.11± 1.98 13.38± 2.84 
Immature neutrophils 
(%) 
0 0 0 
Lymphocytes 
(%) 
75.78± 8.8 75.78± 8.79 81.85± 3.47 
Atypical lymphocytes 
(%) 
0.56± 0.32 0.56± 0.32 1.62± 0.71 
Monocytes 
(%) 
2.17± 0.67 2.17± 0.67 2.54± 0.40 
Eosinophils 
(%) 
1.49± 0.43 1.49± 0.31 0.62± 0.21 
Basophils 
(%) 
0.31± 0.22 0 0 
Metamylocytes 
(%) 
0 0 0 
Myelocytes 
(%) 
0 0 0 
Blast cells 
(%) 
0 0 0 
Nucleated RBC 
(%) 
0 0.78± 0.44 0.5± 0.27 
Abnormal RBC 
(polychromasia, anisocytosis, crenated 
RBCs, Howel Jolly) 
Occasional Occasional Occasional 
* p< 0.05 
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Figure 5. 2: ApcmNLS/Min mice develop more severe anemia and have larger spleens 
than do ApcMin mice. (A-C) Complete blood count from 10 Apc+/+, 21 ApcMin/+ and 13 
ApcmNLS/Min show that ApcmNLS/Min mice have significantly lower hemoglobin (Hg) 
concentration, red blood cell (RBC) count, and hematocrit (HCT) value relative to those 
of Apc+/+ and ApcMin/+ mice. D percentage of spleen weight relative to body weight in 
Apc+/+, ApcMin/+ and ApcmNLS/Min mice. Error bars represent SEM. * and ** indicate p < 
0.05 and p < 0.01, respectively.  
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Figure 5. 3: Pathological examination and LOH in mammary tumors from 
ApcmNLS/Min. Hematoxylin and eosin staining of mammary tumors from mouse #649 (A& 
C) and mouse #650 (B& D). The tumors are squamous cell carcinoma with 
adenoacanthoma. Note the accumulated keratin in the tumor. Scale bar = 100 µm. E& F 
show the qPCR results quantifying the ApcmNLS  (solid lines) and ApcMin (dashed lines) 
alleles from genomic DNA extracted from mammary tumor from mouse #649 (E) and 
mouse #650 (F) (red) and the tail of the same mouse (green). There is a decrease in the 
abundance of the ApcmNLS allele compared to the ApcMin allele in the mammary tumor 
from mouse # 649 and a decrease in the abundance of the ApcMin allele compared to the 
ApcmNLS allele in the mammary tumor from mouse # 650. (G& H) diagrams show the Apc 
protein structure predicted in normal tissue and in mammary tumors from mouse #649 
and # 650 respectively. 
164 
 
 
 References 
1. Luongo, C., et al., Loss of Apc+ in intestinal adenomas from Min mice. Cancer 
Res, 1994. 54(22): p. 5947-52. 
2. Haigis, K.M., et al., Intestinal adenomas can develop with a stable karyotype and 
stable microsatellites. Proc Natl Acad Sci U S A, 2002. 99(13): p. 8927-31. 
3. Zeineldin, M., et al., A knock-in mouse model reveals roles for nuclear Apc in cell 
proliferation, Wnt signal inhibition and tumor suppression. Oncogene, 2011. 
4. Haigis, K.M. and W.F. Dove, A Robertsonian translocation suppresses a somatic 
recombination pathway to loss of heterozygosity. Nat Genet, 2003. 33(1): p. 33-9. 
5. Baran, A.A., et al., The modifier of Min 2 (Mom2) locus: embryonic lethality of a 
mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression. 
Genome Res, 2007. 17(5): p. 566-76. 
6. Tanwar, P.S., et al., Stromal deletion of the APC tumor suppressor in mice 
triggers development of endometrial cancer. Cancer Res, 2011. 71(5): p. 1584-96. 
7. Wang, Y., et al., Loss of APC function in mesenchymal cells surrounding the 
Mullerian duct leads to myometrial defects in adult mice. Mol Cell Endocrinol, 
2011. 341(1-2): p. 48-54. 
8. Fodde, R., et al., Mutations in the APC tumour suppressor gene cause 
chromosomal instability. Nat Cell Biol, 2001. 3(4): p. 433-8. 
9. Wang, Y., et al., Interaction between Tumor Suppressor Adenomatous Polyposis 
Coli and Topoisomerase II{alpha}: Implication for the G2/M Transition. Mol. 
Biol. Cell, 2008. 19(10): p. 4076-4085. 
10. Aoki, K., et al., Colonic polyposis caused by mTOR-mediated chromosomal 
instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat Genet, 2003. 
35(4): p. 323-30. 
11. Aoki, K., et al., Chromosomal instability by beta-catenin/TCF transcription in 
APC or beta-catenin mutant cells. Oncogene, 2007. 26(24): p. 3511-20. 
12. Moser, A.R., H.C. Pitot, and W.F. Dove, A dominant mutation that predisposes to 
multiple intestinal neoplasia in the mouse. Science, 1990. 247(4940): p. 322-4. 
13. Moser, A.R., et al., The Min (multiple intestinal neoplasia) mutation: its effect on 
gut epithelial cell differentiation and interaction with a modifier system. J Cell 
Biol, 1992. 116(6): p. 1517-26. 
14. You, S., et al., Developmental abnormalities in multiple proliferative tissues of 
Apc(Min/+) mice. Int J Exp Pathol, 2006. 87(3): p. 227-36. 
15. Moser, A.R., et al., ApcMin, a mutation in the murine Apc gene, predisposes to 
mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci U S 
A, 1993. 90(19): p. 8977-81. 
16. Coletta, P.L., et al., Lymphodepletion in the ApcMin/+ mouse model of intestinal 
tumorigenesis. Blood, 2004. 103(3): p. 1050-8. 
17. Lane, S.W., et al., The Apc(min) mouse has altered hematopoietic stem cell 
function and provides a model for MPD/MDS. Blood, 2010. 115(17): p. 3489-97. 
18. Ikeda, K., et al., Increase of oxidant-related triglycerides and 
phosphatidylcholines in serum and small intestinal mucosa during development of 
intestinal polyp formation in Min mice. Cancer Sci, 2011. 102(1): p. 79-87. 
19. Kwong, L.N. and W.F. Dove, APC and its modifiers in colon cancer. Adv Exp 
Med Biol, 2009. 656: p. 85-106. 
165 
 
 
166 
20. Dove, W.F., et al., The intestinal epithelium and its neoplasms: genetic, cellular 
and tissue interactions. Philos Trans R Soc Lond B Biol Sci, 1998. 353(1370): p. 
915-23. 
21. Kuraguchi, M., et al., Genetic mechanisms in Apc-mediated mammary 
tumorigenesis. PLoS Genet, 2009. 5(2): p. e1000367. 
 
 
 
 
 Chapter 6 
Characterization and screen for polymorphic loci in the promoter of the 
Pla2ga2/Modifier of Min-1 (Mom-1) gene in three mouse colonies 
  
Abstract 
In this chapter, we show results that define a polymorphic locus in the promoter 
region of a genetic modifier of Min (Pla2g2a, Mom-1) in long-lived mice in our colony.  
We also show the design of a simple and reliable PCR-based method to screen mouse 
colonies for this polymorphic Mom-1 allele.  Furthermore, we show that the presence of 
the polymorphic allele is associated with prolonged longevity in Apc1322T/+ mice and with 
differential expression of the Pla2g2a gene.   
 Introduction  
The number of intestinal tumors that develop in different Apc mouse models 
varies greatly from one laboratory to another. For example, in a C57Bl/6J background, 
the number of reported polyps in a ApcMin/+ mouse, the most characterized Apc mouse 
model, ranges from 20 to >100 [1]. This inter-laboratory variation represents differences 
in environment, including diet, sensitivity of polyp detection, as well as genetic variations 
(see chapter 2 and [2]). In different mouse strains, the number of polyps varies greatly for 
the same Apc mutation. This variation allowed detection of modifier mutations that affect 
intestinal phenotypes [1]. Identification of modifiers in model organisms allows 
delineation of the different pathways that contribute to development of a particular 
phenotype [3]. Several loci have been identified that can alter intestinal polyposis in 
ApcMin/+ mice. These loci were named modifiers of min (Mom) [3]. Specific mutations in 
specific genes have been defined for some, but not all, of these loci [3]. The molecular 
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mechanisms by which some of these modifiers alter intestinal phenotypes have also been 
elucidated (see [2] and chapter 2).  
The first and most characterized modifier of Min is Mom-1, which was discovered 
in the early 1990s [4]. Mom-1 was linked to a 4 cM region, containing the Pla2g2a gene 
(encoding secreted phospholipase A2 enzyme) on mouse chromosome 4 [5, 6]. MacPhee 
et al. found that mouse strains such as AKR that are resistant to intestinal polyposis 
driven by ApcMin showed expression of the Pla2g2a gene in the intestine, while sensitive 
mice showed virtually no Pla2g2a expression [5]. Cormier et al. found that 
overexpression of Pla2g2a gene in a transgenic mouse they made  rescues Mom-1 
phenotype in ApcMin/+ mice and reduces the number of polyps in B6 sensitive strain, 
confirming that Pla2g2a is the candidate gene for Mom-1 phenotype [6].  Although there 
is no evidence for a role for human PLA2G2A in colon cancer [7], it has been shown to 
play a role in human gastric carcinoma [8]. Apart from an intronic mutation, predicted to 
result in alternative splicing, no other mutations were reported in the Pla2g2a gene [5]. 
After observing that some ApcMin/+ and Apc1322T/+ mice in our colonies showed extended 
life span and reduced intestinal polyp burden, we screened these mice for mutations in 
known modifiers. We found an allele with polymorphic loci in the promoter of the 
Pla2g2a gene. The presence of this polymorphic allele was associated with increased 
lifespan in these mice. We also found that this polymorphic allele is associated with a 
higher amount of the Pla2g2a mRNA in the intestinal epithelial cells from C57Bl/6J 
mice. We developed an easy reliable method to screen our colonies through use of PCR-
ARMS primers (amplification refractory mutation system) 
Material and methods 
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Sequencing the Pla2g2a gene and other known mutations in Mom-2, Mom-5, & 
Mom-7mutants 
Genomic DNA extracted from mice tails was amplified with primers covering the 
entire Pla2g2a gene, including exons, exon-intron junctions, and ~ 1 kbp of 5’ UTR and 
3’UTR (table 6. 1). Gel-purified PCR products were sent for sequencing (ACGT Inc.).  
Screening for Pla2g2a polymorphism 
PCR was performed in a 25 µl volume reaction containing 100- 250 ng genomic 
DNA, 0.4 mM dNTPs (NEB), 15 picomoles of common, wild-type, and Mom-1 primers 
(table 6. 1 shows the sequences of these primers) and 0.5 units of Taq DNA polymerase. 
The reaction conditions were 94 o C for 5 minutes, then 35 cycles of denaturation at 94 o 
C for 30 seconds, annealing at 52 o C for 30 seconds and extension at 68 o C for 30 
seconds followed by a final extension at 68 o C for 3 minutes.  
 Measurement of Pla2g2a mRNA levels in intestinal epithelial cells 
Intestinal epithelial cells from jejunum, ileum, and colon were extracted and used 
for qRT-PCR with Pla2g2a- (table 6. 1) and control HGPRT-specific primers, as 
described in chapter 3.  
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Table 6. 1 primers used for screening the modifiers and for quantification of 
Pla2g2a mRNA 
Primer 
name 
Forward primer Backward primer comment 
Mom1-1 5’-gtaaggtggctccgtggtaa-3’ 5’-catacccaatgccctttttg-3’ Promoter 
region 
Mom1-2 5’-ggcagttggaattcaggaaa-3’ 5’-ttgagcctgaaaggaaatgg-3’  
Mom1-3 5’-tcaccaccctttaccaggtc-3’ 5’-ctggaaaccactgggacact-3’  
Mom1-4 5’-gtaaggccaccccagttctc-3’ 5’-atcttttggccacactctgc-3’  
Mom1-5 5’-cctaaaacagggcacacaca-3’ 5’-agtggctgaggatgaccttg-3’  
Mom1-6 5’-gccctctgcagtgtatgaaa-3’ 5’tccaagttatgagaacacacacg-3’  
Mom1-7 5’-aggccctcacaagtaaagca-3’ 5’-cctggtttttgatggctctc-3’ 3’UTR region 
Mom-2* 5’-accatctctccagcaccaag-3’ 5’-ggcaaaatgagacttaaatgctt-3’ Flanks exon 3 
of Atp5a  
Mom-5* 5’-tgttggaacgtgtttttgga-3’ 5’-aatcgcatagatacactgtctgag-3’  
Mom-7* 5’-aacccaggactgcttccttt-3’ 5’- ttagaaggcaggagcagagg-3’  
 
Primers for screening for Pla2g2a promoter polymorphisms 
Mom1-
com 
5’-tgattttgaaacctctcctga-3’ 
 
Common 
primer 
Mom1-
WT 
5’-aaacacacgcagagaattcg-3’ 
 
Wild-type- 
specific primer 
Mom1-
mut 
5’-tcgtatccctgaatgtcttca Polymorphism- 
specific primer 
 
Primers for QRT-PCR for Pla2g2a mRNA 
Pla2g2a 5’-tacaagcgcctggagaaaag-3’ 5’-ggccttatcgcactgacaca-3’  
HGPRT 5’- tgctcgagatgtcatgaagg-3’ 5’- tatgtcccccgttgactgat-3’  
We screened for previously described mutations [9-11]  
Results 
Polymorphisms in the promoter of Pla2g2a gene in old ApcMin/+ and Apc1322T/+ mice 
The average lifespan of ApcMin/+ mice is around 20 weeks [12], while Apc1322T/+ 
mice die at around 16 weeks of age [13]. We observed that some ApcMin/+ and Apc1322T/+ 
mice in our colony lived much longer than the average reported lifespan. We suspected a 
modifier mutation, and decided to screen for known mutations by sequencing the 
published modifier genes before searching for a new modifier. We did our initial analysis 
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on one ApcMin/+ mouse that lived for 57 weeks and an Apc1322T/+ mouse that lived for 37 
weeks. In addition, we used an ApcMin/+ mouse that lived for 18 weeks and another 
Apc1322T/+ mouse that became sick and was sacrificed at 18 weeks as the controls. We 
included DNA from two C57Bl/6J mice purchased directly from Jackson laboratory as 
additional controls. For Mom-2, Mom-5 or Mom-7 mutations, we screened for the 
reported mutations in these loci and did not find any of these mutations in any mouse that 
was screened (data not shown). As there were no reported mutations in the Pla2g2a gene 
(Mom-1), we decided to sequence the entire gene including 1-Kb of the 5’ and 3’ UTR. 
We found a polymorphic allele in the heterozygous state in the long-lived ApcMin/+ and 
Apc13222T mice but not in the short-lived mice or in the wild-type mice provided directly 
from the commercial supplier (figure 6. 1 A- B). We compared the polymorphic 
sequences to the wild-type sequence and found that the polymorphic region extends from 
nucleotide -407 to -818 upstream of the first coding nucleotide (figure 6. 1 C). 
Development of an easy reliable screening test for the Mom-1 promoter 
polymorphism 
  We designed PCR-ARMS primers that could specifically differentiate between 
the wild-type allele and the polymorphic allele in the same reaction. We designed a 
common primer in the promoter region that is the same in both the wild-type and 
polymorphic allele. We designed a primer that is complementary to the polymorphic 
allele that is different from the wild-type allele in its last two 3’ nucleotides, and also 
contained a mismatch mutation at the invariable nucleotide at position -4 from the 3’ end. 
Introducing this mismatch will reduce primer annealing to the wild-type sequence at its 
3’ region, preventing non-specific amplification without interfering with annealing of the 
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same primer to the polymorphic allele. We used the same strategy to design a primer 
specific for the wild-type allele that does not amplify the polymorphic allele. These 
primers produce two PCR products, 293-bp for the polymorphic allele and over 600-bp 
for the wild-type allele, allowing easy discrimination via a 1.5% agarose gel for 
electrophoresis (figure 6. 2). We validated this method using DNA from both long-lived 
and wild-type mice. In addition, we screened 10 other mice by use of this PCR method 
and found that three of them carry the polymorphic allele. We sent the DNA from these 
10 mice for sequencing and the results precisely matched the results from the PCR-
ARMS protocol.  
Pla2g2a promoter polymorphisms are associated with prolonged survival of 
Apc1322T/+ mice 
As we developed a reliable test for screening for the presence of the Pla2g2a 
polymorphic allele, we screened ApcMin, Apc1322T and ApcmNLS mouse colonies for the 
presence of the modifiers. We did this screen mainly to exclude data from mice carrying 
this polymorphic allele from other experiments, but also to investigate the effect of this 
polymorphic allele on the phenotype in these mice. We found this polymorphic allele in 
only a few mice in our ApcMin and ApcmNLS mouse colonies, which made statistical 
analysis  unfeasible. On the other hand, we found that over 50% of the tested mice in our 
Apc1322T colony carried this polymorphic allele. As most of these mice were euthanized at 
different time points, compiling their data was not informative. However, we found that 5 
Apc1322T/+ mice with wild-type Pla2g2a alleles and 7 Apc1322T/+ mice carrying the 
polymorphic allele were found dead or sacrificed when they were sick, thus providing 
overall survival information. Comparing the age of these mice at death, we found that 
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while Apc1322T/+ with the wild-type Pla2g2a gene lived for 16.4± 1.9 weeks, Apc1322T/+ 
mice carrying the polymorphic allele lived for 26.3± 2.3 weeks (p= 0.00753), see figure 
6. 3.  
Mice with the polymorphic Mom-1 promoter have higher levels of Pla2g2a mRNA in 
intestinal epithelial cells   
C57Bl/6J mice carry a virtually null Pla2g2a allele [5]. We used qRT-PCR with 
Pla2g2a-specific primers to determine if the polymorphic allele that we identified in 
long-lived Apc-mutant mice has any effect on the expression level of the gene. We 
measured Pla2g2a mRNA levels in epithelial cells extracted from jejunum, ileum, and 
colons from 3 wild-type C57Bl/6J mice heterozygous for this polymorphic allele, and 
from three mice that carry only the wild-type Pla2g2a allele. Using HGPRT as an 
internal control, we found that mice heterozygous for the Pla2g2a promoter 
polymorphism had 177-, 31- and 77-fold higher Pla2g2a mRNA levels in jejunum, 
ileum, and colon, respectively than did mice with the wild-type Pla2g2a promoter. Figure 
6. 4 shows RT-PCR amplification products after 30 cycles using Pla2g2a- or HGPRT-
specific primers separated on a 1.5% gel. 
Discussion 
Studying genotypic modifiers allows identification of different pathways 
contributing to phenotype development [2]. Mom-1 was the first modifier of the intestinal 
phenotype in ApcMin/+ mice to be identified, in 1992 [4]. Pla2g2a gene was found to be 
the candidate gene responsible for Mom-1 phenotype [5, 14]. We found an allele with 
polymorphic loci in the promoter area of the Pla2g2a gene that is associated with 
prolonged survival in both ApcMin/+ and Apc1322T/+ mice. To the best of our knowledge, 
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this is the first report of a specific mutation in this gene that correlates with expression 
level. Moreover, although Mom1 has been studied in ApcMin/+mice, the effect of Mom-1 
on the phenotype in Apc1322T/+ mice has not been reported. In this study, we showed for 
the first time that the Mom-1 allele could also prolong the survival of Apc1322T/+ mice. 
 We are not sure if this polymorphic allele emerged as a spontaneous mutation in 
our colony or from other mouse strains obtained from different vendors. We also do not 
yet know if the polymorphic allele found in our colony is the same as in different mouse 
strains with reported resistance to intestinal polyposis. We will continue to screen for this 
mutation in AKR/J, Ma/MyJ, and CAST/EiJ mouse strains that are known to have the 
resistant Mom-1 allele [2]. If the Pla2g2a allele found in our colony is the same as that 
present in other mouse strains, it was missed in the previous attempts to sequence this 
gene [5]. The polymorphic region we found is a relatively long one (~411 bps). It is 
likely that the primers used in previous attempts to differentially amplify the wild-type 
and polymorphic alleles hybridized within this polymorphic region and therefore did not 
amplify this region.  In the current study, we used primers that flank a relatively large 
portion of the promoter (~900 bps) and were fortunate that these polymorphic loci were 
included in the PCR product.      
It has been shown that mice resistant to intestinal polyposis show higher 
expression of the Pla2g2a gene [5]. We found that the polymorphism in the Pla2g2a 
promoter is associated with increased Pla2g2a mRNA levels.This correlation, however, 
needs to be expanded upon experimentally. In the future, we will clone both the wild-type 
and the polymorphic promoter regions upstream of a reporter construct (e.g. luciferase 
reporter) and test the effect of these polymorphisms on the reporter expression. 
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In conclusion, we found a polymorphic locus between -407 to -818 bp upstream 
of the first exon of the Pla2g2a gene. This polymorphic promoter area is correlated with 
prolonged survival in our mouse colonies. We also found increased expression of the 
Pla2g2a gene in mice harboring this polymorphic promoter region. 
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Figure 6. 1: Polymorphic region in the Pla2g2a gene promoter in long-lived ApcMin/+ 
and Apc1322T/+ mice. A representative chromatograph showing the sequence in the 
promoter area of the Pla2g2a gene in wild-type mice (A) and in a long-lived ApcMin/+ 
mouse (B). The polymorphic sequences result in double peaks and are marked by red 
arrows. (C) Alignment of the polymorphic (Mom1) and the wild-type (WT) sequences. 
The polymorphic area is marked by the red rectangles while the first codon is marked by 
an arrow.   
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Figure 6. 2: Development of an easy and reliable screen for Pla2g2a gene promoter 
polymorphisms. An example of PCR products separated on a 1.5% agarose gel and 
stained with ethidium bromide for mice heterozygous for? the polymorphic Pla2g2a 
promoter allele (samples 1, 3, 4, 5 & 6) and mice homozygous for the C57Bl/6J wild-type 
allele (samples 2, 7, 8, 9 & 10). First lane (M) is a 100-bp ladder while the last lane is a 
negative control with no template. 
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Figure 6. 3: Pla2g2a gene with polymorphic allele is associated with prolonged 
survival of Apc1322T/+ mice. Scatter plot for the recorded survival of Apc1322T/+ mice with 
wild-type (WT) and with polymorphic Pla2g2a promoter (Mom1). The lines represent the 
median survivals of both groups while (*) indicates p< 0.05. 
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Figure 6. 4: Mice heterozygous for the Pla2g2a polymorphic promoter allele have 
higher levels of mRNA in their small and large intestinal epithelial cells. RT-PCR 
products using Pla2g2a- (upper) and HGPRT-specific (lower) primers and mRNA 
isolated from jejunum (J), ileum (I), and colon epithelial cells from mice heterozygous to 
the polymorphic promoter allele and from wild-type mice. The first lane is a 100-bp 
ladder (M) while the last lane is a negative control sample without template (-ve). 
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Chapter 7 
Induction of the heat-shock response upregulates the tumor suppressor APC and 
alters intestinal tumorigenesis in mice 
Abstract 
Mutation of the tumor suppressor gene Adenomatous Polyposis Coli (APC) is 
considered an initiating event in the development of most intestinal tumors.  Although 
much effort has been spent determining functions of the APC protein, to date little is 
known about the mechanisms that regulate cellular APC levels. Here we report that in 
cultured cells, induction of a heat-shock response, via heat or compounds such as the 
HSP90 inhibitor 17-AAG, resulted in increased levels of APC. A novel non-toxic small 
molecule, KU-32, also induced a heat-shock response and led to increased APC levels in 
both cultured cells and mice. To investigate the effect of induction of the heat-shock 
response and elevation of Apc level in intestinal tumorigenesis, we performed a series 
experiments in mice with KU-32 and 17-AAG. We tested these compounds on two 
mouse models with mutations in Apc, the ApcMin/+ and the Apc1322T/+ mice.  In both 
cases, a moderate dose of either drug did not change tumor burden, but surprisingly 
altered the location of intestinal polyps.  A higher dose of KU-32 actually increased 
tumor size and number in ApcMin/+ mice.  In a third mouse model where colonic tumors 
are induced via administration of the mutagen azoxymethane and dextran sodium sulfate 
(AOM-DSS model) rather than through germline Apc mutation, KU-32 reduced both 
tumor incidence and multiplicity.  We conclude that induction of the heat-shock response 
affects intestinal tumorigenesis in germline Apc-mutant and colitis-induced tumor 
models.   
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Introduction 
Colorectal cancer is one of the leading causes of cancer-related death in the 
United States [1]. Loss of the tumor suppressor functions of Adenomatous Polyposis Coli 
(APC) is the initiating step in most cases of colorectal cancer [2]. APC is a large 
multidomain protein (2843 amino acids) that has been implicated in many cellular 
functions in the cells, including proliferation, migration, cytoskeletal regulation, 
apoptosis, and chromosomal segregation [3]. APC is best known for its role in opposing 
Wnt signaling-induced cellular proliferation by forming a complex that phosphorylates 
the oncoprotein-catenin and targets it for proteasomal degradation. APC mutation in 
colorectal cancers results in accumulation and nuclear translocation of -catenin, to 
induce expression of Wnt target genes that drive cellular proliferation [3]. Control of 
cellular APC level is not completely understood, but seems to occur at the transcriptional, 
translational, and posttranslational levels (see chapter 1).   
To facilitate studying Apc, several mouse models have been made [4]. The first 
and most characterized model is the ApcMin/+ mouse. ApcMin/+ mice have a heterozygous 
nonsense mutation resulting in a truncated 850-amino acid Apc protein. ApcMin/+ mice 
develop between 20 and 100 intestinal polyps predominantly in the small intestine [5]. It 
has been shown that loss of the wild-type allele (LOH) is required for polyp formation 
[6]. Another mouse model that was recently generated is the Apc1322T/+ mouse. In 
Apc1322T/+ mice, a truncation mutation results in a longer Apc protein (1322 amino acids) 
than in ApcMin/+ mice. The mutation in Apc1322T/+ mice is more close to mutations detected 
in human colorectal cancer. Apc1322T/+ mice develop intestinal tumors, though with a 
different distribution. Most polyps in Apc1322T/+ mice are in the proximal part of the small 
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intestine, while in ApcMin/+ mice, tumors tend to be more distal, in the ileal region [7]. As 
in ApcMin/+ mice, intestinal polyps in Apc1322T/+ mice show LOH. Since Apc1322T protein 
retains the first 20-amino acid repeat domain that can bind to -catenin while this domain 
is lost in ApcMin/+ mice, it is not surprising that Wnt signaling activity is not as strongly 
upregulated in polyps from Apc1322T/+ mice relative to those from ApcMin/+ mice [8]. 
Chronic inflammation in the colon (chronic colitis) is a major risk factor for the 
development of colorectal cancer. Patients with inflammatory bowel disease (Crohn’s 
disease and ulcerative colitis) have a significant increased risk of developing an 
aggressive form of colorectal cancer (colitis-associated colorectal cancer) [9]. Treatment 
of mice with Azoxymethane- Dextran Sodium Sulfate (AOM-DSS) has been described as 
a model of colitis-associated colorectal cancer [10]. In this model, colon cancer is 
initiated in mice by injecting mice with the mutagen AOM followed by induction of 
chronic colitis through cycles of DSS in the drinking water [10]. Unlike mouse models 
with Apc-germline mutations, which develop tumors mainly in the small intestine, AOM-
DSS-treated mice develop colonic tumors [10]. In the AOM-DSS mouse model, Apc is 
usually not mutated, but instead, mutations occur in -catenin that prevent its 
phosphorylation and proteasomal degradation (stabilizing mutations). Wnt signaling is 
thereby activated to initiate colonic tumorigenesis [11].  
The heat-shock response describes induction of specific cellular proteins (heat-
shock proteins/ stress proteins) to deal with sudden changes in the cellular environment. 
Heat-shock proteins (molecular chaperones) bind to damaged proteins to assist in 
refolding and preventing toxic aggregates [12]. Even in the absence of stress, heat-shock 
proteins help fold many proteins and translocate some proteins to different organelles, 
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including the mitochondria [12]. The most abundant heat-shock protein in the cell is 
HSP90. HSP90 is a target of several anticancer drugs that are currently in clinical trials 
[13]. As HSP90 is critical for the proper folding and function of many proteins involved 
in cellular transformation, HSP90 serves as a potential target to decrease survival of 
cancer cells. HSP90 inhibitors interfere with proper folding of HSP90 client proteins, 
resulting in their ubiquitination and degradation [14]. 
Here we show that induction of the heat-shock response either through application 
of the commercially-available HSP90 inhibitor 17-AAG, or by heating the cells, 
increases the cellular level of APC in colon cancer cell lines. We also show that induction 
of the heat-shock response by means of the novel non-toxic drug KU-32 upregulates the 
level of APC both ex vivo in cultured colon cancer cells and in vivo in mouse intestinal 
epithelial cells. The increase in APC level in cultured cells is associated with reduced -
catenin transcriptional activity. To test the effect of induction of the heat-shock response 
and upregulation of Apc on intestinal tumorigenesis, we treated ApcMin/+ mice with 2 
different doses of KU-32 and monitored the effect of the compound on intestinal 
polypogenesis. We also treated ApcMin/+ mice with 17-AAG to induce the heat-shock 
response with a known HSP90 inhibitor, and examined changes in intestinal 
tumorigenesis. Moreover, we tested KU-32 on two additional mouse models: Apc1322T/+ 
and AOM-DSS mice. We found that, the higher but not the lower dose of KU-32 
increases the polyp burden in ApcMin/+ mice. The lower dose of KU-32 does not affect 
polyp burden in Apc1322T/+ mice. 17-AAG does not affect polyp number in all intestinal 
regions but decreases polyp size in the upper (stomach and duodenum) and lower (colon) 
gastrointestinal tract of ApcMin/+ mice. However, KU-32 and 17-AAG changes the 
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distribution of intestinal polyps in ApcMin/+ and Apc1322T/+ mice. Finally, we found that 
KU-32 reduces colonic tumor incidence and multiplicity in AOM-DSS treated mice. We 
concluded that induction of the heat-shock response increases APC level and impacts 
intestinal tumorigenesis.    
Materials and methods 
Mouse Husbandry 
Mice were maintained in the Animal Care Unit at the University of Kansas 
according to animal use statement number 137-01. The research complied with all 
relevant federal guidelines and institutional policies. Mice were fed ad libitum with 
Purina Lab Diet 5001. ApcMin/+ mice were purchased from The Jackson Labs and were 
maintained by breeding males with C57BL/6J females. Apc1322T/+ mice were provided as 
a generous gift from Ian Tomlinson’s lab, University of Oxford, and were maintained by 
breeding Apc1322T/+ males with C57Bl/6J females. 
Mouse genotyping  
After weaning, mouse pups were tagged with a metal ear tag. Each mouse pup 
was genotyped for ApcMin or Apc1322T alleles using isolated tail DNA and PCR according 
to published protocols [7; 15]. 
Counting the polyps and measuring polyp diameters 
For each mouse, after euthanization, the GI tract from the stomach to the anal 
canal was dissected, opened longitudinally, and fixed in 10% buffered formalin. Using a 
dissecting microscope, an investigator blind to the treatment protocol examined the 
intestinal luminal surface for polyps. Polyp diameter was measured with the aid of a 
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dissection microscope (Leica, MZ8) equipped with an eyepiece graticule and calibrated 
to a 50-mm scale stage micrometer with 0.1 and 0.01-mm gradation [16].   
Treatment of cultured cells 
HCT116W and HT29 colon cancer cell lines were maintained on McCoy’s 5A 
medium with 10% fetal bovine serum. When the cells were 60-80% confluent, media was 
removed, and fresh media containing either the drug or the drug vehicle (DMSO for 17-
AAG and MG132, and Captisol for KU-32) was added. For thermal treatment, fresh 
media was added to cells when they were 60-80% confluent. The cells were transferred to 
a preheated incubator with 5% CO2 at 42 ͦ C for different times.  
Luciferase reporter assay for-catenin transcriptional activity 
β-catenin transcriptional activity was measured using the standard Super 
TOPFlash luciferase reporter system, in which the firefly luciferase gene is transcribed 
under the control of a minimal promoter and 16 TCF/LEF1 binding sites [17]. A DNA 
construct with mutations in the TCF/LEF1-binding sites (FOPFlash) was used as a 
control. We transfected HCT116 cells with 1.8 µg of either the TOPFlash or FOPFlash 
DNA construct and 0.2 µg Renilla luciferase as a transfection control. After 24 hours, we 
treated the cells with either 1.5 µM KU-32 or the drug vehicle (captisol) for 24 hours. 
The cells were harvested in 1X reporter buffer, and firefly and Renilla luciferase 
activities were measured by use of the ‘Dual Luciferase Reporter Assay System” 
(Promega) according to the manufacturer’s protocol. Firefly luciferase activity was 
normalized to Renilla luciferase acitivty. The normalized firefly TOPFlash luciferase 
activity was then normalized to normalized firefly FOPFlash luciferase in KU-32-treated 
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cells and was compared to the normalized firefly TOPFlash activity in captisol-treated 
cells.   
Western blot of total cell lysates from cultured and mouse intestinal epithelial cells 
After washing twice in cold PBS, cultured cells were harvested in 1X reporter 
lysis buffer (Promega) with protease inhibitors. Intestinal epithelial cells were isolated as 
described in Chapter 3 [16], and cells were lysed in 1X reporter buffer (Promega) with 
protease inhibitors. The cultured and intestinal epithelial cells were heated to 95°C for 3 
minutes in 1X loading buffer (15% glycerol, 1% SDS and 3% 2-mercaptoethanol, pH 
6.8) prior to protein separation via SDS-PAGE on a 7% polyacrylamide gel, and 
transferred to nitrocellulose. We used rabbit anti-APC M2 (1:3000) [18], mouse 
monoclonal anti--actin (1:5000, Sigma), mouse monoclonal anti-GAPDH (1:1000, 
Sigma) and mouse monoclonal anti-HSP70 (1:1000, BD transduction laboratories). The 
following secondary antibodies were diluted as indicated: HRP goat anti-mouse (1:10-
25,000, Zymed) and HRP goat anti-rabbit (1:10-25,000, Bio-Rad). Band analysis was 
conducted with Kodak ID Image Analysis Software, with protein levels normalized to -
actin or GAPDH.  
Dissection and weighing of liver and spleens 
After being euthanized by means of CO2,
 ApcmNLS/Min, ApcMin/+, and Apc+/+ mice 
were weighed. The livers and spleens were removed, washed in PBS, weighed, and fixed 
in 10% saline-buffered formalin overnight, then in 70% ethanol.  
Complete blood count analysis 
Immediately after euthanasia, blood (0.5 - 1 ml) was drawn from the mouse via 
intra-cardiac puncture using a 20 G heparinized needle. The blood was sent to “Physician 
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Reference Laboratory” (Overland Park, KS) for complete and differential blood count 
(CBC) analysis. 
Results 
Induction of a heat-shock response increases APC level in colon cancer cell lines 
To test the requirement of HSP90 in stabilization of APC, we treated two colon 
cancer cell lines (HCT116 W with wild-type full-length APC and HT29 with truncated 
APC) with HSP90 inhibitor 17-AAG. We reasoned that if APC is an HSP90-client 
protein, inhibiting this molecular chaperone using 17-AAG would result in reduced 
cellular APC levels. However, we found that the levels of both full-length APC in 
HCT116 W and truncated APC in HT29 cells were increased (figure 7.1). These results 
argue against a role of HSP90 in stabilizing APC. It has been suggested that APC is 
degraded by the ubiquitin-proteasome pathway [19]. To test if the observed increase in 
APC level in 17-AAG-treated cells involves the proteasome pathway, we treated the 
same cell lines with 17-AAG plus the proteasome inhibitor MG132. As expected, we 
found that MG132 increases the cellular level of APC. However, simultaneous treatment 
of the cells with both drugs resulted in a greater increase in APC level than with either 
treatment alone (figure 7.1). We conclude that 17-AAG and MG132 work through two 
different pathways. One pathway that is induced by 17-AAG is the heat-shock response 
(see chapter 1, figure 1.4). Inhibition of HSP90 using 17-AAG has been shown to result 
in destabilizing the complex containing HSP90 and heat-shock factor 1 (HSF1). Free 
HSF1 goes to the nucleus, forms a homotrimer, and undergoes phosphorylation. Nuclear 
HSF1 binds to a heat-shock response element (HSE) in the promoters of inducible heat-
shock genes, to induce their expression [13]. MG132 also induces the heat-shock 
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response by inhibiting the proteasome and increasing the level of unfolded proteins. 
Unfolded proteins bind to HSP90, which increases the level of free HSF1, which in turn 
induces the heat-shock response [12]. Taken together, we hypothesized that the increase 
in APC level in 17-AAG-treated cells occurs through induction of a heat-shock response. 
Supporting this hypothesis, we found that the cellular level of the HSF1-inducible heat-
shock protein HSP70 is increased in both 17-AAG- and MG132-treated cells (figure 7.1). 
In addition, we induced the heat-shock response in HCT116W and HT29 cells by 
incubating the cells at 42 ͦ C for different durations. We found that APC levels are 
increased in these heated cells (figure 7.2). We concluded that induction of the heat-
shock response increases the cellular APC level in colon cancer cell lines. 
A novel small molecule induces a heat-shock response and increases cellular APC 
level both in cultured cells and in mouse intestinal epithelial cells 
Mutations in APC initiate colorectal carcinogenesis [2]. We hypothesized that 
upregulation of APC through induction of the heat-shock response could affect intestinal 
tumor initiation and/or progression. To test this possibility, we examined a small 
molecule, KU-32, formulated by Dr. Brian Blagg at the University of Kansas Department 
of Medicinal Chemistry. KU-32 induces the heat-shock response, but is 10,000 times less 
toxic than is 17-AAG [20]. In addition, studies in mice have shown that KU-32 has 
favorable pharmacological properties, such as stability in solution, and nearly complete 
absorption after an oral dose [20].  
First, we tested the effect of KU-32 on APC cellular levels by treating cultured 
colon cancer cells with 1.5 μM KU-32 for 24 hours. We found that KU-32 induced the 
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heat-shock response, as shown by upregulation of HSP70 level and increased 
concentrations of APC (figure 7.3 A-B). 
The best-known function of APC is to antagonize the Wnt signaling pathway by 
targeting β-catenin for proteasome-mediated destruction [21]. If APC induced by KU-32 
actively inhibits -catenin, cells treated with KU-32 should show reduced -catenin 
activity. Using standard reporter constructs to estimate -catenin activity as a 
transcription co-factor, we determined that cells treated with KU-32 displayed a 25% 
reduction in β-catenin activity compared to cells treated with vehicle alone (figure 7.3 C). 
We conclude that KU-32 leads to reduced -catenin signaling activity, most likely 
through upregulation of APC. 
To test whether KU-32 alters the level of Apc in intestinal epithelial cells of a 
whole organism, we administered intraperitoneal injections of 30mg/kg KU-32 to 
C57BL/6 mice. Sibling mice were injected with the drug vehicle only. Four mice were 
sacrificed at each of two time points post injection. Relative Apc levels were determined 
in whole-cell lysates of epithelial cells isolated from the small and large intestines of KU-
32-treated mice. APC levels were higher in intestinal epithelial cells from mice treated 
with KU-32 compared to mice treated with vehicle alone for 24 hours (figure 7.3 D-E). 
By 48 hours post injection, Apc levels remained elevated in the jejunum and to a lesser 
extent, in the ileum (figure 7.3 F-G). Together, these data provide evidence that KU-32 
increases the amount of APC in intestinal epithelial cells grown in culture and in mice. 
To determine the minimal dose of KU-32 that could increase APC levels in mouse 
intestinal epithelial cells, mice were injected with doses of KU-32 ranging from 0.3 to 30 
mg/kg, and the change of Apc level was assessed 24 hours later.. We found that the 
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smallest KU-32 dose that could increase Apc level in mouse intestinal epithelial after 24 
hours is 7.5 mg/kg (figure 7.3 H). Next, we treated mice with this dose of KU-32 (7.5 
mg/kg) for 7, 9, and 14 days in order to determine the duration of Apc increase. We 
found that Apc levels remained elevated after one week in intestinal epithelial cells. We 
conclude that 7.5 mg/kg weekly is the smallest dose that maintains an elevated level of 
Apc in mouse intestinal epithelial cells.   
KU-32 alters intestinal tumorigenesis in ApcMin/+ mice 
KU-32 increases the level of APC and reduces -catenin transcriptional activity in 
cultured cells. As KU-32 also upregulates Apc in mouse intestinal epithelial cells, we 
expected that this novel non-toxic compound could reduce intestinal tumorigenesis in 
ApcMin/+ mice. The ApcMin/+ mouse is the best characterized Apc mouse model. These 
mice have a nonsense mutation in the Apc gene that results in a truncated protein at 
amino acid 850 (see chapter 2) [22]. We used two different KU-32 treatment protocols in 
ApcMin/+ mice. In the first protocol, we gave 9 ApcMin/+ mice intraperitoneal injections of 
30mg/kg KU-32 every 2 weeks starting at 2 weeks old. We also injected 10 other 
ApcMin/+ mice with the drug vehicle only, and these mice served as a control group. After 
7 doses (14 weeks), mice were euthanized and the entire gastrointestinal tract from the 
stomach to the anus was dissected to determine the number and size of the polyps. In 
KU-32-treated mice, there was a significant reduction in size of polyps found in the 
jejunum. However, KU-32-treated mice had more polyps, on average, in all intestinal 
tissues examined, and polyps of the ileum and colon were significantly larger in the KU-
32 treated group (figure 7.4 A-D). In addition to the effect on the intestinal polyp burden, 
KU-32 also significantly changed the distribution of polyps in ApcMin/+ mice. There was a 
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distal shift in intestinal polyps, increasing the ratio of ileal polyps from 55% in the 
control group to 71% in KU-32-treated mice (figure 7.4 E).  
Second, we treated 10 ApcMin/+ mice with intraperitoneal injections of 7.5 mg/ kg 
KU-32 every week starting at the age of 6 weeks, and ending at 10 weeks. We also 
treated 9 ApcMin/+ mice with the drug vehicle as a control group. We reasoned that this 
short KU-32 treatment protocol could address some caveats in the previous study. As the 
mouse intestine is not fully developed by the age of 2 weeks, using KU-32 at this young 
age may influence the development of the intestine. Therefore, we began KU-32 
injections in older mice (6 weeks) and used the smallest dose of KU-32 that could 
increase Apc level in mouse intestinal epithelial cells (figure 7.3 H-I). The end point was 
set to 10 weeks, at which time the polyps are easily detectable in the intestinal tract of the 
mice. We also weighed spleens and livers, and collected blood for complete and 
differential blood count from the mice in both groups. We found that there was no 
significant change in either polyp multiplicity or polyp size in ApcMin/+ mice treated with 
the short KU-32 regimen relative to the control group (figure 7.5 A-D). However, we 
noticed the same trend of altered polyp distribution in different intestinal regions (figure 
7.5 E). We did not find significant differences in spleen weight, liver weight, or blood 
count in KU-32-treated mice relative to the control group (data not shown). We conclude 
that KU-32 influences intestinal tumorigenesis in ApcMin/+ mice.  
17-AAG changes intestinal polyp size and distribution in ApcMin/+ mice 
To investigate whether the effects of KU-32 on ApcMin/+ polyps are the result of 
heat-shock response induced by the compound, we tested the effects of 17-AAG on 
intestinal tumorigenesis in ApcMin/+ mice. 17-AAG is an HSP90 inhibitor that induces the 
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heat-shock response by releasing HSF1 from the cytoplasmic complex that sequesters it 
(see chapter 1; figure 1-4) [23]. We gave 9 ApcMin/+ mice intraperitoneal injections of 
50mg/kg 17-AAG three times a week starting at 6 weeks of age. This dose appears to be 
well-tolerated in mice [24]. A control group of 10 ApcMin/+ mice was included, and 
received injections of the drug vehicle. After 4 weeks, the mice of both groups were 
sacrificed, and the intestinal polyps in the 17-AAG-treated and control groups were 
counted and measured. Liver and spleen weights were recorded, and complete and 
differential blood counts were measured as described previously. We did not find a 
significant change in the polyp multiplicity (figure 7.6 A-C), liver weight, spleen weight, 
or hematological profile in both groups. There was also no significant difference in the 
diameter of polyps in jejunum or ileum. However, 17-AAG significantly reduced the 
average sizes of polyps in the proximal (stomach and duodenum) and distal 
gastrointestinal tract (colon) from treated mice relative to the control group (figure 7.6 
D). As observed with KU-32, 17-AAG significantly altered polyp distribution in ApcMin/+ 
mice by increasing the percentage of ileal polyps from 51% in the control group to 64% 
in the treated group (figure 7.6 E). We conclude that both 17-AAG and KU-32 alter 
intestinal polyp distribution in ApcMin/+ mice.  
KU-32 changes polyp distribution in Apc1322T/+ mice 
APC is a large multi-domain protein and has many cellular roles [21]. The best 
characterized function of APC is to antagonize Wnt signaling by targeting the 
oncoprotein -catenin for proteasomal degradation. Most colon cancer-associated-
mutations in APC result in truncation of the C-terminal half of the protein, retaining the 
first 20-amino acid repeat, which has the ability to bind -catenin [3]. The Apc mutation 
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in ApcMin./+ mice results in a shorter truncated protein (850 amino acids) that is rarely 
seen in human disease. This first 20-amino acid repeat region is absent in the truncated 
ApcMin protein [22]. We tested KU-32 in another mouse model, the Apc1322T/+ mouse. We 
reasoned that as the mutation in APC1322T/+ mice more closely resembles the mutations in 
human colorectal cancer [7], testing KU-32 in these mice may provide more relevant 
information for the human disease. In addition, we have shown that upregulation of APC 
is associated with decreased -catenin transcriptional activity in HCT116 W colon 
cancer cell line. As Apc1322T/+ mice retain the first 20-amino acid repeats, Apc 
upregulation in these mice could result in reduction of -catenin transcriptional activity 
and decrease intestinal tumorigenesis. Comparing the effects of KU-32 on ApcMin/+ 
versus Apc1322T/+ mice should help understand the effect of heat-shock response in 
intestinal tumorigenesis.  
We injected 10 Apc1322T/+ mice with 7.5 mg/kg KU-32 every week starting at the 
age of 4.5 weeks. Ten other Apc1322T/+ mice were treated with the drug vehicle only, and 
served as a control group. As described in chapter 6, we found a polymorphic allele in the 
promoter of Modifier of Min 1 (Mom-1) that is associated with prolonged survival in 
some mice in our Apc1322T/+ mouse colony. We screened mice in this study for the 
presence of this polymorphic allele. We found 3 mice from the KU-32-treated group and 
5 mice from the control group carried the Mom-1 promoter polymorphisms (see chapter 
6), and excluded the data collected from these mice. After excluding these data, we found 
that KU-32 does not significantly affect liver weight, spleen weight, or blood counts in 
Apc1322T/+ mice. There was an increase in polyp burden (polyp multiplicity and size) in all 
intestinal regions in KU-32-treated mice compared to the control group. However, this 
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trend was not statistically significant (figure 7.7 A-D). Interestingly, we found that KU-
32 significantly changed the distribution of polyps in Apc1322T/+ mice, the same trend we 
observed in ApcMin/+ mice treated with KU-32 or 17-AAG. Polyps in Apc1322T/+ mice are 
distributed more proximally than those in ApcMin/+ mice [7]. In KU-32-treated mice, most 
of the polyps still developed in the jejunum, but the ratio of ileal polyps was almost 
doubled from 10% to 19%. We conclude that KU-32 affects intestinal tumor distribution 
in Apc1322T/+ mice.    
KU-32 protects against colitis associated colon cancer in mice 
We have shown that KU-32 alters intestinal tumorigenesis in two different mouse 
models containing germline mutations in Apc. We next tested KU-32 on the AOM-DSS 
mouse model. In the AOM-DSS model, colon cancer is induced via somatic rather than 
germline mutations [10]. Unlike ApcMin/+ and Apc1322T/+ mice which develop tumors 
mainly in the small intestine, AOM-DSS-treated mice develop colonic tumors. Another 
advantage of the AOM-DSS mouse model [11] is that Apc is usually not mutated, which 
allows testing the effect of KU-32-induction of full-length Apc on tumor formation. We 
treated two wild-type C57Bl/6 mouse groups, ten mice each, with a single intraperitoneal 
injection of 7.5mg/kg AOM at the age of 6 weeks. This was followed by three cycles of 
2.5% DSS in drinking water for 5 days at age 7, 11, and 15 weeks. One mouse group 
received a weekly intra-peritoneal injection of 7.5mg/kg KU-32 starting at ~5.5 weeks (3 
days before the AOM injection). The other group received injections of the vehicles only 
and served as a control (figure 7.8 A). In addition, two other groups, 10 mice per group, 
received the same KU-32 or vehicle treatment without AOM-DSS, and served as control 
groups. Body weight was recorded weekly with every injection of either KU-32 or the 
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vehicle. Two AOM-DSS treated mice on the vehicle had rectal prolapse and were 
euthanized at the age of 22 weeks. The remaining mice were euthanized at the age of 24 
weeks. All mice not treated with AOM-DSS developed no intestinal tumors. These mice 
gained weight normally, and did not show detectable abnormalities. On the other hand, 
KU-32-injected AOM-DSS-treated mice gained more weight relative to AOM-DSS 
treated mice injected with the vehicle only (figure 7.8 B). In addition, KU-32-injected 
AOM-DSS-treated mice had significantly less colonic tumor incidence and multiplicity 
(figure 7.8 C-D). While 90% of AOM-DSS-treated mice injected with the vehicle 
developed at least one colonic tumor, only 60% of the KU-32-treated mice developed 
colonic tumors. The average number of colonic tumors in KU-32-treated mice was half 
that in the vehicle-treated mice. In addition, the vehicle-injected mice had significantly 
more large tumors (≥ 2mm in diameter) relative to the KU-32-treated group (figure 7.8 
E). KU-32-injected AOM-DSS-treated mice had significantly fewer lymphoid follicles in 
their colons compared to the vehicle-treated mice (figure 7.8 F). There was no significant 
change in the hematological profiles in AOM-DSS-treated groups. KU-32-injected 
AOM-DSS-treated mice had smaller spleens relative to the vehicle-injected AOM-DSS-
treated mice.  This same trend was also observed in KU-32-injected mice that were not 
treated with AOM-DSS, however, which suggests that this effect is not related to colonic 
inflammation and tumorigenesis (figure 7.8 G).   
Discussion 
Although the role of APC in protecting from colorectal cancer is well 
documented, little is known about how APC cellular levels are regulated. In this report, 
we show that induction of the heat-shock response through heating, treatment with 17-
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AAG, or treatment with the novel small molecule KU-32, increases the cellular level of 
APC. This increase in cellular APC level is not through proteasomal pathway as treating 
cells with both the proteasome inhibitor MG132 and 17-AAG results in greater increase 
than with either compound. We think that MG132 might augment 17-AAG increase in 
APC level by direct and indirect mechanisms. Inhibiting destruction of APC by 
proteasomes directly increases the cellular APC level. On the other hand, induction of the 
heat shock response by inhibiting proteasomes could boost the effect of 17-AAG on 
inducing the heat-shock response.  
Although the mechanism by which the heat-shock response upregulates APC is 
not known, one possible model is that induction of the heat-shock response stabilizes 
APC protein through upregulation of chaperones. APC interacts with HSP70 through the 
co-chaperone human homologue of Drosophila melanoganster tumorous imaginal disc 
(hTid) [18; 25]. In addition, Wang et al. has shown that APC co-immunoprecipitates with 
two forms of HSP70 (HSP70-5 and HSP70-2) [18].These data may suggest that HSP70 
stabilizes APC. We will further explore this possibility in the future. 
As mutations of APC are the initiating step in the majority of colorectal cancer, 
we expected that increasing the Apc level in mouse intestinal epithelial cells would 
reduce intestinal tumorigenesis. We used a novel non-toxic compound, KU-32, to 
increase APC levels in cultured cells and in mouse intestinal epithelial cells. We 
predicted that upregulation of Apc by use of KU-32 would protect against intestinal 
tumorigenesis in mice. This prediction was based on the observation that reduction of 
Apc levels below a certain threshold results in intestinal polyp formation in mice [26; 
27], and that upregulation of full-length Apc in mouse intestinal epithelial cells decreased 
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intestinal polyposis in ApcMin/+ mice [28]. We found that KU-32 surprisingly increased 
the polyp burden in ApcMin/+ mice, when the drug was administered at a high dose. One 
possible explanation of the increased polyp burden in ApcMin/+ mice is through 
upregulation of the truncated ApcMin protein, which has been proposed to have a 
dominant-negative effect in intestinal carcinogenesis [29]. Supporting this model, we 
observed an increase in truncated Apc in HT29 cells when cells were heated. We plan to 
directly test this possibility by treating ApcMin/+ mice with KU-32, and monitor truncated 
Apc level in intestinal epithelial cells in these mice. It is also important to note that 
although other groups have proposed a dominant negative role of truncated APC in 
cultured cells [29; 30], there is no evidence for this role in Apc mouse models [7; 31; 32]. 
Another KU-32 treatment regimen did not change tumor burden in ApcMin/+ mice (figure 
7.5). These data may suggest that the increase in polyp load by KU-32 is dose-dependent. 
However, the two KU-32 regimens used in ApcMin/+ mice also differ in the mice age at 
the start and end points and the duration of the treatment. We will investigate possible 
contributions of these factors on polyp formation in KU-32-treated ApcMin/+ mice in the 
future.  
We also treated ApcMin/+ mice with an established drug that induces the heat-
shock response, 17-AAG. 17-AAG is an HSP90 inhibitor that is in clinical trials as an 
anti-cancer drug. We reasoned that by comparing the effects of both drugs, we could 
dissect the effects that are related to the induction of the heat-shock response from those 
that are drug-specific. We found that 17-AAG decreased polyp size in the stomach and 
duodenum and colon, an effect that was not observed in ApcMin/+ mice treated with KU-
32, which suggests that polyp size reduction in 17-AAG-treated ApcMin/+ mice is related 
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to specific effects of 17-AAG, rather than a general effect of induced heat-shock 
response. We found that KU-32-treated Apc1322T/+ mice developed more polyps than did 
vehicle-treated mice, although not significantly so. These results are inconsistent with our 
model that KU-32 affects intestinal polyposis in a manner dependent on the particular 
size of the truncated Apc. However, we have not determined yet if the truncated Apc 
protein is upregulated in KU-32-treated Apc1322T/+ mice.  
One of the most intriguing results from this study is that induction of the heat-
shock response in17-AAG- or KU-32-treated mice changes polyp distribution. In 17-
AAG- and KU-32-treated mice, intestinal polyps were shifted to the ileal region.  The 
regional distribution of polyps in different Apc mouse models is not fully understood (see 
chapter 2), but it is potentially related to the mechanism of the second Apc hit [33]. 
Induction of heat-shock response might alter the molecular machinery that affects the 
mechanism of the second Apc mutation. An alternative hypothesis is that induction of 
heat-shock response has difference effects on different intestinal regions, imposing 
positive or negative selection over the growth of intestinal tumors. Further studies could 
differentiate between these possibilities. 
We have shown that KU-32 protects against colitis-associated colon cancer in the 
AOM-DSS mouse model. AOM-DSS-treated mice that received weekly injection of KU-
32 developed fewer and smaller tumors relative to mice injected with the drug vehicle 
only. We propose two mechanisms that are not mutually exclusive for this protection 
against colitis-associated tumorigenesis. KU-32 decreases colitis-associated 
tumorigenicity through upregulation of Apc. In the AOM-DSS model, Apc is typically 
not mutated, and tumorigenicity is initiated via stabilizing mutations in -catenin. [34; 
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35]. These mutations prevent phosphorylation and degradation of -catenin by the 
cytoplasmic destruction complex. However, we propose that upregulation of Apc by KU-
32 might decrease -catenin transcriptional activities by sequestering -catenin in the 
nucleus or importing the transcriptional repressor CtBP to the nucleus (see chapter 3). 
Alternatively, a KU-32-induced heat-shock response might protect the tissue from 
inflammation. KU-32-treated mice gained more weight and had fewer visible lymphoid 
follicles in their colons, which are both indicators of a decreased inflammatory process. 
Future work could differentiate between these two mechanisms. 
In conclusion, we show that induction of the heat-shock response increases Apc 
levels in both cultured cells and intestinal epithelial cells in mice. Induction of the heat-
shock response by the novel non-toxic compound KU-32 affects polyp number, size, and 
distribution in mouse models with germline mutations of Apc. KU-32 protects against 
inflammation-induced colon tumorigenesis in mice with full-length APC. 
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Figure 7.1: 17-AAG and MG132 increases APC and HSP70 levels in colon cancer 
cell lines. (A) Colon cancer cell lines HCT116 W with full length APC and (C) HT29 
with truncated APC (t-APC) were treated with the HSP90 inhibitor, 17-AAG, the 
proteasome inhibitor, MG132 or with both for 24 hours. Total protein lysates from 
treated cells were resolved via SDS-PAGE, and Western blots were probed for APC, 
HSP70, and -actin, which served as a loading control. (B & D) Data from at least five 
(HCT116 W cells) and three (HT29 cells) independent experiments are presented as 
average fold-change of normalized APC or HSP70 band intensity (APC or HSP70/-
actin) compared to untreated cells.  Error bars represent SEM. 
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Figure 7.2: Heat shock increases APC level in colon cancer cell lines (A) Colon 
cancer cell lines HCT116 W with full-length APC and (C) HT29 with truncated APC (t-
APC) were incubated at 42 ͦ C for different times as indicated. Total protein lysates from 
heated cells were resolved via SDS-PAGE, and Western blots were probed for APC, 
HSP70, and -actin that served as a loading control. (B) Data from four independent 
experiments and (D) data from 3 independent experiments are presented as average fold 
change of normalized APC band intensity (APC/-actin) after heating for 4 hours, 
compared to cells incubated at 37 ͦ C.  Error bars represent SEM. 
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Figure 7.3: KU-32 increases APC level in colon cancer cell lines and in vivo in mouse 
intestinal epithelial cells. (A) HCT116W cells expressing full-length APC were treated 
with 1.5 M KU-32 for 24 hours. Proteins from whole-cell lysates were resolved via 
SDS-PAGE, and immunoblots were probed for APC, Hsp70, and -actin, which served 
as a loading control.  (B) Data from five independent experiments are presented as 
average fold change of normalized APC or HSP70 band intensity (APC or HSP70/-
actin) compared to untreated cells. (C) HCT116 cells were transiently transfected with 
the -catenin reporter TOPFlash or the control reporter FOPFlash. Cells were treated 
with KU-32 for an additional 24 hours, and the -catenin activity was determined as 
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described in materials and methods. Data from three independent experiments are 
presented as average -catenin transcriptional activity (TOPFlash-luciferase divided by 
FOPFlash) of KU-32-treated cells compared to level of untreated cells, which was set to 
100% (p=0.04, Mann-Whitney nonparametric test). (D &F) Four C57Bl/J mice were 
injected with either 30mg/kg KU-32 or the drug vehicle alone. After 24 hours (D) and 48 
hours (F), epithelial cells were isolated from jejunum (J), ileum (I), and colon (C).  
Proteins from whole cell lysates were resolved via SDS-PAGE, and immunoblots probed 
for APC, HSP70, and GAPDH, which served as a loading control. (E &G) Data are 
presented as average fold change of normalized APC band intensity (APC/ GAPDH) 
from KU-32-injected mice compared to mice injected with vehicle alone. (H) A graph 
showing the fold change in Apc and Hsp70 levels in total protein lysates from mouse 
intestinal epithelial cells from the small intestine (S.I) and colon after 24 hours of treating 
the mouse with 7.5 mg/kg KU-32. * indicates  p<0,05 (Mann-Whitney nonparametric 
test). Error bars represent SEM.  
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Figure 7.4: A high dose of KU-32 increases polyp burden in ApcMin/+ mice. Nine 
ApcMin/+ mice were given seven intra-peritoneal injections with 30mg/ Kg KU-32 every 2 
weeks starting at the age of 2 weeks. Ten other ApcMin/+ mice were injected with the drug 
vehicle following the same protocol and served as a control group. (A & B) Average 
number of polyps in different intestinal regions (C) Average total number of polyps per 
mouse in both groups of ApcMin/+ mice. (D) Average diameter in mm of polyps in 
different intestinal regions. (E) The distribution of intestinal polyps in different intestinal 
regions. * indicates p < 0.05 Student t-test (A, B, C &D) and Chi-square test (E). Error 
bars are SEM.
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Figure 7.5: A low dose of KU-32 does not increase polyp burden in ApcMin/+ mice. 
Ten ApcMin/+ mice were given seven intra-peritoneal injections (7.5 mg/ Kg) of KU-32 
every week starting at the age of 6 weeks for 4 weeks. Nine other ApcMin/.+ mice were 
injected with the vehicle following the same protocol and served as a control group. (A & 
B) Average number of polyps in different intestinal regions (C) Average total number of 
polyps per mouse in both groups of ApcMin/+ mice. (D) Average diameter of polyps (in 
mm) in different intestinal regions. (E) The distribution of intestinal polyps in different 
intestinal regions. Error bars are SEM
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Figure 7.6: 17-AAG affects intestinal polyposis in ApcMin/+ mice. Nine ApcMin/+ mice 
were given intra-peritoneal injections of 50mg/ Kg 17-AAG three times a week starting 
at the age of 6 weeks until the age of 10 weeks. Ten other ApcMin/.+ mice were injected 
with the drug vehicle following the same protocol and served as a control group. (A & B) 
Average number of polyps in different intestinal regions (C) Average total number of 
polyps per mouse in both groups of ApcMin/+ mice. (D) Average diameter in mm of 
polyps in different intestinal regions. (E) The distribution of intestinal polyps in different 
intestinal regions. * indicates p < 0.05 Student t-test (A, B, C &D) and Chi square test 
(E). Error bars are SEM 
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Figure 7.7: KU-32 alters intestinal tumerogenesis in Apc1322T. Seven Apc1322T/+ mice 
were given 5 intra-peritoneal injections of 7.5 mg/ Kg KU-32 every week starting at the 
age of 4.5 weeks. Five other Apc1322T/+ mice were injected with the drug vehicle 
following the same protocol, and served as a control group. (A & B) Average number of 
polyps in different intestinal regions (C) The average total number of polyps per mouse in 
both groups of ApcMin/+ mice. (D) Average diameter in mm of polyps in different 
intestinal regions. (E) The distribution of intestinal polyps in different intestinal regions. 
* indicates p < 0.05 Student t-test (A, B, C &D) and Chi square test (E). Error bars are 
SEM. 
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Figure 7.8: KU-32 protects against colitis-associated colon tumorigenesis in mice. 
(A) Ten wild-type mice were administered a weekly dose of 7.5 mg/kg KU-32 (arrows), 
starting at 5.5 weeks. The mice also received a single dose of AOM (arrowhead) at 6 
weeks followed by 3 cycles of 5 days of 2.5% DSS (blocks) in drinking water at age 7, 11 
and 15 weeks. The mice were sacrificed at age 24 weeks. Ten other mice received the 
AOM-DSS treatment, but received a weekly injection of the drug vehicle only, and 
served as a control group. Two other control groups (10 mice each) received either KU-
32 or the vehicle, but not the AOM-DSS treatment. (B) KU-32-treated mice gained more 
weight relative to mice injected with the drug vehicle only. (C) Colonic tumor incidence 
in AOM-DSS treated mice. (D) The average number of colonic tumors per mouse in 
AOM-DSS treated mouse groups. (E) The size distribution of colonic tumors in AOM-
DSS-treated mice. Polyps are classified into small tumors with diameter less than 2 mm 
and larger tumors with diameter equal to or exceeding 2 mm. (F) The average number of 
lymphoid follicles per mouse detected under 10X magnification in AOM-DSS-treated 
mice. (G) Spleen weights in different groups included in this study. * indicates p < 0.05 
Student t-test (D, F, &G) and Chi square test (C &E). Error bars are SEM. 
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Chapter 8 
Conclusions and future directions 
The gatekeeper APC plays a key role in preventing colorectal carcinogenesis [1]. 
APC is best known for its role in antagonizing Wnt-signal-mediated cellular proliferation, 
by forming  a cytoplasmic complex that targets the oncoprotein -catenin for proteasomal 
degradation [2]. APC shuttles between the cytoplasm and the nucleus, aided by two 
nuclear localization signals and five nuclear export signals. Several reports showed a role 
for nuclear APC in Wnt signaling, transcription regulation, DNA replication, and DNA 
repair. However, these studies were performed using cultured cells and purified proteins 
[3]. In this dissertation work, we characterized the phenotype of a mouse model that was 
made in our lab. In this mouse model, the ability of APC to go to the nucleus is hindered 
by mutations in both nuclear localization signals (ApcmNLS). We propose that the ApcmNLS 
mouse model will expand our understanding of nuclear functions of Apc within the 
whole organism. This model will also allow us to test the physiological relevance of 
nuclear APC functions identified from use of other models such as cultured cells and 
purified proteins. For instance, we found that ApcmNLS/mNLS mice have high expression of 
Wnt target genes, and increased proliferation in the intestinal epithelial cells, which 
supportsthe hypothesis that  nuclear Apc antagonizes Wnt signaling.  
Based on studies performed in cultured cells, nuclear APC was proposed to 
antagonize Wnt signaling via three possible mechanisms: 1- nuclear APC binds to and 
exports nuclear -catenin to the cytoplasm [4, 5];2- Nuclear APC sequesters -catenin in 
the nucleus [6], and; 3- APC facilitates nuclear import of the transcriptional repressor 
CtBP, and thus decreases -catenin transcriptional activity [7]. We did  not find changes 
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in -catenin localization in cells from ApcmNLS/mNLS mice, which is inconsistent with the 
first mechanism.  Future work using ApcmNLS/mNLS mice will differentiate between the 
latter two mechanisms. For example, determining the amount of -catenin bound to 
promoters of Wnt target genes, or interacting with TCF/LEF, as determined by means of 
chromatin immunoprecipitation (ChIP), might allow us to validate the second proposed 
mechanism. Similarly, measuring changes in nuclear localization of the transcriptional 
suppressor CtBP, by means of immunostaining or cellular fractionation, will allow 
validation of the third mechanism.  
CRC-associated APC mutations result in loss of the C-terminal part of APC, 
including both nuclear localization signals [8]. As these mutations also disrupt other APC 
domains, including -catenin binding and degradation domains, it is difficult to 
determine the contribution of NLSAPC to tumorigenesis. Using Apc
mNLS/mNLS mice, we 
showed direct evidence that nuclear Apc suppresses tumorigenesis.  ApcmNLS increases 
intestinal and mammary tumorigenesis in ApcmNLS/Min mice relative to the number of 
tumors in ApcMin/+ mice. We do not completely understand the mechanism of enhanced 
tumorigenicity afforded by the ApcmNLS allele. However, increased Wnt signaling and 
proliferation, as we demonstrated in intestinal tissue, may play a role in the mammary 
tissue as well. Moreover, we showed that intestinal polyps in ApcmNLS/Min mice show loss 
of the ApcmNLS allele. As discussed in detail in chapter 5, these results are consistent with 
the ApcmNLS allele increasing the rate of LOH in intestinal epithelial cells. Using 
fluorescence in situ hybridization (FISH) and array-comparative genomic hybridization 
(CGH), we will determine if the ApcmNLS allele increases chromosomal instability in cells 
from ApcmNLS/Min mice. Alternatively, nuclear Apc may have a role in inducing tumor 
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growth in a cell-non-autonomous manner. To test this proposed mechanism, we could 
isolate living epithelial cells from intestinal polyps from ApcMin/+ mice as described [9], 
or use embryonic stem cells homozygous for the ApcMin allele [10]. We will implant these 
cells in the walls of the large intestine of ApcMin/+ and ApcmNLS/Min mice, and determine if 
the genotype of the surrounding tissues affects the growth rate of these cells. As ApcMin/+ 
and ApcmNLS/Min mice are congenic C57Bl/6J animals, we do not expect immunological 
rejection of the implanted cells.   
In addition, ApcmNLS/mNLS mice are more sensitive to colitis-induced 
tumorigenesis in the AOM-DSS model. We also showed that ApcmNLS/mNLS mice have 
higher expression of the inflammatory mediators Cox2 and MIP2 in intestinal epithelial 
cells from ApcmNLS/mNLS colons, which may contribute to the enhanced tumorigenesis in 
these mice. We plan to explore these possibilities and directly test the role of nuclear Apc 
in inflammation. We will induce acute inflammation in the colons of ApcmNLS/mNLS and 
Apc+/+ mice using a higher dose of DSS, and will assess the degree of colonic 
inflammation both pathologically and biochemically.      
Although much work has been done to understand APC, little is known about how 
cellular APC levels are regulated. In the second part of this dissertation, we showed that 
cellular APC levels are increased with induction of the heat-shock response. In the future, 
we will investigate the mechanism underlying this APC protein increase. We will 
differentiate between two not necessarily mutually exclusive, mechanisms: heat shock 
response increases APC level via upregulation of APC transcription; or the increase 
occurs through stabilization of APC protein. We will measure APC transcription in 
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response to induction of the heat-shock response by measuring mRNA levels, or using a 
reporter assay.   
We found that KU-32, a novel non-toxic compound that induces the heat-shock 
response, increases APC levels both in cultured cells and in mouse intestinal epithelial 
cells. We explored the effect of KU-32 on intestinal tumorigenicity in two mouse models 
with different germline mutations in Apc (ApcMin/+ and Apc1322T/+ mice). We also tested 
another small molecule that induces the heat-shock response, 17-AAG, in ApcMin/+ mice. 
We did not detect prophylactic properties of these drugs on intestinal tumorigenesis in 
mice with germline mutations in Apc. However, we found that KU-32 and 17-AAG 
change intestinal polyp distribution in ApcMin/+ and Apc1322T/+ mice. As discussed in 
detail in chapter 2, changes in intestinal polyp distribution in Apc mouse models might 
represent differential changes in different aspects of intestinal tumorigenicity, including 
the mechanism of loss of the Apc wild-type allele, cellular proliferation, and apoptosis. 
Future work will elucidate the contribution of these mechanisms in altering intestinal 
polyp distribution in Apc mouse models treated with KU-32 and 17-AAG, by assessing 
LOH, proliferation indices, and apoptosis in polyps from different intestinal regions. 
We found that KU-32 reduces colitis-associated colon tumorigenesis in the AOM-
DSS mouse model. It is not clear if this KU-32-mediated protective effect requires 
upregulation of wild-type Apc, or is mediated by other aspects of the induced heat-shock 
response. Further studies will delineate the contribution of Apc to this protection by 
assessing the protective effects of KU-32 in inflammation-induced tumorigenesis in Apc 
mutant (ApcMin/+) mice. We will also test the contribution of HSP70 in protection from 
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colitis-mediated tumorigenesis, by testing KU-32 in AOM-DSS-treated HSP70 knockout 
mice [11].    
In conclusion, findings described in this dissertation contribute to understanding 
several aspects of APC biology. First, they demonstrate a role for nuclear Apc in 
antagonizing Wnt signaling, suppressing intestinal proliferation, and suppressing 
intestinal and extra-intestinal tumorigenesis. Second, these findings support a novel 
mechanism by which cellular Apc levels are regulated: induction of the heat-shock 
response. Finally, we show that induction of the heat-shock response alters intestinal 
tumorigenesis in mice. We think that this line of work will ultimately contribute to 
improving preventive, diagnostic, prognostic, and therapeutic measures for colorectal 
cancer.   
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